<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN"  "JATS-archivearticle1-3-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">92672</article-id><article-id pub-id-type="doi">10.7554/eLife.92672</article-id><article-id pub-id-type="doi" specific-use="version">10.7554/eLife.92672.3</article-id><article-version article-version-type="publication-state">version of record</article-version><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cancer Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Immunology and Inflammation</subject></subj-group></article-categories><title-group><article-title>Tissue-resident natural killer cells support survival in pancreatic cancer through promotion of cDC1-CD8 T activity</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Go</surname><given-names>Simei</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Demetriou</surname><given-names>Constantinos</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Valenzano</surname><given-names>Giampiero</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Hughes</surname><given-names>Sophie</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Lanfredini</surname><given-names>Simone</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Ferry</surname><given-names>Helen</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Arbe-Barnes</surname><given-names>Edward</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Sivakumar</surname><given-names>Shivan</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Bashford-Rogers</surname><given-names>Rachel</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Middleton</surname><given-names>Mark R</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-0167-1685</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Mukherjee</surname><given-names>Somnath</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Morton</surname><given-names>Jennifer</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="other" rid="fund8"/><xref ref-type="other" rid="fund6"/><xref ref-type="other" rid="fund7"/><xref ref-type="other" rid="fund5"/><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Jones</surname><given-names>Keaton</given-names></name><email>keaton.Jones@nds.ox.ac.uk</email><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Neill</surname><given-names>Eric O</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-0060-6278</contrib-id><email>eric.oneill@oncology.ox.ac.uk</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con14"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/052gg0110</institution-id><institution>Department of Oncology, University of Oxford</institution></institution-wrap><addr-line><named-content content-type="city">Oxford</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/052gg0110</institution-id><institution>Experimental Medicine Division, University of Oxford</institution></institution-wrap><addr-line><named-content content-type="city">Oxford</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/052gg0110</institution-id><institution>University of Oxford Medical School</institution></institution-wrap><addr-line><named-content content-type="city">Oxford</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/052gg0110</institution-id><institution>Department of Biochemistry, University of Oxford</institution></institution-wrap><addr-line><named-content content-type="city">Oxford</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03h2bh287</institution-id><institution>Oxford University Hospitals NHS Foundation Trust</institution></institution-wrap><addr-line><named-content content-type="city">Oxford</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03pv69j64</institution-id><institution>CRUK Beatson Institute</institution></institution-wrap><addr-line><named-content content-type="city">Glasgow</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00vtgdb53</institution-id><institution>School of Cancer Sciences, University of Glasgow</institution></institution-wrap><addr-line><named-content content-type="city">Glasgow</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/052gg0110</institution-id><institution>Nuffield Department of Surgical Sciences, University of Oxford</institution></institution-wrap><addr-line><named-content content-type="city">Oxford</named-content></addr-line><country>United Kingdom</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Baiocchi</surname><given-names>Robert</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00rs6vg23</institution-id><institution>The Ohio State University</institution></institution-wrap><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Ng</surname><given-names>Tony</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0220mzb33</institution-id><institution>King's College London</institution></institution-wrap><country>United Kingdom</country></aff></contrib></contrib-group><author-notes><fn fn-type="con" id="equal-contrib1"><label>†</label><p>These authors contributed equally to this work</p></fn></author-notes><pub-date publication-format="electronic" date-type="publication"><day>10</day><month>12</month><year>2024</year></pub-date><volume>13</volume><elocation-id>RP92672</elocation-id><history><date date-type="sent-for-review" iso-8601-date="2023-10-13"><day>13</day><month>10</month><year>2023</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint.</event-desc><date date-type="preprint" iso-8601-date="2023-10-18"><day>18</day><month>10</month><year>2023</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2023.10.14.562332"/></event><event><event-desc>This manuscript was published as a reviewed preprint.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2024-01-08"><day>08</day><month>01</month><year>2024</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.92672.1"/></event><event><event-desc>The reviewed preprint was revised.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2024-06-24"><day>24</day><month>06</month><year>2024</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.92672.2"/></event></pub-history><permissions><copyright-statement>© 2024, Go, Demetriou, Valenzano et al</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>Go, Demetriou, Valenzano et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-92672-v1.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-92672-figures-v1.pdf"/><abstract><p>The immunosuppressive microenvironment in pancreatic ductal adenocarcinoma (PDAC) prevents tumor control and strategies to restore anti-cancer immunity (i.e. by increasing CD8 T-cell activity) have had limited success. Here, we demonstrate how inducing localized physical damage using ionizing radiation (IR) unmasks the benefit of immunotherapy by increasing tissue-resident natural killer (trNK) cells that support CD8 T activity. Our data confirms that targeting mouse orthotopic PDAC tumors with IR together with CCR5 inhibition and PD1 blockade reduces E-cadherin positive tumor cells by recruiting a hypoactive NKG2D<sup>-ve</sup> NK population, phenotypically reminiscent of trNK cells, that supports CD8 T-cell involvement. We show an equivalent population in human single-cell RNA sequencing (scRNA-seq) PDAC cohorts that represents immunomodulatory trNK cells that could similarly support CD8 T-cell levels in a cDC1-dependent manner. Importantly, a trNK signature associates with survival in PDAC and other solid malignancies revealing a potential beneficial role for trNK in improving adaptive anti-tumor responses and supporting CCR5 inhibitor (CCR5i)/αPD1 and IR-induced damage as a novel therapeutic approach.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>KPC</kwd><kwd>NK cells</kwd><kwd>pancreatic</kwd><kwd>tissue resident</kwd><kwd>immune</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100008919</institution-id><institution>Kidani Memorial Trust</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Go</surname><given-names>Simei</given-names></name><name><surname>Lanfredini</surname><given-names>Simone</given-names></name><name><surname>O Neill</surname><given-names>Eric</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100013373</institution-id><institution>NIHR Oxford Biomedical Research Centre</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Ferry</surname><given-names>Helen</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100009795</institution-id><institution>Pancreatic Cancer UK</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Go</surname><given-names>Simei</given-names></name><name><surname>O Neill</surname><given-names>Eric</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000289</institution-id><institution>Cancer Research UK</institution></institution-wrap></funding-source><award-id>A25233</award-id><principal-award-recipient><name><surname>Neill</surname><given-names>Eric O</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100018703</institution-id><institution>Beatson Institute for Cancer Research</institution></institution-wrap></funding-source><award-id>A31287</award-id><principal-award-recipient><name><surname>Morton</surname><given-names>Jennifer</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100018703</institution-id><institution>Beatson Institute for Cancer Research</institution></institution-wrap></funding-source><award-id>A29996</award-id><principal-award-recipient><name><surname>Morton</surname><given-names>Jennifer</given-names></name></principal-award-recipient></award-group><award-group id="fund7"><funding-source><institution-wrap><institution>CRUK Scotland Centre</institution></institution-wrap></funding-source><award-id>CTRQQR-2021\100006</award-id><principal-award-recipient><name><surname>Morton</surname><given-names>Jennifer</given-names></name></principal-award-recipient></award-group><award-group id="fund8"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000289</institution-id><institution>Cancer Research UK</institution></institution-wrap></funding-source><award-id>CTRQQR-2021\100002</award-id><principal-award-recipient><name><surname>Morton</surname><given-names>Jennifer</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Tissue-resident natural killer cells are important mediators of CD8 T responses in human cancers and these cells can be harnessed to increase immunity against pancreatic ductal adenocarcinoma.</meta-value></custom-meta><custom-meta specific-use="meta-only"><meta-name>publishing-route</meta-name><meta-value>prc</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Over the past decade, immune checkpoint inhibitors have shown significant success in the treatment of various solid malignancies. Treatment of pancreatic cancer using immunotherapy (IT) alone or in combination with radiotherapy or chemotherapy has unfortunately seen limited clinical success over either modality alone (<xref ref-type="bibr" rid="bib8">Bockorny et al., 2020</xref>; <xref ref-type="bibr" rid="bib24">Doi et al., 2019</xref>; <xref ref-type="bibr" rid="bib56">Royal et al., 2010</xref>; <xref ref-type="bibr" rid="bib74">Weiss et al., 2018</xref>; <xref ref-type="bibr" rid="bib73">Weiss et al., 2017</xref>; <xref ref-type="bibr" rid="bib46">Mohindra et al., 2015</xref>). This is likely due to several tumor microenvironmental factors, including the dense stroma that supports an immunosuppressive environment while also obstructing the infiltration of cytotoxic immune cells (<xref ref-type="bibr" rid="bib45">Mills et al., 2022</xref>; <xref ref-type="bibr" rid="bib51">Piper et al., 2023</xref>). Novel strategies comprising dual targeting of (programmed cell death-1) PD-1/IL-2Rβγ with radiotherapy are beginning to indicate that potential benefits may require a coordinated alteration in the suppressive microenvironment involving loss of regulatory T-cells (Tregs) and increased natural killer (NK) cell infiltration, in addition to simply increasing CD8 T-cell infiltration (<xref ref-type="bibr" rid="bib51">Piper et al., 2023</xref>).</p><p>We previously identified serum CCL5 (RANTES) as a negative prognostic marker for late-stage advanced pancreatic cancer (<xref ref-type="bibr" rid="bib76">Willenbrock et al., 2021</xref>). CCL5 is pro-inflammatory and an acute response to injury or infection that promotes recruitment of monocytes and lymphoid immune cells through the receptors CCR5, CCR3, and CCR1. In cancer, sustained CCL5-mediated inflammation leads to a suppressive environment via attraction of CCR5<sup>+</sup> immunoregulatory components including Tregs, tumor-associated macrophages (TAMs), and myeloid-derived suppressor cells (MDSCs) normally involved in resolving inflammatory events (<xref ref-type="bibr" rid="bib27">Hemmatazad and Berger, 2021</xref>). Pancreatic tumors that are poorly differentiated produce higher levels of CCL5 and express more of its main receptor, CCR5, compared to well-differentiated and non-cancerous tissue (<xref ref-type="bibr" rid="bib47">Monti et al., 2004</xref>; <xref ref-type="bibr" rid="bib59">Singh et al., 2018</xref>). Disrupting this loop by the FDA-approved CCR5 inhibitor (CCR5i) maraviroc reduces pancreatic tumor cell migration, invasiveness (<xref ref-type="bibr" rid="bib59">Singh et al., 2018</xref>), and proliferation (<xref ref-type="bibr" rid="bib28">Huang et al., 2020</xref>). Silencing CCL5 expression in Panc02 cells or systemic administration of the CCR5i TAK-779 reduces Treg migration and tumor volume in a murine subcutaneous tumor model (<xref ref-type="bibr" rid="bib65">Tan et al., 2009</xref>). These studies suggest that the CCL5/CCR5 axis may be a promising therapeutic target in pancreatic cancer as it has the potential to alter both the intrinsic properties of tumor cells and immune cell migration.</p><p>In established pancreatic tumors, the immune suppressive environment promotes more tissue repair/resolution signaling and prevents pro-inflammatory signaling (<xref ref-type="bibr" rid="bib38">Mantovani et al., 2017</xref>). Radiotherapy is delivered to localized tumors to stimulate a pro-inflammatory environment and increase the opportunity for tumor neoantigens to be recognized by infiltrating adaptive response cells (<xref ref-type="bibr" rid="bib6">Benkhaled et al., 2023</xref>). As such, stereotactic ablative radiotherapy delivers high doses of radiotherapy in a minimal number of fractions to maximize an inflammatory cascade but the sensitivity of lymphocytes to DNA damage and the immune suppressive environment prevent benefit or meaningful tumor control (<xref ref-type="bibr" rid="bib45">Mills et al., 2022</xref>). In NSCLC, single-cell RNA sequencing (scRNA-seq) of immune cells within tumors identifies a distinct subset of CD49a<sup>+</sup> CD103<sup>+</sup> tissue-resident memory (TRM) CD8<sup>+</sup> T-cells that have capacity to respond to neoantigens but are functionally suppressed (<xref ref-type="bibr" rid="bib16">Caushi et al., 2021</xref>). In this case, the use of an anti-PD1 antibody (αPD1) supports TRM activation but additional disruption of the immune suppressive environment is still required, indicating that additional components are required in addition to simply activating CD8<sup>+</sup> T-cell neoantigen recognition.</p><p>Kirchhammer et al. recently reported that a tissue-resident NK (trNK) cell population is induced in NSCLC in response to viral delivery of IL-12, which crucially supported type 1 conventional dendritic cell (cDC1) infiltration and increased DC-CD8<sup>+</sup> T-cell interactions (<xref ref-type="bibr" rid="bib35">Kirchhammer et al., 2022</xref>). Together with PD1 blockade, IL-12-mediated recruitment of trNK cells enhances cross-presentation of antigen to CD8 T via cDC1, suggesting this represents a substantial barrier for T-cell focused therapy and that improving the NK/DC/T-cell crosstalk can promote anti-tumor immunity and tumor control. Notably, this was dependent on CCL5 and points to a positive role for inflammatory CCL5 signaling in the absence of CCR5-mediated suppression (<xref ref-type="bibr" rid="bib35">Kirchhammer et al., 2022</xref>).</p><p>Given the negative prognosis associated with high CCL5 serum levels in human patients and its diverse functions in chemokine and paracrine signaling (<xref ref-type="bibr" rid="bib2">Aldinucci et al., 2020</xref>), we hypothesized that inhibiting CCR5 rather than CCL5, in combination with radiotherapy and anti-PD1 IT, may improve tumor control via a multimodal approach. To test this, we employed a murine orthotopic pancreatic cancer model and monitored for tumor growth and immune infiltration. We find that while the use of a CCR5i alone restricts Treg involvement, it did not therapeutically beneficially impact tumor viability alone or together with αPD1. However, in combination with radiotherapy, we see a significant alteration in MDSCs, NK, and CD8 T-cells and better tumor control. Interestingly, we observe that IR/CCR5i/αPD1 combination treatment induced a trNK population in which the NKG2D<sup>-</sup> NK cells are the highly correlated immune population with tumor control. Exploration of scRNA-seq datasets from human pancreatic ductal adenocarcinoma (PDAC) studies confirms the presence of trNK cells as immunomodulatory in human PDAC, and in which these cells seem to directly support cDC1-CD8 communication. Strikingly, a specific trNK signature indicates that higher levels of this NK subtype are significantly correlated with better PDAC patient overall and disease-free survival. Moreover, pan-cancer analysis reveals that trNK cell involvement is associated with better patient survival across a number of solid tumors and supports the potential utility of a combination regimen comprising ionizing radiation (IR) and CCR5i/αPD1 IT as a promising strategy to increase NK/cDC1/CD8-mediated tumor control in solid cancers.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>CCL5 is a negative prognostic marker in pancreatic cancer</title><p>We previously identified serum CCL5 as a bona fide negative prognostic marker for pancreatic cancer (<xref ref-type="bibr" rid="bib76">Willenbrock et al., 2021</xref>, and found that, in two independent PDAC cohorts, CPTAC3 [<xref ref-type="bibr" rid="bib14">Cao et al., 2021</xref>] and TCGA [<xref ref-type="bibr" rid="bib67">Uhlen et al., 2017</xref>]), higher CCL5 expression associates with poor overall and disease-free survival, confirming the negative implication of elevated levels of CCL5 in pancreatic cancer (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). To understand the cause of CCL5-mediated reduced survival in PDAC, we hypothesized that immune cells responsive to a CCL5 chemotactic gradient (through expression of the cognate receptors CCR5, CCR3, or CCR1) could be potential contributors to an adverse tumor immune environment (<xref ref-type="fig" rid="fig1">Figure 1B</xref>, <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A</xref>). scRNA-seq of human tumors has revealed genetic signatures for myeloid-derived suppressor cells of polymorphonuclear (PMN-MDSC) or monocytic origin (<xref ref-type="bibr" rid="bib3">Alshetaiwi et al., 2020</xref>), TAMs (<xref ref-type="bibr" rid="bib71">Wang et al., 2021</xref>), CD4 Tregs (<xref ref-type="bibr" rid="bib44">Mijnheer et al., 2021</xref>), and NK cells (<xref ref-type="bibr" rid="bib61">Smith et al., 2020</xref>), but none of these immune populations have yet been implicated as a causative agent in the poor outcome associated with high CCL5 expression in PDAC (<xref ref-type="fig" rid="fig1">Figure 1C</xref>). Notably, exploration of individual genes within these signatures indicated stark opposing correlations within each signature pool - particularly for genes associated with MDSCs (<italic>S100P</italic> vs <italic>ARG2</italic>) and NK cells (CD56 vs CD16) (<xref ref-type="fig" rid="fig1">Figure 1C</xref>, <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1B</xref>). CD56 (<italic>NCAM1</italic>) is a key marker that represents functionally distinct subpopulations of NK cells where CD56<sup>bright</sup> NK cells represent immature states that move to CD56<sup>dim</sup> upon maturation to full cytotoxic potential, whereas conversely CD16<sup>+</sup> expression marks activation and CD16<sup>-</sup> immature or quiescent NK cells (<xref ref-type="bibr" rid="bib52">Poli et al., 2009</xref>). Thus, these distinct subtypes may differentially contribute to survival, e.g., association of CD16 with poor survival may implicate a detrimental role of CD56<sup>dim</sup>CD16<sup>+</sup> NK cells, whereas the strong positive prognosis associated with CD56 expression could indicate benefit of CD56<sup>bright</sup>CD16<sup>-</sup> NK cells. The benefit of CD56 can be attributed to NK cells over neuronal expression as the neuronal cell-specific homolog <italic>NCAM2</italic> has no prognostic value (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1C</xref>).</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>CCL5 is clinically significant in pancreatic cancer.</title><p>(<bold>A</bold>) Overall and disease-free Kaplan-Meier survival plots of pancreatic ductal adenocarcinoma (PDAC) patients segregated into high or low CCL5 gene expression levels within pancreatic tumors. Data are derived from CTPAC3 and TCGA cohorts and optimal cut-off values were calculated using the max-stat method for each respective cohort. (<bold>B</bold>) Schematic overview of CCL5-responsive immune cells and corresponding CCL5 receptor repertoire expression. (<bold>C</bold>) Correlation between overall and single-cell gene signatures of CCL5-responsive immune cells with overall PDAC prognosis. Color depicts positive (green), negative (red), or neutral (black) prognostic outcomes (*p&lt;0.05, **p&lt;0.01, ***p&lt;0.005). Data are derived from the Pathology Dataset of the Human Protein Atlas and based on human tissue micro arrays and correlated log-rank p-value for Kaplan-Meier analysis αPD1/CCR5i/IR (n=8).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-92672-fig1-v1.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>CCL5 receptors are distributed across different immune cells.</title><p>(<bold>A</bold>) Human Protein Atlas-derived single-cell RNA-seq data of immune cells and relative CCL5 receptor expression. (<bold>B</bold>) Overall Kaplan-Meier survival curves of pancreatic ductal adenocarcinoma (PDAC) patients (derived from TCGA cohorts) correlated to single specific immune gene signatures with the most opposing correlations (as shown in <xref ref-type="fig" rid="fig1">Figure 1C</xref>). Color depicts positive (green) or negative (red) correlations. (<bold>C</bold>) Normalized expression of <italic>NCAM1</italic>, encoding neural cell adhesion molecule 1 (more commonly known as CD56); and <italic>NCAM2</italic>, encoding neural cell adhesion molecule 2, in different cells from the brain and immune cells. Data are derived from the Human Protein Atlas-derived single-cell RNA sequencing dataset (left). Overall Kaplan-Meijer survival curve of PDAC does not significantly correlate with NCAM2 expression (right).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-92672-fig1-figsupp1-v1.tif"/></fig></fig-group></sec><sec id="s2-2"><title>CCR5i modulates Treg infiltration in a murine orthotopic pancreatic tumor model</title><p>We next employed a syngeneic orthotopic pancreatic cancer model where cells derived from <italic>Kras<sup>G12D</sup></italic>, <italic>Trp53<sup>R172H</sup></italic>, <italic>Pdx1-Cre</italic> (KPC) tumor bearing mice are injected into the pancreas of wildtype C57BL/6 mice, thereby recapitulating a human pancreatic cancer microenvironment (<xref ref-type="bibr" rid="bib41">Matzke-Ogi et al., 2016</xref>). From a selection of independently isolated KPC-derived cell lines, we first determined the cell line KPC-F as an appropriate model for human PDAC tumor based on the expression of epithelial (E-cadherin), mesenchymal (vimentin), and stromal (Collagen I, αSMA) markers as well as displaying growth kinetics (determined by MRI) amenable for the study and expression of high levels of CCL5 (<xref ref-type="fig" rid="fig2">Figure 2A</xref>, <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A and B</xref>). To address which immune subsets are involved in CCL5 signaling in pancreatic cancer, we developed a 17-color spectral flow cytometry panel to monitor the tumor-infiltrating immune microenvironment in parallel (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1C</xref>) and employed a specific CCR5i (maraviroc), to block CCR5, the most widespread and highest-affinity receptor for CCL5 expressed on Tregs (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A</xref>).</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>CCR5i restricts Tregs in a pancreatic ductal adenocarcinoma (PDAC) orthotopic tumor model.</title><p>(<bold>A</bold>) Three different lineages of KPC pancreatic tumor cells (derived from Kras<sup>G12D</sup>p53<sup>R172H</sup>Pdx1-Cre mice) were obtained and stained for DAPI (blue; nucleus), E-cadherin (green; epithelial), and vimentin (red; mesenchymal). Growth curve of orthotopically injected KPC-F cells (500cells) into the pancreas of wildtype C57BL/6 over time in weeks. Tumor volume was measured using MRI. Representative MRI images over time are displayed, white arrow denotes tumor mass. (<bold>B</bold>) Timeline of maraviroc (CCR5 inhibitor [CCR5i]) treatment regimen. A total of 12 days post-orthotopic injection, tumor-bearing mice were treated daily with maraviroc (10 mg/kg via intraperitoneal injection) for 6 days and followed for up to 30 days after starting treatment. Frequencies of pancreatic tumor-infiltrating immune cells harvested at day 30 with or without maraviroc using spectral flow cytometry are shown. Data are represented as mean percentage positive cells of Live/CD45<sup>+</sup> cells ± SD. For Tregs, the mean percentage positive cells of Live/CD45<sup>+</sup> CD3<sup>+</sup> cells ± SD are shown. Significance was tested using the Welch and Brown-Forsythe ANOVA for parametric data or Kruskal-Wallis test for non-parametric data. Mock (n=6), IR (n=3), aPD1 (n=8), aPD1+IR (n=8), CCR5i (n=3), CCR5i+IR (n=8), aPD1+CCR5i (n=5), αPD1/CCR5i/IR (n=8). *p&lt;0.05.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-92672-fig2-v1.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Set up for the mouse orthotopic model immune monitoring.</title><p>(<bold>A</bold>) Representative H&amp;E staining of pancreatic tumors derived from orthotopically injected KPC-A, KPC-F, and KPC-G cells 30 days post-injection (left). Representative immunofluorescence of KPC_A, KPC_F, and KPC_G in vitro cultured cells stained with DAPI (blue; nucleus) and stromal markers (Collagen I; red, αSMA; cyan). (<bold>B</bold>) Chemiluminescent cytokine array for KPF_F cell line. (<bold>C</bold>) Optimized panel for immune profiling using multispectral flow cytometry (Aurora Cytek) and gating strategy of respective cells as shown in <xref ref-type="fig" rid="fig2">Figure 2B</xref>.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-92672-fig2-figsupp1-v1.tif"/></fig></fig-group><p>Pilot experiments injecting 500 KPC-F cells yielded robust and replicative growth kinetics (indicated by matching volumes of ±100 mm<sup>3</sup> at the beginning of exponential growth), permitting direct comparisons of infiltrating immune cells across different treatment groups (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). Next, tumors were allowed to reach 50 mm<sup>3</sup> (approx. 12 days) before initiation of treatment with daily administration of CCR5i for 7 days. Mice were culled 30 days post-treatment for the characterization of infiltrating immune cells (<xref ref-type="fig" rid="fig2">Figure 2B</xref>). Mice in the CCR5i-treated group showed a trend toward reduction in NK cells and all T-cell subsets with a significant reduction in Treg (Live/CD45<sup>+</sup>CD3<sup>+</sup>CD4<sup>+</sup>FOXP3<sup>+</sup>) infiltration, indicating the active recruitment of CCR5<sup>+</sup> Tregs in PDAC (<xref ref-type="fig" rid="fig2">Figure 2B</xref>). Given the enhanced effect of CCR5i on tumor growth kinetics (<xref ref-type="fig" rid="fig3">Figure 3A</xref>), however, standalone inhibition of CCR5 is unlikely to clinically benefit PDAC progression.</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Immune profiling of pancreatic ductal adenocarcinoma (PDAC) orthotopic tumours in response to therapy.</title><p>(<bold>A</bold>) Timeline of triple treatment regimen (maraviroc, αPD1, and radiotherapy) following orthotopic injection of KPC<bold>-</bold>F cells. A total of 12 days post-orthotopic injection of 500 KPC-F cells in the pancreas of wildtype C57BL/6 mice, mice were treated as follows: 7 consecutive days of 10 mg/kg intraperitoneal injection of maraviroc and 4 alternating days of 10 mg/kg intraperitoneal injection of αPD1. Mice were followed for up to 30 days following the start of the treatment regimen. Tumor volumes were measured by MRI and growth curves of individual treatment groups are plotted with or without radiotherapy as measured by MRI. Average growth curves ± SD are depicted in bold, individual mice are shaded (without IR; dashed, with IR; solid). Insert: expanded view of triple combination to show ‘responders’ display a significant benefit over RT alone. (<bold>B</bold>) Quantification of pancreatic tumors derived from (<bold>A</bold>) stained by IHC for p53. (<bold>C</bold>) Quantification of necrotic areas in pancreatic tumors derived from (<bold>A</bold>) based on H&amp;E staining. (<bold>D</bold>) Quantification of infiltrating CD8 T-cells in pancreatic tumors derived from (<bold>A</bold>) by flow cytometry. (<bold>E</bold>) Profiling of infiltrating immune cells in pancreatic tumors derived from (<bold>A</bold>) by flow cytometry as in <xref ref-type="fig" rid="fig2">Figure 2B</xref>. Single, live cells were included for analysis and are represented as frequencies of Live/CD45<sup>+</sup> cells or total CD3<sup>+</sup> for FoxP3<sup>+</sup> Tregs. Significance was tested using the Welch and Brown-Forsythe ANOVA for parametric data. <sup>#</sup>p&lt;0.05, <sup>##</sup>p&lt;0.01, or Kruskal-Wallis test for non-parametric data <sup>#</sup>p&lt;0.01; pairwise comparisons (Student’s t-test). *p&lt;0.05, **p&lt;0.01, ***p&lt;0.005, ****p&lt;0.001.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-92672-fig3-v1.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>Accessory data to support pancreatic ductal adenocarcinoma (PDAC) tumour model immune monitoring.</title><p>(<bold>A</bold>) Representative images of cross-sectional anatomy of a mouse abdomen, obtained through respiratory gated MRI (left), SARRP (center; labeled CT), and an overlay of the MRI and CT images for tumor-specific dosage of 4 Gy (right). (<bold>B</bold>) Gross tumor volume at day 30 post-treatment as measured by MRI of mice as treated in <xref ref-type="fig" rid="fig3">Figure 3A</xref>. Data are represented as mean tumor volume ± SD. (<bold>C</bold>) Quantitative measurement of DAPI<sup>+</sup> cells based on H&amp;E staining of mice treated as in <xref ref-type="fig" rid="fig3">Figure 3A</xref>. (<bold>D</bold>) Percentage of αSMA<sup>+</sup> cells based on IHC. (<bold>E</bold>) Quantification of IHC slides showing the percentage of CD8<sup>+</sup> T-cell infiltrating the tumor (left). Tumor borders are marked as dashed lines. T=tumor, NT=non-tumor (right). (<bold>F</bold>) Profiles of infiltrating immune cells in pancreatic tumors by all treatments including single control treatments as measured by Aurora Cytek. Single, live cells were included for analysis and represented as frequencies of CD45<sup>+</sup> cells in percentage. *p&lt;0.05, **p&lt;0.01, ***p&lt;0.005.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-92672-fig3-figsupp1-v1.tif"/></fig></fig-group></sec><sec id="s2-3"><title>Combination immunotherapy following localized damage alters tumor immune composition</title><p>Induction of a localized inflammatory microenvironment with IR can drive anti-tumor responses, but there is limited evidence for clinical benefit of radiotherapy in combination with immune checkpoint inhibitors in PDAC (ClinicalTrials.gov identifier: NCT04098432) (<xref ref-type="bibr" rid="bib18">Chen et al., 2022</xref>). Therefore, we next examined whether the addition of CCR5i to tumor-targeted IR could improve this by further modulating immune cell migration, in particular by reducing Treg involvement (<xref ref-type="fig" rid="fig3">Figure 3A</xref>, <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A</xref>). As expected, radiotherapy (3×4 Gy) produced a strong effect on gross tumor volume, significantly reducing volumes over standalone treatment with αPD1, CCR5i, or CCR5i+αPD1 (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). Responses to combination of IR with CCR5i, αPD1, or CCR5i+αPD1 (IR+IT) showed larger variations compared to IR alone, implying mixtures of ‘responders’ and ‘non-responders’ to immune-modulatory treatments. Moreover, IR/CCR5i/αPD1-treated tumor sections had significantly reduced DAPI<sup>+</sup> and p53<sup>+</sup> KPC cells compared to all other conditions, suggesting significantly more loss of tumor cells by triple combination treatment (<xref ref-type="fig" rid="fig3">Figure 3B</xref>, <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1B and C</xref>). Tumor sections from the triple combination treatment also presented with increased loss of active stroma (αSMA staining, <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1D</xref>) and increased necrotic areas over standalone radiotherapy (<xref ref-type="fig" rid="fig3">Figure 3C</xref>). In line with apparent increased tumor control, the triple combination treatment demonstrated infiltration of CD8<sup>+</sup> T-cells (<xref ref-type="fig" rid="fig3">Figure 3D</xref>), supporting greater penetration of CD8<sup>+</sup> T-cells into the center of tumors (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1E</xref>). These results support improved tumor control with combination of IR/CCR5i/αPD1 over standalone radiotherapy or IR in combination with αPD1 and CCR5i alone. To elucidate the immune mechanisms behind this control, we analyzed the immune infiltrate of pancreatic tumors. In line with the results above, the triple combination reduced Treg infiltration, enhanced CD8<sup>+</sup> T-cell infiltration, and supported a moderate increase in CD4<sup>+</sup> T helper cells (<xref ref-type="fig" rid="fig3">Figure 3E</xref>, <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1F</xref>).</p><p>Interestingly, no alteration was seen in the myeloid compartment, except for a reduced infiltration of PMN-MDSCs, whereas a significant infiltration of NK and NKT cells could be observed in pairwise comparisons between IR+αPD1 vs IR+CCR5i or IR/CCR5i/αPD1 (<xref ref-type="fig" rid="fig3">Figure 3E</xref>, <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1F</xref>). These results collectively support the notion that IR/CCR5i/αPD1 combination treatment alters immune infiltration by reducing Tregs and increasing NK and CD8 T-cells, thereby resulting in greater local tumor control.</p></sec><sec id="s2-4"><title>CD8 T- and NKG2D<sup>-</sup> NK cells correlate with increased tumor control</title><p>To derive more granularity on the potential roles of NK cell and T-cell populations in tumor control, tissue sections were stained using an optimized multiplex immunofluorescence panel and analyzed by HALO AI software to identify tumor cells (E-cadherin<sup>+</sup> - blue), CD8<sup>+</sup> T-cells (CD3<sup>+</sup>CD8<sup>+</sup> - orange), CD4<sup>+</sup> T-cells (CD3<sup>+</sup>CD8<sup>-</sup> - green), and NK cells (CD3<sup>-</sup>CD8<sup>-</sup>NK1.1<sup>+</sup> - red) (<xref ref-type="fig" rid="fig4">Figure 4A</xref>, <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A</xref>). As observed with flow cytometric and immunohistochemical analyses, multiplex staining of tumor sections also revealed a significant increase of CD8<sup>+</sup> T-cells per mm<sup>3</sup> when IR was used in combination with CCR5i or CCR5i+αPD1 (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1B</xref>). Notably, despite having responders and non-responders in the combination groups (<xref ref-type="fig" rid="fig4">Figure 4A</xref>), a significant overall reduction in E-cadherin<sup>+</sup> tumor cells as a percentage of total DAPI<sup>+</sup> cells was observed (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1C</xref>), supporting a decrease in cellularity and an increase in tumor necrosis with the IR/CCR5i/αPD1 combination (<xref ref-type="fig" rid="fig3">Figure 3B and C</xref>). The increase in CD8<sup>+</sup> T-cells with combination treatment appears independent of tumor area and is matched by a similar increase in NK cells (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1B and C</xref>). To correlate immune infiltration against loss of tumor cells (a measure of local tumor control), we determined relationships between CD4 T-, CD8 T-, and NK cell populations and E-cadherin<sup>+</sup> cells across all tumor sections (independent of treatment) and found a significant inverse correlation for both CD8 T- and NK cells (r<sup>2</sup>=−0.3, p=0.038 and r<sup>2</sup>=−0.33, p=0.026, respectively), but not CD4 T-cells (<xref ref-type="fig" rid="fig4">Figure 4B</xref>).</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Non-cytotoxic natural killer (NK) cells associate with tumor control.</title><p>(<bold>A</bold>) Spatial plots of individual cells identified using HALO software of scanned multiplex immunofluorescence murine orthotopic pancreatic tumor slices. Positive staining is identified as the marker of interest and DAPI<sup>+</sup> (nucleus stain) signal. Responders and non-responders to treatment are based on loss of E-cadherin staining. (<bold>B</bold>) Correlations of total CD4 T (CD3<sup>+</sup>CD8<sup>-</sup>), CD8 T (CD3<sup>+</sup>CD8<sup>+</sup>), and NK cells (CD3<sup>-</sup>NK1.1<sup>+</sup>) plotted against %positive E-cadherin<sup>+</sup> cells as derived from (<bold>A</bold>). (<bold>C</bold>) Correlation of %positive segregated NK cells plotted against %positive E-cadherin<sup>+</sup> cells as derived from (<bold>A</bold>). K cells were segregated based on expression of NKG2D; NK<sup>Active</sup>; NK1.1<sup>+</sup>NKG2D<sup>+</sup>; NK<sup>NKG2D-ve</sup>; NK1.1<sup>+</sup>NKG2D<sup>-</sup>. (<bold>D</bold>) Intra-tumoral immune cells of stratified pancreatic tumors based on low or high E-cadherin percentage (cut-off: 20%). Significance was tested for p&lt;0.05 with a two-tailed Student’s t-test. *Censored non-responder. (<bold>E</bold>) Proportion of infiltrating tissue-resident NK (trNK) (Live/CD45<sup>+</sup>CD3<sup>-</sup>CD19<sup>-</sup>NK1.1<sup>+</sup>CD103<sup>+</sup>CD49a<sup>+</sup>), conventional NK cells (Live/CD45<sup>+</sup>CD3<sup>-</sup>CD19<sup>-</sup>NK1.1<sup>+</sup>CD103<sup>-</sup>CD49a<sup>-</sup>), CD103<sup>+</sup> NK, and CD49a<sup>+</sup> NK cells isolated from orthotopic pancreatic tumors of mice treated with the IR+IT regimen and controls, as a percentage of CD45<sup>+</sup> cells. Significance was tested for p&lt;0.05 with a Student’s t-test. (<bold>F</bold>) Comparative surface expression of activation marker (CD69), activating receptors (NKp46, NKG2D), and exhaustion marker (TIM-3) on conventional NK (cNK) cells and trNK cells isolated from orthotopic pancreatic tumors. Significance was tested for p&lt;0.05 with a Student’s t-test. *p&lt;0.05, ***p&lt;0.005, ****p&lt;0.001.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-92672-fig4-v1.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>Identification of a tissue-resident natural killer (trNK) population in mice.</title><p>(<bold>A</bold>) Representative image of a multiplex immunofluorescence staining of a pancreatic tumor. (<bold>B</bold>) Quantification of CD8<sup>+</sup> cells (identified as DAPI<sup>+</sup>CD3<sup>+</sup>CD8<sup>+</sup>) across the different treatment groups. Markers are as indicated. Significance was tested for p&lt;0.05 with a two-way ANOVA, *p&gt;0.05, ***p&gt;0.005. (<bold>C</bold>) Percentages of total DAPI<sup>+</sup> immune cells (left) and E-cadherin<sup>+</sup> tumor cells (right) derived from <xref ref-type="fig" rid="fig4">Figure 4A</xref> following treatment. Significance was tested using two-way ANOVA with Tukey multiple comparison (blue significance lines), or one-way ANOVA with Tukey multiple comparison (yellow significance lines) using a p&lt;0.05. (<bold>D</bold>) Percentage of NKG2D<sup>+</sup> and NKG2D<sup>-</sup> cells as a proportion of NK1.1<sup>+</sup> cells as derived from <xref ref-type="fig" rid="fig4">Figure 4A</xref>. (<bold>E</bold>) Uniform manifold approximation and projection (UMAP) of intra-tumoral natural killer (NK) cells (NK1.1<sup>+</sup>CD3<sup>-</sup>CD19<sup>-</sup>) in mice treated with the IR/CCR5i+αPD1 combination. (<bold>F</bold>) Representative example of gating strategy for the identification of tissue-resident (CD103<sup>+</sup>CD49a<sup>+</sup>) and conventional (CD103<sup>-</sup>CD49a<sup>-</sup>) NK cells. (<bold>G</bold>) Proportion of trNK, conventional NK (cNK), CD103<sup>+</sup> NK, and CD49a<sup>+</sup> NK in mice treated with the IR+IT regimen and control (mock), as a fraction of total NK cells.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-92672-fig4-figsupp1-v1.tif"/></fig></fig-group><p>We next wondered whether the association between NK cells and tumor control was due to cytotoxicity of functionally active NK cells by focusing our analysis on the NKG2D<sup>+</sup> NK cell population, given that this is one of the major activating receptors on NK cells and is required for the lysis of target cells (<xref ref-type="bibr" rid="bib12">Bryceson and Ljunggren, 2008</xref>). Surprisingly, the proportion of infiltrating CD3<sup>-</sup>NK1.1<sup>+</sup>NKG2D<sup>+</sup> cells (NK<sup>Active</sup>) in stained tissue sections was reduced under IR/CCR5iαPD1 combination treatment, implying a decrease in total NK cell cytotoxic capacity (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1D</xref>). The reduced NKG2D expression on NK cells may be a result of the prolonged engagement by ligands expressed on tumor cells, followed by ligand-induced endocytosis and degradation (<xref ref-type="bibr" rid="bib53">Quatrini et al., 2015</xref>), or the shedding of NKG2D ligands by tumor cells (<xref ref-type="bibr" rid="bib31">Kaiser et al., 2007</xref>). In both instances, receptor downregulation causes a reduction in cytotoxicity and impairs NK cell responsiveness to tumor cells, potentially contributing to exhaustion (<xref ref-type="bibr" rid="bib25">Groh et al., 2002</xref>). Moreover, circulating NK cells from PDAC patients show reduced NKG2D levels compared to healthy controls (<xref ref-type="bibr" rid="bib50">Peng et al., 2013</xref>) supporting the notion that chronic exposure to NKG2D ligands expressed or shed by PDAC cells might cause NKG2D down-modulation and a hypo-responsive phenotype. Indeed, the reciprocal CD3<sup>-</sup>NK1.1<sup>+</sup>NKG2D<sup>-</sup> population increases upon triple combination treatment (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1D</xref>). Surprisingly, the correlation of NK cells with decreased frequency of E-cadherin<sup>+</sup> cells was completely abrogated with selection for more functionally competent NK cells (NK<sup>Active</sup>), implying that the opposite hypoactive NKG2D<sup>-</sup> NK population (NK<sup>NKG2D-ve</sup>) is responsible for correlation of NK cells with E-cadherin loss and indeed, a superior inverse correlation is observed for NK<sup>NKG2D-ve</sup> and E-cadherin compared to NK<sup>Active</sup> or NK<sup>Total</sup> (r<sup>2</sup>=0.52, p=0.003) (<xref ref-type="fig" rid="fig4">Figure 4C</xref>). To explore this association is relation to tumor control, sections were split into either E-cadherin<sup>high</sup> or E-cadherin<sup>low</sup> and the extent of immune involvement was represented as a percentage of total DAPI<sup>+</sup>. While CD8 T-cells significantly segregated with E-cadherin<sup>low</sup>, implying a contribution to tumor control, the association of NK<sup>NKG2D-ve</sup> was vastly more significant (<xref ref-type="fig" rid="fig4">Figure 4D</xref>).</p><p>To further dissect the association between NK cells and loss of tumor cells, we immunophenotyped NK cells infiltrating tumors of mice treated with the IR/CCR5i/αPD1 regimen with an NK cell dedicated spectral flow cytometry panel. Using a combination of uniform manifold approximation and projection (UMAP) dimensionality reduction and manual gating, we found that more than two-thirds of tumor-infiltrating NK cells expressed the canonical markers of tissue residency CD103 and CD49a (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1E and F</xref>), with the double positive population (hereafter referred to as bona fide trNK cells) being barely detectable in untreated mice and rising nearly 40-fold after treatment (<xref ref-type="fig" rid="fig4">Figure 4E</xref>). The remainder cells expressed neither marker of tissue residency and were, therefore, named conventional NK cells.</p><p>We then compared these two clusters and found that trNK were less likely to be activated and expressed significantly lower levels of the activating receptors NKG2D and NKp46, as well as significantly higher levels of the inhibitory receptor TIM-3 (<xref ref-type="fig" rid="fig4">Figure 4F</xref>). In line with our multiplex IF data (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1D</xref>), these data indicate that NK cells infiltrating tumors of mice treated with the IR/CCR5i/αPD1 combination were predominantly tissue resident and hypoactive, with a minority displaying a more conventional, fully active phenotype.</p></sec><sec id="s2-5"><title>Heterogenous subsets of NK cells in PDAC exhibit differential inhibitory and activating signatures</title><p>To extrapolate our findings to the human setting, we explored scRNA-seq data from isolated NK and T-cells derived from human pancreatic cancer patients. A total of 51,561 cells were catalogued into 17 distinct cell lineages annotated with canonical gene signatures as described in Steele et al. using unsupervised clustering (<xref ref-type="bibr" rid="bib64">Steele et al., 2020</xref>; <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>). UMAP of the lymphocyte compartment did not delineate NK subpopulations and showed overlap with CD8 T-cells (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>). Therefore, we focused on UMAP of the CD8 and NK compartment alone, which led to three clear NK subpopulations that are distinct from CD8 T-cells and clearly separate out in clusters of hypoactive (NK_C1), fully active (NK_C2), and cytotoxic (NK_C3) NK cells from T-cells (<xref ref-type="fig" rid="fig5">Figure 5A</xref>). In agreement with downregulation of circulating NKG2D<sup>+</sup> in PDAC patients, NKG2D (<italic>KLRK1</italic>) expression was below detection across all CD8 and NK subpopulations retrieved from patient tumors (<xref ref-type="bibr" rid="bib25">Groh et al., 2002</xref>). As expected, CD16<sup>high</sup> (<italic>FCGR3a</italic>) cytolytic NK cells (NK_C3) cluster separately from CD16<sup>-</sup> NK cells (NK_C1) which are more enriched for genes related to cytokine secretion than cytolytic function (<xref ref-type="fig" rid="fig5">Figure 5D</xref>, <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>). The NK_C1 cluster correlates best with the tissue-resident, hypoactive NK phenotype observed in mice as they similarly displayed reduced cytolytic (reduced <italic>NKG7</italic>, <italic>NKp80</italic>, <italic>GZMA,</italic> and <italic>PRF1</italic>) with additional expression of tissue residency markers <italic>CD103</italic>, <italic>CD49a,</italic> and the adaptive activating receptor NKG2C (<italic>KLRC2</italic>) (<xref ref-type="fig" rid="fig5">Figure 5B and C</xref>). While adaptive NK cells in the peripheral circulation are associated with a CD56<sup>dim</sup>CD16<sup>+</sup> phenotype, adaptive-like (i.e. NKG2C<sup>+</sup>) CD56<sup>bright</sup>CD16<sup>dim</sup> trNK cells have been identified in other epithelial sites such as the lungs (<xref ref-type="bibr" rid="bib10">Brownlie et al., 2021</xref>), therefore, our pancreatic tissue NK_C1 cells could comprise, at least in part, adaptive-like trNK cells. Downstream UMAP analysis of the NK cell population distinguishes these three subsets of NK cells (NK_C1, NK_C2, and NK_C3) based on 41 differentially expressed genes (<xref ref-type="fig" rid="fig5">Figure 5D and E</xref>).</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Identification of a tissue-resident natural killer (trNK) signature from single cell data of pancreatic ductal adenocarcinoma (PDAC) patients.</title><p>(<bold>A</bold>) Uniform manifold approximation and projection (UMAP) of the CD8<sup>+</sup> T and natural killer (NK) sub-clusters from Steele et al. (<bold>B</bold>) Dot plot showing the expression of exhaustion-related genes across CD8<sup>+</sup> T- and NK cell sub-clusters. (<bold>C</bold>) Dot plot showing highly expressed genes for each sub-cluster. (<bold>D</bold>) UMAP of the three NK sub-clusters (left), and violin plots comparing the expression of NK subtype-associated genes between the sub-clusters (right). (<bold>E</bold>) Dot plot showing the different gene expression programs across the three NK sub-clusters. (<bold>F</bold>) Heatmap showing the top 15 upregulated markers for each NK sub-cluster compared against total NK cluster.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-92672-fig5-v1.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>Human single cell data indicating a non-cytotoxic population of natural killer (NK) cells.</title><p>(<bold>A</bold>) Uniform manifold approximation and projection (UMAP) of the main cell types from the integrated single-cell RNA sequencing (scRNA-seq) Steele dataset (left) and dot plot showing canonical marker expression for each respective cell type (right). Color indicates average normalized expression; dot size represents percentage of cells of each cell type expressing the respective gene. (<bold>B</bold>) UMAP plot of lymphocyte sub-clusters from the Steele dataset (left) and their marker expressions (dot plot, right). (<bold>C</bold>) Violin plots showing NK-related gene signatures for each NK sub-cluster. (<bold>D</bold>) UMAP plot of lymphocyte sub-clusters from the Peng dataset, with the arrows representing the proposed functional development. (<bold>E</bold>) UMAP showing the expression levels of CD16(FCGR3a), CD56 (NCAM1), CD103 (ITGAE), and CD49a (ITGA1) across the NK sub-clusters. (<bold>F</bold>) Dot plot showing the different gene expression programs across the NK sub-clusters from the Peng dataset.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-92672-fig5-figsupp1-v1.tif"/></fig></fig-group><p>Given that CD56 expression correlates with increased survival in PDAC patients (<xref ref-type="fig" rid="fig1">Figure 1C</xref>), we were intrigued to notice that the hypoactive NK_C1 cluster is enriched for CD56 but not CD16 expression (<xref ref-type="fig" rid="fig5">Figure 5D</xref>). These data suggest that the NK_C1 cluster represents a subset of NK cells in PDAC that display tissue residency markers (<italic>ITGAE,</italic> CD103 and <italic>ITGA1,</italic> CD49a) and have an immune-secretory phenotype (XCL1) as opposed to cytotoxic phenotype (NK_C2 CD16<sup>+</sup>, NKG7<sup>+</sup>) (<xref ref-type="fig" rid="fig5">Figure 5E</xref>). Furthermore, we defined a core signature gene set to distinguish NK_C1 from other NK subpopulations (<xref ref-type="fig" rid="fig5">Figure 5F</xref>). Verification of the NK_C1 population as trNK cells in a second scRNA-seq pancreatic cancer dataset of <xref ref-type="bibr" rid="bib50">Peng et al., 2013</xref>, further supports the existence of these hypoactive cells in an independent PDAC cohort (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1E and F</xref>).</p></sec><sec id="s2-6"><title>trNK cells in PDAC show differential communication</title><p>The NK_C1 population had the highest expression of the chemokines XCL1 and XCL2, which have been demonstrated to attract cDC1 (<xref ref-type="bibr" rid="bib9">Böttcher et al., 2018</xref>) and thereby increase cross-presentation to CD8<sup>+</sup> T-cells. We next explored myeloid populations in the Steele et al. scPDAC dataset (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1A</xref>) and identified cDC1 cells as XCR1<sup>+</sup> enriched compared to other DC subsets (<xref ref-type="fig" rid="fig6">Figure 6A</xref>, <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1B</xref>). As XCR1 is the receptor for XCL1/2, this suggests that one of the main directions of communication from NK_C1 cells in PDAC is to cDC1 (<xref ref-type="fig" rid="fig6">Figure 6B</xref>). We next employed the R package ‘CellChat’ (<xref ref-type="bibr" rid="bib29">Jin et al., 2021</xref>) to further dissect the crosstalk between NK_C1 and other cells found in the pancreatic tumor microenvironment. We again observed that NK_C1-derived XCL1/2 is the strongest signal to XCR1<sup>+</sup> cDC1s (<xref ref-type="fig" rid="fig6">Figure 6C</xref>), supporting active crosstalk between NK_C1 and cDC1. Analysis of specific ligand-receptor pairs between NK_C1 and 24 other cell groups yielded 32 significant interactions, of which the <italic>TNFSF14</italic> (LIGHT)-<italic>TNFRSF14</italic> pair was the most universal intercellular interaction, whereas CD74 (or <italic>MIF</italic>) signaling showed the highest communication probability (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1C</xref>).</p><fig-group><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>CellChat communication indicates tissue-resident natural killer (trNK) communicate directly to cDCs.</title><p>(<bold>A</bold>) Uniform manifold approximation and projection (UMAP) of the dendritic cell sub-clusters from the Steele dataset. (<bold>B</bold>) Violin plot showing the expression of XCL1, XCL2, and XCR1 across all cell types. (<bold>C</bold>) Circle plots showing interactions across all cell types (top left), signals coming from the tissue-resident natural killer (trNK) cells (top right), the XCL1-XCR1 interaction (bottom left), and the XCL2-XCR1 interaction (bottom right). The width of edges represents the communication strength. (<bold>D</bold>) Heatmap showing the summary of secreted signaling communications of outgoing (left) and incoming (right) signals. The color bar represents the communication strength, and the size of the bars represents the sum of signaling strength for each pathway or cell type. (<bold>E</bold>) Schematic overview of the trNK to type 1 conventional dendritic cell (cDC1) and cDC1 to CD8 T-cell communication axis (top). Circle plots of all outgoing signals from cDC1 (bottom left) and the CXCL16-CXCR6 signaling (bottom right). (<bold>F</bold>) Correlation of HALO data on total NK<sup>NKG2D-ve</sup> NK cells (CD3<sup>-</sup>NK1.1<sup>+</sup>NKG2D<sup>-</sup>) with CD8 T-cells (CD3<sup>+</sup>CD8<sup>+</sup>) from stained sections of treated KPC_F orthotopic tumors, R<sup>2</sup> and p-values indicate positive correlation across all tumors (gray, n=15) or limited to mock, CCR5i+IR and IR/CCR5i/αPD1 combination (red, n=9). (<bold>G</bold>) Correlation of trNK signature with CD8A (left) or CD8B (right) in bulk RNA-seq from TCGA_PAAD and binned into quartiles based on extent of cDC1 involvement as assumed by cDC1 signature (<xref ref-type="supplementary-material" rid="fig6sdata1">Figure 6—source data 1</xref>).</p><p><supplementary-material id="fig6sdata1"><label>Figure 6—source data 1.</label><caption><title>Gene signatures for trNK and cDC1.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-92672-fig6-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-92672-fig6-v1.tif"/></fig><fig id="fig6s1" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 1.</label><caption><title>Profiling of dendritic cells indicates specific communication.</title><p>(<bold>A</bold>) Uniform manifold approximation and projection (UMAP) of the myeloid cell types from the Steele dataset (top) and the dot plot showing the canonical cell markers (bottom). (<bold>B</bold>) Heatmap of the top 15 markers for each DC sub-cluster. (<bold>C</bold>) Dot plot showing the estimated outgoing secreted signals from the natural killer (NK) C1 cell population. (<bold>D</bold>) Dot plot showing the estimated secreted and cell-cell contact signals from the type 1 conventional dendritic cell (cDC1) cell population. Color of the dots represents the communication probability, and the size of the dot represents the significance level.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-92672-fig6-figsupp1-v1.tif"/></fig></fig-group><p>Within the immune cell compartment, communication signals between NK_C1 and macrophages were the most abundant and diverse, followed by cDCs (cDC2 and cDC1) and Tregs (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1C</xref>). Similarly, cDC1 in these PDAC samples also seem capable of presenting MHC class I peptides to CD8<sup>+</sup> T-cells, but surprisingly also MHC class II to CD4<sup>+</sup> Tregs (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1D</xref>). Next, significant receptor-ligand interactions were segregated as ‘outgoing’ or ‘incoming’ signals to understand directionality of communication. Among the outgoing signals from different cell types, NK_C1 cells contributed the highest IL-16, CSF, LIGHT (TNFSF14), FASLG, and MIF signals in tumors (<xref ref-type="fig" rid="fig6">Figure 6D</xref>). IL-16 is mainly known as a chemoattractant for CD4<sup>+</sup> T-cells, however CD4<sup>+</sup> dendritic cells have also been demonstrated to be recruited by IL-16 (<xref ref-type="bibr" rid="bib7">Bialecki et al., 2011</xref>; <xref ref-type="bibr" rid="bib32">Kaser et al., 1999</xref>; <xref ref-type="bibr" rid="bib69">Vremec et al., 2000</xref>). IL-16 has also been described to increase HLA-DR levels in CD4<sup>+</sup> T-cells and eosinophils, indicating that it has the potential to induce MHC antigen presentation in CD4<sup>+</sup> cells (<xref ref-type="bibr" rid="bib21">Cruikshank et al., 1987</xref>; <xref ref-type="bibr" rid="bib54">Rand et al., 1991</xref>). Taken together, these interactions support the hypothesis that trNK cells may improve tumor control via recruitment of cDC1 via XCR1, while promoting DC maturation via LIGHT-CD86 signaling (<xref ref-type="bibr" rid="bib79">Zou and Hu, 2005</xref>) and supporting DC antigen presentation to both CD4<sup>+</sup> and CD8<sup>+</sup> T-cells via MIF-CD74 signaling (<xref ref-type="bibr" rid="bib5">Basha et al., 2012</xref>; <xref ref-type="fig" rid="fig6">Figure 6E</xref>). On the other hand, dendritic cell-secreted BAG6 could promote both survival and cytokine release of NK cells by binding to NKp30 (<xref ref-type="bibr" rid="bib58">Simhadri et al., 2008</xref>) and directly signal to CD8 T-cells via CXCL16-CXCR6 (<xref ref-type="bibr" rid="bib23">Di Pilato et al., 2021</xref>; <xref ref-type="bibr" rid="bib68">Vella et al., 2021</xref>), thereby generating an anti-tumor feedforward loop (<xref ref-type="fig" rid="fig6">Figure 6E</xref>). IL-16 also communicates to CD4<sup>+</sup> Tregs, which could contribute to immunosuppression via enhanced Treg migration and expansion (<xref ref-type="fig" rid="fig6">Figure 6D</xref>; <xref ref-type="bibr" rid="bib42">McFadden et al., 2007</xref>). However, Tregs may also be susceptible to Fas-mediated cell death due to NK_C1 expression of Fas ligand (<xref ref-type="fig" rid="fig6">Figure 6D</xref>). This could enhance immune cell infiltration and revoke the immunosuppressive environment, ultimately contributing to increased tumor control.</p><p>These results so far suggest the presence of immunoregulatory trNK cells in PDAC that are involved in an intricate immune communication network with DCs and CD8 T-cells to enhance anti-tumor immunity. To support this hypothesis, we explored the correlation between trNK and CD8 T infiltration in our murine orthotopic tumor model and found a highly significant positive association (R²=0.6571, p=0.003), which was strengthened when we focused on untreated (Mock) vs IR+IT combinations where trNK cells are evident (R²=0.9223, p=0.0004) (<xref ref-type="fig" rid="fig6">Figure 6F</xref>). To ascertain if this also holds true in human PDAC, we first specified the NK_C1 signature as a 14-gene signature that was specific for our trNK cells over all other cells to interrogate these cells in bulk datasets (<xref ref-type="supplementary-material" rid="fig6sdata1">Figure 6—source data 1</xref>). We next explored the CD8 T:trNK cell relationship in PAAD_TCGA and, as the model in <xref ref-type="fig" rid="fig6">Figure 6E</xref> predicts, this interaction to be cDC1 dependent, binned the PAAD_TCGA cohort into quartiles based on differential cDC1 signature expression to test dependence of CD8 T:trNK on cDC1 levels (<xref ref-type="fig" rid="fig6">Figure 6G</xref>). PDAC patient tumors with the lowest evidence for cDC1 involvement had a weak correlation of trNK_C1 with CD8A and CD8B (p=0.047; p=0.045, respectively) which rises to a strong highly significant correlation when the highest levels of cDC1s are present (R=0.55, trNK_C1 vs CD8A p=0.0001; R=0.58, trNK_C1 vs CD8B p=0.000047) (<xref ref-type="fig" rid="fig6">Figure 6G</xref>).</p></sec><sec id="s2-7"><title>NK cell signature correlates with improved survival</title><p>As the presence of trNK and correlation with CD8 T-cells appears boosted by IR, we next further explored our original finding that CD56 correlates with highly significant survival in PDAC (<xref ref-type="fig" rid="fig1">Figure 1</xref>, <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>). We hypothesized that tumors with a high <italic>NCAM1</italic>/CD56 signature may reflect a greater indication of NK cell recruitment, including a high proportion of trNK (CD56<sup>bright</sup>CD16<sup>low</sup>), whereas tumors with a low CD56 signature might have a lower proportion of infiltrating (tr)NK cells and, therefore, could benefit from IR. Indeed, separating PAAD_TCGA patients into those who received radiotherapy (RTx) vs those that did not showed that the benefit in overall survival of PDAC patients is only apparent in the CD56<sup>low</sup> patient group (log-rank p&lt;0.0001, <xref ref-type="fig" rid="fig7">Figure 7</xref>). We next explored whether CD56-associated survival is specifically due to the presence of trNK cells using our NK_C1 signature (<xref ref-type="supplementary-material" rid="fig6sdata1">Figure 6—source data 1</xref>). Analysis of primary PDAC tumors from the TCGA (TCGA_PAAD) demonstrates that patients with tumors enriched for the trNK cell (NK_C1) gene signature were associated with improved PDAC survival compared to patients without trNK involvement (<xref ref-type="fig" rid="fig7">Figure 7</xref>, <xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1A</xref>). Similarly to CD56<sup>low</sup> patients, we find that patients with trNK<sup>low</sup> benefit from RTx (log-rank p&lt;0.005, <xref ref-type="fig" rid="fig7">Figure 7</xref>). Notably, we find that despite an overall poor prognosis, CCL5<sup>high</sup> patients (TCGA and CPTAC3) are significantly enriched for the trNK_C1 gene signature (<xref ref-type="fig" rid="fig7">Figure 7</xref>), potentially due to strong CCR5 or CCR1-mediated recruitment (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A</xref>). However, as CCL5 also recruits MDSCs, TAMs, Tregs, and conventional NK cells via CCR5, CCR5i could prevent a tumor suppressive microenvironment, both directly and indirectly by retaining trNK cells that remove Tregs through FASL (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1</xref>). Therefore, we would expect that patients with CCL5<sup>high</sup> NK_C1<sup>low</sup> would perform significantly worse than patients with CCL5<sup>high</sup>NK_C1<sup>high</sup>. Indeed, CCL5<sup>high</sup> patients enriched for the NK_C1 signature or CD56 had significantly improved overall and disease-free survival (<xref ref-type="fig" rid="fig7">Figure 7</xref>). This also supports a model where CCL5-mediated recruitment of NK cells can be beneficial in the absence of CCL5-CCR5 recruitment, likely via CCR1 signaling (<xref ref-type="bibr" rid="bib1">Ajuebor et al., 2007</xref>; <xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1</xref>, <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A</xref>). These results suggest that despite high CCL5 levels and an overall poor prognostic outcome, the presence of trNK cells significantly improves survival and provides an opportunity for intervention with the IR+IT combination.</p><fig-group><fig id="fig7" position="float"><label>Figure 7.</label><caption><title>Tissue-resident natural killer (trNK) associate with better survival in pancreatic ductal adenocarcinoma (PDAC).</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-92672-fig7-v1.tif"/></fig><fig id="fig7s1" position="float" specific-use="child-fig"><label>Figure 7—figure supplement 1.</label><caption><title>Model for CCL5 mediated recruitment of immune cells in the presence of CCR5i.</title><p>(<bold>A</bold>) Tissue-resident natural killer (trNK) cell (NK_C1) signature and overall survival in pancreatic ductal adenocarcinoma (PDAC) using the CPTAC3 dataset. (<bold>B</bold>) Schematic overview of proposed mode of action of CCL5 gradients: CCL5 leads to the recruitment of CCR5<sup>+</sup> immune cells, including regulatory T-cells (Tregs). Blockade of the CCL5-CCR5 axis, however by CCR5 antagonists, allows recruitment of trNK cells via CCL5-CCR1 signaling while Tregs recruited into the microenvironment are killed off via FasL-mediated trNK killing.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-92672-fig7-figsupp1-v1.tif"/></fig></fig-group><p>Finally, we explored whether the NK_C1 gene signature could be a prognostic marker in solid malignancies other than PDAC by expanding our TCGA analysis. The majority of cancers with enriched expression of our NK_C1 gene signature showed improved survival (<xref ref-type="fig" rid="fig8">Figure 8</xref>) (apart from endometrium and prostate) as a continuous variable or as a high vs low in a univariate Cox regression (<xref ref-type="fig" rid="fig8s1">Figure 8—figure supplement 1</xref>). The latter result supports our hypothesis that enrichment of trNK cells is a protective factor across most solid malignancies. Moreover, the ability to enrich for this population with IR+IT combinatorial strategies supports the idea that trNK cells generally improve overall survival though improving CD8 T-cell activity in solid cancers.</p><fig-group><fig id="fig8" position="float"><label>Figure 8.</label><caption><title>Tissue-resident natural killer signature associates with survival pan cancer.</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-92672-fig8-v1.tif"/></fig><fig id="fig8s1" position="float" specific-use="child-fig"><label>Figure 8—figure supplement 1.</label><caption><title>Tissue-resident natural killer cell signature survival hazard ratios.</title><p>(<bold>A</bold>) Cox regression of tissue-resident natural killer cell signature vs overall survival and disease-free survival across indicated malignancies as a continuous variable (<bold>B</bold>) or segregated into low/high NK_C1.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-92672-fig8-figsupp1-v1.tif"/></fig></fig-group></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>Novel approaches such as immunotherapies struggle to improve outcome in PDAC as tumors are stromal-rich, myeloid-involved immunosuppressive microenvironments devoid of cytotoxic lymphocytes (<xref ref-type="bibr" rid="bib19">Chouari et al., 2023</xref>). Most strategies to combat immune suppression, e.g., targeting inhibitory checkpoints such as PD1/PDL1, fail as single therapies because PDAC is largely devoid of the CD8 T-cells as these agents are designed to reactivate. Combining them with inhibitors of myeloid suppression (e.g. CXCR2) to increase CD8 T penetration also failed to impact survival in clinical trials despite showing promise in preclinical studies (<xref ref-type="bibr" rid="bib63">Steele et al., 2015</xref>, <xref ref-type="bibr" rid="bib60">Siolas et al., 2020</xref>). Similarly, high-dose hypo-fractionated ablative radiotherapy has been employed to create an acute localized inflammatory response to stimulate intra-tumoral penetration of CD8 T-cells, but even in conjunction with PD1/PDL1 blockade this approach has not shown benefit in PDAC (<xref ref-type="bibr" rid="bib49">Parikh et al., 2021</xref>). Novel strategies in preclinical PDAC models comprising IR, αPD1, and BMS-687681 (a dual CCR2/CCR5i) have shown promising increases in CD8 T-cells (<xref ref-type="bibr" rid="bib72">Wang et al., 2022</xref>), whereas the combination of IR and the bifunctional agent αPD-1/IL-2Rβγ stimulates tumor penetration of polyfunctional stem-like activated CD8 T-cells and DNAM1<sup>+</sup> cytotoxic NK cells (<xref ref-type="bibr" rid="bib51">Piper et al., 2023</xref>). Together, these approaches indicate potential benefits of a coordinated alteration of the suppressive microenvironment and checkpoint blockade to reduce Tregs and increase NK cell infiltration in addition to supporting CD8 T-cell activity. The utility of RT for localized PDAC has been controversial, but innovative technology can now deliver IR at higher doses with greater precision (<xref ref-type="bibr" rid="bib45">Mills et al., 2022</xref>). Rather than simple ablative radiotherapy, this strategy is being employed to increase localized damage that stimulates an acute damage response in immune-cold tumors or increase tumor neoantigens to stimulate adaptive responses (<xref ref-type="bibr" rid="bib62">Sodergren et al., 2020</xref>). In support of this, the use of IR alongside αPD-1/IL-2Rβγ or FAKi appeared to induce durable immunity in preclinical models (<xref ref-type="bibr" rid="bib36">Lander et al., 2022</xref>; <xref ref-type="bibr" rid="bib51">Piper et al., 2023</xref>), suggesting the induction of immunologic memory against tumor antigens is possible.</p><p>We were led by our previous clinical trial results implicating serum CCL5 levels as a negative prognostic marker for PDAC survival, which we now validate in two independent validation datasets. CCL5 has both pro-inflammatory roles as a chemoattractant for leukocytes and anti-inflammatory activity via recruitment of CCR5<sup>+</sup> Tregs (<xref ref-type="bibr" rid="bib65">Tan et al., 2009</xref>). To maintain beneficial signals but limit pro-tumorigenic signaling, we targeted CCR5 alone using maraviroc. Not surprisingly, in an orthotopic KPC model of PDAC, we found that Tregs were restricted by CCR5i directly and the combination of IR and IT (CCR5i, αPD1, or CCR5i/αPD1) correlates with a progressive enrichment of CD8 T-cells. Intriguingly, CD8 T-cells alone were insufficient to explain the loss of cellularity or the increase in necrotic tumors seen with the IR/CCR5i/αPD1 combination, but we do observe a significant increase in total NK and NKT cells that correlates with better local tumor control.</p><p>NK infiltration has been associated with positive outcomes in many solid tumors, considered to be due to the positive impact of cytotoxic NK cells in cytotoxic CD8 T-mediated tumor clearance (<xref ref-type="bibr" rid="bib48">Nersesian et al., 2021</xref>). However, the data supporting the independent contribution of NK activity is difficult to discern due to overlap of expression profiles of cytotoxic cells. Surprisingly, markers of cytotoxic cells or specific CD8/CD4 lymphocyte receptors do not perform as indicators of survival from bulk mRNA-seq datasets (<xref ref-type="fig" rid="fig5">Figure 5</xref>). This may be due to sensitivity issues but, more likely, the presence of cytotoxic cells alone does not necessarily indicate beneficial responses in patients (<xref ref-type="bibr" rid="bib48">Nersesian et al., 2021</xref>). This is supported by the limited efficacy of IT strategies to tumors with a high mutational burden. NK cells represent a variety of subsets defined by surface markers, found in the periphery (circulating), secondary lymphoid organs (spleen, lymph nodes), and specific tissues (e.g. lung, liver, uterus) where markers of tissue residency increase retention or prevent egress (<xref ref-type="bibr" rid="bib26">Hashemi and Malarkannan, 2020</xref>). In addition to trNK cells, tumors appear to accumulate NK populations that become less cytotoxic through downregulation of activating receptors, (NKG2D, NKp46, NKp44) and increased expression of inhibitory receptors (NKG2A) or repression/exhaustion markers (e.g. TIGIT, TIM3) (<xref ref-type="bibr" rid="bib26">Hashemi and Malarkannan, 2020</xref>; <xref ref-type="bibr" rid="bib39">Marcon et al., 2020</xref>). Importantly, trNK or hypoactive NK cell subsets commonly display a reduction in cytotoxicity but become highly active immunomodulatory players via expression of XCL1 and XCL2 (<xref ref-type="bibr" rid="bib22">de Andrade et al., 2019</xref>). In melanoma, NK-mediated expression of XCL1 is crucial for the migration of XCR1<sup>+</sup> cDC1 and therefore the non-cytotoxic NK subsets in tumors may be vital for cDC1-mediated cross-presentation of tumor antigens to CD8 T-cells (<xref ref-type="bibr" rid="bib9">Böttcher et al., 2018</xref>). This may explain why levels of CD8 T-cells in tumors or removal of inhibitory signaling is insufficient to gain tumor control. NK-derived FLT3L correlated with increased cDC1 infiltration and improved overall survival and enhanced αPD1 treatment responses in melanoma (<xref ref-type="bibr" rid="bib4">Barry et al., 2018</xref>), while intra-tumoral NK cells correlate with increased T-cell and dendritic cell infiltration and improved survival in neuroblastoma (<xref ref-type="bibr" rid="bib43">Melaiu et al., 2020</xref>). Although our NK_C1 cells are not enriched for <italic>FLT3LG</italic> (data not shown), the data collectively demonstrate that therapeutic strategies aimed at increasing the presence of cDC1 or NK cells may work in combination to support treatments that induce CD8 T-cell activity.</p><p>Our data suggest that combination therapy to stimulate an acute inflammatory response (IR) together with CCR5i/αPD1 (IT) sufficiently modulates the tumor immune microenvironment to improve tumor control. As frequently observed in solid tumors, reduction of cancer cells correlates with intra-tumoral infiltration of NK cells (CD56<sup>bright</sup>CD16<sup>-</sup>) and improved CD8 T-cell penetration (<xref ref-type="bibr" rid="bib77">Wu et al., 2020</xref>). Surprisingly, our tumors were penetrated by tissue-resident, hypoactive NKG2D<sup>-</sup> NK cells, suggesting a population with reduced cytotoxicity (<xref ref-type="fig" rid="fig4">Figure 4F</xref>, <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>) which we correlated to a similar population (NK_C1) identified from scRNA-seq of human PDAC samples (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>). This population was CD56<sup>+</sup>CD16<sup>-</sup>, in keeping with the apparent beneficial association of CD56 expression with PDAC survival we identified above. NKG2C is a marker of adaptive NK cells during viral infections where they offer a potential memory capability to innate immunity (<xref ref-type="bibr" rid="bib10">Brownlie et al., 2021</xref>; <xref ref-type="bibr" rid="bib37">López-Botet et al., 2023</xref>). Adaptive NK cells were first identified as a subpopulation of blood-derived CD16<sup>+</sup> NK cells in response to viral infection but more recently found to be independent of CD16 expression in lung tissue (<xref ref-type="bibr" rid="bib10">Brownlie et al., 2021</xref>). Although we did not specifically examine markers for adaptive NK cells in our mouse model, the expression of NKG2C in the NK_C1 human cluster led us to believe that at least some of these NK cells might be adaptive-like, trNK cells similar to those identified in the lung (<xref ref-type="bibr" rid="bib10">Brownlie et al., 2021</xref>). Notably, these cells were marked with receptors for tissue residency CD103 (<italic>ITGAE</italic>), CD49a (<italic>ITGA1</italic>), chemokine expression (XCL1/2), and lymphocyte exhaustion markers TIM3 (<italic>HAVCR2</italic>, TIGIT, <italic>TNFRSF4</italic>), potentially suggesting conversion of cytotoxic NK cells to an immunomodulatory phenotype that can persist in tissues (<xref ref-type="bibr" rid="bib10">Brownlie et al., 2021</xref>; <xref ref-type="bibr" rid="bib57">Rückert et al., 2022</xref>). scRNA-seq from PDAC tissue confirm that trNKs could mediate recruitment of cDC1s via XCL1-XCR1, but communicate additional signals, including IL-16, LIGHT (<italic>TNFSF14</italic>), and MIF-CD74, which have the potential to upregulate MHC-I expression, antigen presentation, and co-stimulatory molecules to contribute to cross-presentation (<xref ref-type="bibr" rid="bib5">Basha et al., 2012</xref>; <xref ref-type="bibr" rid="bib21">Cruikshank et al., 1987</xref>; <xref ref-type="bibr" rid="bib79">Zou and Hu, 2005</xref>). We also find that trNK may also recruit CD4<sup>+</sup> Tregs via IL-16 but concomitant FAS signaling would lead to Treg apoptosis and support tumor control (<xref ref-type="fig" rid="fig6">Figure 6D</xref>, <xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1</xref>).</p><p>Strikingly, using our trNK signature we find that elevated involvement of trNKs in PDAC correlates with CD8 T-cell recruitment in a cDC1-dependent manner (<xref ref-type="fig" rid="fig6">Figure 6G</xref>). Moreover, this supports a model where the inactivation of cytotoxic NK cells in tumors appears to be a conversion to immunomodulatory trNKs and perhaps an important mechanistic switch from innate to adaptive immunity. Our therapeutic combination strategy of short ablative radiation-induced damage (IR) followed by CCR5i/αPD1 (IT) offers a potential regimen to increase disease-free survival in PDAC. Likewise, trNK-like cells with similar traits are increasingly being observed across a variety of cancers (<xref ref-type="bibr" rid="bib11">Brownlie et al., 2023</xref>; <xref ref-type="bibr" rid="bib35">Kirchhammer et al., 2022</xref>; <xref ref-type="bibr" rid="bib40">Marquardt et al., 2015</xref>). Finally, our trNK signature identifies patients with a significant survival benefit across 14 tumor types, indicating a universal phenomenon attributable to this hypoactive, tissue-resident, immunomodulatory NK subset.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><sec id="s4-1"><title>Mice and cell culture</title><p>Female wildtype C57BL/6 mice (6–8 weeks) were purchased from Charles River (Kent, UK) and maintained in accordance with the UK Animal Law (Scientific Procedures Act 1986). Animal procedures were carried out under local ethics approval. NKPCB-NBC12.1F (KPC-F) cells, derived from a KPC mouse (LSL-Kras<sup>G12D</sup>; LSL-Trp53<sup>R172H</sup>; Pdx1<sup>Cre</sup>) derived from a CD57BL/6 background were cultured in DMEM (Gibco) supplemented with 10% FBS, 2 mM glutamine, 100 U/mL penicillin, 100 µg/mL streptomycin and maintained under 5% CO<sub>2</sub>, 37°C. The cells were kindly donated by Jennifer Morton (Beatson Institute, Glasgow) and stocks were generated to keep cells at low passage numbers and checked regularly for mycoplasma contamination (Lonza).</p></sec><sec id="s4-2"><title>Orthotopic surgery</title><p>A total of 500 KPC-F cells (passages 9–11) were injected into female C57BL/6 mice in a volume of 5 µL in a mixture of 94% Matrigel and 6% DMEM (Gibco) using a 26-gauge syringe (Hamilton). Following anesthesia of the mice using 4% isoflurane/oxygen and clipping of hair, an incision of 2 cm was made in the left abdominal site. The spleen and pancreas were exteriorized using forceps and KPC-F cells were injected in the tail of the pancreas. Successful injection was verified by the appearance of a wheal at the injection site with no leakage through the pancreatic capsule. Spleen and pancreas were gently moved back into the peritoneal cavity; the peritoneum was sutured with absorbable 4.0 Vicryl suture (Ethicon) and the skin was closed using a 7 mm wound clip.</p></sec><sec id="s4-3"><title>In vivo drug treatments and radiation</title><p>Animals were randomized to different treatment groups following orthotopic implementation. For radiation, mice were anesthetized and locally irradiated with 4 Gy using a combination of MRI and the small animal radiation research platform. The CCR5i maraviroc (R&amp;D) was administered intraperitoneally (10 mg/kg in PBS) from day 0 until day 6. Monoclonal Ultra-LEAF purified anti-PD1 antibody (BioLegend) was administered (5 mg/kg in PBS) via IP injection on alternate days from day 1 until day 7. Mice were culled at 30 days or if maximum tumor volume was reached.</p></sec><sec id="s4-4"><title>Monitoring of tumor growth via MRI</title><p>Mice were anesthetized using 1.5–3% isoflurane, positioned into a custom-made, 3D printed, multimodality cradle and scanned using a 4.7 T 310 mm horizontal bore Biospec AVANCE III HD preclinical imaging system equipped with 114 nm bore gradient insert (Bruker BioSpin GmbH, Germany). Respiration was maintained at 40–60 breaths/min and monitored using a pneumatic balloon (VX010, Viomedex Ltd, UK) coupled to a pressure transducer and placed against the chest. A threshold-based respiration gating control signal was generated on a custom-built gating device, which allows efficient multi-slice MRI scanning with limited interference of respiratory motion (<xref ref-type="bibr" rid="bib34">Kinchesh et al., 2019</xref>). Tumor volumes were calculated using ITK-SNAP (<xref ref-type="bibr" rid="bib78">Yushkevich and Gerig, 2016</xref>).</p></sec><sec id="s4-5"><title>Blood and tissue collection</title><p>Following reaching (humane) endpoints, mice were euthanized by approved Schedule 1 methods. Blood (≤1 mL) was collected via cardiac puncture under anesthesia (3–3.5% isoflurance/oxygen) using a 25-gauge syringe (Thermo Fisher Scientific) coated with anticoagulant ACD buffer (0.5 M glucose, 0.5 M trisodium citrate, 0.5 M citric acid; 100 µL). A total of 700 µL of blood was lysed with 12 mL of 1× RBC Lysis buffer and incubated for 10–15 min on a rotor, centrifuged, and washed with buffer (2% FBS, 1 mM EDTA in PBS). Three transverse sections of orthotopic tumors were taken and used for flow cytometry or fixed and stored in 10% neutral buffered formalin. Tumors were disassociated using a mixture of collagenase I, II, and IV (Worthington) and DNAse (Thermo Fisher Scientific) in HBSS (Gibco), and continuously mixed at 850 rpm for 45 min at 37°C, followed by rigors pipetting and additional dissociation for 50 min at 850 rpm and 37°C. The disassociated tissue was strained through a 70 µm cell strainer and neutralized with DMEM+10% FBS prior to incubation with flow antibodies.</p></sec><sec id="s4-6"><title>Multicolor spectral flow cytometry</title><p>A total of 1×10<sup>6</sup> cells for blood and disassociated tissue were surface stained in a 100 µL volume at 4°C in the dark (see <xref ref-type="table" rid="table1">Table 1</xref> for list of antibodies and optimized dilutions). Cells and reference controls were centrifuged at 500<italic>×g</italic> for 2 min at room temperature and fixed and permeabilized using the FOXP3 Fixation/Permeabilization kit (Thermo Fisher Scientific). Samples were intracellularly stained at 4°C in the dark, washed, re-suspended in buffer and stored at 4°C in the dark prior to acquisition. Samples were acquired on a 4-laser Aurora (Cytek) with SpectroFlo software (Cytek, v2). A minimum of 10,000 events for reference control samples and 100,000 of CD45-gated events were recorded. Samples were acquired on a 3-laser (42-channel, V-16, B-16, R-10) or 4-laser (58-channel, UV-16, V-16, B-16, R-10) Cytek Aurora.</p><table-wrap id="table1" position="float"><label>Table 1.</label><caption><title>Aurora spectral panel and antibodies list.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Antigen</th><th align="left" valign="bottom">Clone</th><th align="left" valign="bottom">Fluorochrome</th><th align="left" valign="bottom">Company, catalogue number</th><th align="left" valign="bottom">Dilution</th></tr></thead><tbody><tr><td align="left" valign="bottom">Live/dead</td><td align="left" valign="bottom">–</td><td align="left" valign="bottom">Blue</td><td align="left" valign="bottom">Thermo Fisher, L23105</td><td align="char" char="." valign="bottom">1:1000</td></tr><tr><td align="left" valign="bottom">CD45</td><td align="char" char="hyphen" valign="bottom">30-F11</td><td align="left" valign="bottom">AF532</td><td align="left" valign="bottom">Thermo Fisher, 58-0451-80</td><td align="char" char="." valign="bottom">1:50</td></tr><tr><td align="left" valign="bottom">CD19</td><td align="char" char="." valign="bottom">1D3</td><td align="left" valign="bottom">SB436</td><td align="left" valign="bottom">Thermo Fisher, 62-0193-80</td><td align="char" char="." valign="bottom">1:50</td></tr><tr><td align="left" valign="bottom">CD3</td><td align="char" char="." valign="bottom">17A2</td><td align="left" valign="bottom">eF450</td><td align="left" valign="bottom">BioLegend, 48-0032-80</td><td align="char" char="." valign="bottom">1:50</td></tr><tr><td align="left" valign="bottom">NK1.1</td><td align="left" valign="bottom">PK136</td><td align="left" valign="bottom">BV650</td><td align="left" valign="bottom">BioLegend, 108735</td><td align="char" char="." valign="bottom">1:25</td></tr><tr><td align="left" valign="bottom">CD8a</td><td align="char" char="ndash" valign="bottom">53–6.7</td><td align="left" valign="bottom">BV570</td><td align="left" valign="bottom">BioLegend, 100739</td><td align="char" char="." valign="bottom">1:25</td></tr><tr><td align="left" valign="bottom">CD4</td><td align="left" valign="bottom">RM4-5</td><td align="left" valign="bottom">BV510</td><td align="left" valign="bottom">BD Biosciences, 100553</td><td align="char" char="." valign="bottom">1:100</td></tr><tr><td align="left" valign="bottom">CD25</td><td align="char" char="." valign="bottom">7D4</td><td align="left" valign="bottom">AF647</td><td align="left" valign="bottom">BD Biosciences, 563598</td><td align="char" char="." valign="bottom">1:100</td></tr><tr><td align="left" valign="bottom">FOXP3</td><td align="left" valign="bottom">FJK-16s</td><td align="left" valign="bottom">PE</td><td align="left" valign="bottom">Thermo Fisher, 12-5773-80</td><td align="char" char="." valign="bottom">1:20</td></tr><tr><td align="left" valign="bottom">CD206</td><td align="left" valign="bottom">C068C2</td><td align="left" valign="bottom">BV785</td><td align="left" valign="bottom">BD Biosciences, 141729</td><td align="char" char="." valign="bottom">1:25</td></tr><tr><td align="left" valign="bottom">F4/80</td><td align="left" valign="bottom">T45-2342</td><td align="left" valign="bottom">BV480</td><td align="left" valign="bottom">BD Biosciences, 565635</td><td align="char" char="." valign="bottom">1:100</td></tr><tr><td align="left" valign="bottom">CD80</td><td align="left" valign="bottom">REA983</td><td align="left" valign="bottom">APC</td><td align="left" valign="bottom">Miltenyi Biotech, 130-116-46</td><td align="char" char="." valign="bottom">1:100</td></tr><tr><td align="left" valign="bottom">CD279 (PD-1)</td><td align="left" valign="bottom">J43</td><td align="left" valign="bottom">PE-Cy7</td><td align="left" valign="bottom">Thermo Fisher, 25-9985-82</td><td align="char" char="." valign="bottom">1:25</td></tr><tr><td align="left" valign="bottom">CD195 (CCR5)</td><td align="left" valign="bottom">REA354</td><td align="left" valign="bottom">VB-FITC</td><td align="left" valign="bottom">Miltenyi Biotech, 30-105-141</td><td align="char" char="." valign="bottom">1:20</td></tr><tr><td align="left" valign="bottom">CD11b</td><td align="left" valign="bottom">M1/70</td><td align="left" valign="bottom">AF700</td><td align="left" valign="bottom">BioLegend, 101222</td><td align="char" char="." valign="bottom">1:100</td></tr><tr><td align="left" valign="bottom">Ly6C</td><td align="left" valign="bottom">HK1.4</td><td align="left" valign="bottom">PE-Dazzle</td><td align="left" valign="bottom">BioLegend, 128043</td><td align="char" char="." valign="bottom">1:200</td></tr><tr><td align="left" valign="bottom">Ly6G</td><td align="char" char="." valign="bottom">1A8</td><td align="left" valign="bottom">BV421</td><td align="left" valign="bottom">BioLegend, 127627</td><td align="char" char="." valign="bottom">1:25</td></tr></tbody></table></table-wrap></sec><sec id="s4-7"><title>Immunohistochemistry</title><p>A total of 24 hr post-fixation at room temperature, tissues were transferred to 70% ethanol and stored overnight at 4°C. Fixed tissues were overnight processed using the STP120 Spin Tissue Processor (Thermo Fisher Scientific) and embedded the next day in paraffin wax. Tissues were cut into 4 µm sections using a Leica RM215 microtome and adhered onto SuperFrost Ultra Plus Adhesion slides (Thermo Fisher Scientific) before being dried overnight in a 37°C incubator.</p></sec><sec id="s4-8"><title>Multiplex immunofluorescence</title><p>Multiplex immunofluorescence staining was carried out on 4-µm-thick FFPE sections by the Translation Histopathology Laboratory (THL, University of Oxford). In brief, sections were stained using the OPAL protocol (AKYOA Biosciences) on a Leica BOND RXm Auto-Stainer (Leica, Microsystems). Six consecutive staining cycles were performed using primary antibody-Opal fluorophore pairings detailed in <xref ref-type="table" rid="table2">Table 2</xref>. Primary antibodies were incubated for 30 min and detected using the BOND Polymer (Lecia Biosystems) as per the manufacturer’s instructions. In brief, sections were baked, dewaxed with BOND dewax solution, rehydrated with alcohol, and incubated with Epitope Retrieval Solution 1 or 2 (ER1, ER2) (Lecia Biosystems) at 100°C for 20 min. Sections were washed X3 with BOND wash, blocked with peroxidase block (3–4% [vol/vol] hydrogen peroxide) for 5 min and subsequently washed 3× with BOND wash. Primary antibodies were incubated for 30 min, washed as before, and incubated with Anti-Rabbit Poly-HRP IgG for 8 min. Sections were washed twice in BOND wash, once in deionized water prior to Opal antibody incubation for 10 min. Sections were washed three times in deionized water and finally incubated with spectral DAPI (Akoya Biosciences) and slides mounted with VECTASHIELD Vibrance Antifade Mounting Medium (Vector Laboratories). Whole slide multispectral images were obtained on the AKOYA Bioscience Vectra Polaris (scanned at ×20 magnification). Batch analysis and spectral unmixing of the tissues was performed with inForm 2.4.11 software. Batch analyzed multispectral images were fused in HALO AI to produce a spectrally unmixed reconstructed whole tissue image.</p><table-wrap id="table2" position="float"><label>Table 2.</label><caption><title>Multiplex IF panel.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Antigen</th><th align="left" valign="bottom">Coupled to</th><th align="left" valign="bottom">Company, catalogue number</th><th align="left" valign="bottom">Dilution</th></tr></thead><tbody><tr><td align="left" valign="bottom">NKG2D</td><td align="left" valign="bottom">Opal 520</td><td align="left" valign="bottom">Abcam, ab203353</td><td align="char" char="." valign="bottom">1:600</td></tr><tr><td align="left" valign="bottom">CD161/NK1.1</td><td align="left" valign="bottom">Opal 620</td><td align="left" valign="bottom">Abcam, ab234107</td><td align="char" char="." valign="bottom">1:20,000</td></tr><tr><td align="left" valign="bottom">CD3</td><td align="left" valign="bottom">Opal 480</td><td align="left" valign="bottom">Abcam, ab5690</td><td align="char" char="." valign="bottom">1:300</td></tr><tr><td align="left" valign="bottom">CD8</td><td align="left" valign="bottom">Opal 570</td><td align="left" valign="bottom">Cell Signaling, 98941</td><td align="char" char="." valign="bottom">1:800</td></tr><tr><td align="left" valign="bottom">E-cadherin</td><td align="left" valign="bottom">Opal 780</td><td align="left" valign="bottom">Cell Signaling, 3195</td><td align="char" char="." valign="bottom">1:500</td></tr></tbody></table></table-wrap></sec><sec id="s4-9"><title>Data analysis and statistics</title><p>Flow cytometry data was analyzed using FlowJo software. HALO AI software was used for analysis of multiplex immunofluorescence. Due to variations in staining, thresholds for individual colors were manually determined for individual tissue sections and analysis was carried out blinded fashion.</p></sec><sec id="s4-10"><title>Bulk RNA-seq analysis</title><p>Gene expression and clinical data were obtained via the TCGAbiolinks (2.24.3) R package for TCGA-PAAD (‘Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma’, 2017), and GDC data portal (<ext-link ext-link-type="uri" xlink:href="https://portal.gdc.cancer.gov/analysis_page?app=Downloads">https://portal.gdc.cancer.gov/analysis_page?app=Downloads</ext-link>) for CPTAC-3 (<xref ref-type="bibr" rid="bib14">Cao et al., 2021</xref>). Raw read counts were transformed to counts-per-million (CPM) and log-CPM using the ‘edgeR’ Bioconductor package (3.38.0). Inter-sample variation was normalized using the trimmed mean of M-values (TMM) method of ‘edgeR’. The ‘GSVA’ package (1.44.0) was used to generate the trNK signature (<xref ref-type="supplementary-material" rid="fig6sdata1">Figure 6—source data 1</xref>) score for individual patients. Gene signature scores and gene expressions were transformed to categorical groups via the maximally selected rank statistics (maxstat) method of the ‘survival’ package. Kaplan-Meier plots were performed using the ‘survival’ (3.3-1), and ‘survminer’ (0.4.9) R packages and the log-rank test was used to statistically compare survival estimates between groups.</p></sec><sec id="s4-11"><title>TCGA pan-cancer analysis</title><p>For the pan-cancer TCGA survival analysis, gene expression and clinical data were obtained via the <ext-link ext-link-type="uri" xlink:href="https://xenabrowser.net/datapages/?cohort=TCGA%20Pan-Cancer%20(PANCAN)&amp;removeHub=https%3A%2F%2Fxena.treehouse.gi.ucsc.edu%3A443">UCSC Xena platform</ext-link>. The trNK signature was analyzed for the individual cancer types for Kaplan-Meier survival similar to above. Univariate COX regression of the NK signature for both overall survival and disease-free survival was performed using the ‘ezcox’ (1.0.2) package.</p></sec><sec id="s4-12"><title>Analysis of human scRNA-seq data</title><p>Raw scRNA-seq data from the Steele dataset (<xref ref-type="bibr" rid="bib64">Steele et al., 2020</xref>) were obtained from the NIH GEO database by using the accession number GSE155698. The samples included 16 treatment naïve primary tumors (6 surgical resections and 10 fine-needle biopsy specimens) and 3 non-malignant pancreas samples. All analysis was performed using the ‘Seurat’ (4.3.0) package. Cells with low number of detected genes (&lt;200), high number of mitochondrial genes (&gt;25%), and high number of gene counts (&gt;100,000) were filtered out from further analysis. Data were integrated to remove batch effects using a reciprocal principal component analysis (rPCA) based on the developer’s pipeline (<ext-link ext-link-type="uri" xlink:href="https://satijalab.org/seurat/articles/integration_rpca.html">https://satijalab.org/seurat/articles/integration_rpca.html</ext-link>). Following integration, data were scaled, and visualized using UMAP on the top 40 principal components. Cell clusters were identified using the ‘FindNeighbors’ and ‘FindClusters’ Seurat functions and annotated based on canonical cell markers. Gene expression differences across cell clusters were visualized using the ‘DotPlot’ and ‘DoHeatmap’ Seurat functions. Curated gene sets were calculated using the ‘AddModuleScore’ and compared using violin plots with the ‘VlnPlot’ function.</p></sec><sec id="s4-13"><title>Inference of cell-cell interactions</title><p>The ‘CellChat’ (1.6.1) R package was used to identify and visualize significant cell-cell interactions based on curated ligand-receptor pairs for both secreted signaling and cell-cell contact categories (<xref ref-type="bibr" rid="bib29">Jin et al., 2021</xref>). Network centrality scores were calculated with the ‘netAnalysis_computeCentrality’ function and global communication patterns were visualized using the ‘netAnalysis_signalingRole_heatmap’. Specific interactions of cells of interest were visualized by circle and dot plots by using the ‘netVisual_circle’ and ‘netVisual_bubble’ functions, respectively.</p></sec><sec id="s4-14"><title>Packages/tools used for analysis</title><table-wrap id="inlinetable1" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Package (version)</th><th align="left" valign="bottom">Repository</th><th align="left" valign="bottom">Source or reference</th></tr></thead><tbody><tr><td align="left" valign="bottom">TCGABiolinks 2.24.3</td><td align="left" valign="bottom">Bioconductor</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://bioconductor.org/packages/TCGAbiolinks/">https://bioconductor.org/packages/TCGAbiolinks/</ext-link>; <xref ref-type="bibr" rid="bib20">Colaprico et al., 2008</xref></td></tr><tr><td align="left" valign="bottom">edgeR 3.38.0</td><td align="left" valign="bottom">Bioconductor</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://bioconductor.org/packages/edgeR/">https://bioconductor.org/packages/edgeR/</ext-link>; <xref ref-type="bibr" rid="bib17">Chen et al., 2016</xref></td></tr><tr><td align="left" valign="bottom">GSVA 1.44.0</td><td align="left" valign="bottom">Bioconductor</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://bioconductor.org/packages/GSVA/">https://bioconductor.org/packages/GSVA/</ext-link>; <xref ref-type="bibr" rid="bib15">Castelo et al., 2004</xref></td></tr><tr><td align="left" valign="bottom">Survival 3.3-1</td><td align="left" valign="bottom">CRAN</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://cran.r-project.org/package=survival">https://cran.r-project.org/package=survival</ext-link>; <xref ref-type="bibr" rid="bib66">Therneau et al., 2022</xref></td></tr><tr><td align="left" valign="bottom">Survminer 0.4.9</td><td align="left" valign="bottom">CRAN</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://cran.r-project.org/package=survminer">https://cran.r-project.org/package=survminer</ext-link>; <xref ref-type="bibr" rid="bib33">Kassambara et al., 2021</xref></td></tr><tr><td align="left" valign="bottom">Ezcox 1.0.2</td><td align="left" valign="bottom">CRAN</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://cran.r-project.org/package=ezcox">https://cran.r-project.org/package=ezcox</ext-link> ; <xref ref-type="bibr" rid="bib70">Wang, 2021</xref></td></tr><tr><td align="left" valign="bottom">Seurat 4.3.0</td><td align="left" valign="bottom">CRAN</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://cran.r-project.org/package=Seurat">https://cran.r-project.org/package=Seurat</ext-link>; <xref ref-type="bibr" rid="bib13">Butler et al., 2022</xref></td></tr><tr><td align="left" valign="bottom">CellChat 1.6.1</td><td align="left" valign="bottom">GitHub</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://github.com/sqjin/CellChat">https://github.com/sqjin/CellChat</ext-link>; <xref ref-type="bibr" rid="bib30">Jin, 2023</xref></td></tr><tr><td align="left" valign="bottom">Tidyverse 2.0.0</td><td align="left" valign="bottom">CRAN</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://cran.r-project.org/package=tidyverse">https://cran.r-project.org/package=tidyverse</ext-link>; <xref ref-type="bibr" rid="bib75">Wickham, 2023</xref></td></tr></tbody></table></table-wrap></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Formal analysis, Visualization, Writing – original draft</p></fn><fn fn-type="con" id="con2"><p>Data curation, Formal analysis, Visualization, Methodology, Writing – original draft</p></fn><fn fn-type="con" id="con3"><p>Investigation, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con4"><p>Data curation, Formal analysis, Methodology</p></fn><fn fn-type="con" id="con5"><p>Data curation, Formal analysis, Investigation, Methodology</p></fn><fn fn-type="con" id="con6"><p>Resources, Software</p></fn><fn fn-type="con" id="con7"><p>Formal analysis</p></fn><fn fn-type="con" id="con8"><p>Methodology</p></fn><fn fn-type="con" id="con9"><p>Supervision, Methodology</p></fn><fn fn-type="con" id="con10"><p>Funding acquisition</p></fn><fn fn-type="con" id="con11"><p>Conceptualization, Project administration</p></fn><fn fn-type="con" id="con12"><p>Resources, Supervision, Funding acquisition, Methodology</p></fn><fn fn-type="con" id="con13"><p>Formal analysis, Supervision, Investigation, Visualization, Methodology, Project administration</p></fn><fn fn-type="con" id="con14"><p>Conceptualization, Data curation, Formal analysis, Supervision, Funding acquisition, Investigation, Visualization, Methodology, Writing – original draft, Project administration, Writing – review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>This study was performed in strict accordance with the recommendation in the guide for the care of laboratory animals and the Animals (Scientific Procedures) Act 1986 (UK). All animals were handled according to at University of Oxford Biomedical services and Protocols were approved by Animal Welfare Ethical Review Body under the Personal project licence PF0F1EF6E at appropriate facilities within Oxford the hold establishment licences.</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-92672-mdarchecklist1-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>The authors confirm that the data supporting the findings of this study are available within the article and as source data. Sources of publicly available data and analysis packages are referenced with the text or methods.</p></sec><ack id="ack"><title>Acknowledgements</title><p>The authors thank the oncology preclinical imaging core (S Smart, V Kersemans, PD Allen, M Hill, and JM Thompson) for providing contracted small animal MRI and radiotherapy services, Biomedical Services (K Watson) and H Xu for technical support. Funding: Kidani Memorial Trust, Pancreatic Cancer UK, Cancer Research UK, Precision Panc (A25233), CRUK Beatson Institute (A31287, A29996), and CRUK Scotland Centre (CTRQQR-2021\100006). This work was supported by Cancer Research UK (CR-UK) grant number CTRQQR-2021\100002, through the Cancer Research UK Oxford Centre.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ajuebor</surname><given-names>MN</given-names></name><name><surname>Wondimu</surname><given-names>Z</given-names></name><name><surname>Hogaboam</surname><given-names>CM</given-names></name><name><surname>Le</surname><given-names>T</given-names></name><name><surname>Proudfoot</surname><given-names>AEI</given-names></name><name><surname>Swain</surname><given-names>MG</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>CCR5 deficiency drives enhanced natural killer cell trafficking to and activation within the liver in murine T cell-mediated hepatitis</article-title><source>The American Journal of Pathology</source><volume>170</volume><fpage>1975</fpage><lpage>1988</lpage><pub-id pub-id-type="doi">10.2353/ajpath.2007.060690</pub-id><pub-id pub-id-type="pmid">17525265</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aldinucci</surname><given-names>D</given-names></name><name><surname>Borghese</surname><given-names>C</given-names></name><name><surname>Casagrande</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>The CCL5/CCR5 axis in cancer progression</article-title><source>Cancers</source><volume>12</volume><elocation-id>1765</elocation-id><pub-id pub-id-type="doi">10.3390/cancers12071765</pub-id><pub-id pub-id-type="pmid">32630699</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alshetaiwi</surname><given-names>H</given-names></name><name><surname>Pervolarakis</surname><given-names>N</given-names></name><name><surname>McIntyre</surname><given-names>LL</given-names></name><name><surname>Ma</surname><given-names>D</given-names></name><name><surname>Nguyen</surname><given-names>Q</given-names></name><name><surname>Rath</surname><given-names>JA</given-names></name><name><surname>Nee</surname><given-names>K</given-names></name><name><surname>Hernandez</surname><given-names>G</given-names></name><name><surname>Evans</surname><given-names>K</given-names></name><name><surname>Torosian</surname><given-names>L</given-names></name><name><surname>Silva</surname><given-names>A</given-names></name><name><surname>Walsh</surname><given-names>C</given-names></name><name><surname>Kessenbrock</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Defining the emergence of myeloid-derived suppressor cells in breast cancer using single-cell transcriptomics</article-title><source>Science Immunology</source><volume>5</volume><elocation-id>eaay6017</elocation-id><pub-id pub-id-type="doi">10.1126/sciimmunol.aay6017</pub-id><pub-id pub-id-type="pmid">32086381</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barry</surname><given-names>KC</given-names></name><name><surname>Hsu</surname><given-names>J</given-names></name><name><surname>Broz</surname><given-names>ML</given-names></name><name><surname>Cueto</surname><given-names>FJ</given-names></name><name><surname>Binnewies</surname><given-names>M</given-names></name><name><surname>Combes</surname><given-names>AJ</given-names></name><name><surname>Nelson</surname><given-names>AE</given-names></name><name><surname>Loo</surname><given-names>K</given-names></name><name><surname>Kumar</surname><given-names>R</given-names></name><name><surname>Rosenblum</surname><given-names>MD</given-names></name><name><surname>Alvarado</surname><given-names>MD</given-names></name><name><surname>Wolf</surname><given-names>DM</given-names></name><name><surname>Bogunovic</surname><given-names>D</given-names></name><name><surname>Bhardwaj</surname><given-names>N</given-names></name><name><surname>Daud</surname><given-names>AI</given-names></name><name><surname>Ha</surname><given-names>PK</given-names></name><name><surname>Ryan</surname><given-names>WR</given-names></name><name><surname>Pollack</surname><given-names>JL</given-names></name><name><surname>Samad</surname><given-names>B</given-names></name><name><surname>Asthana</surname><given-names>S</given-names></name><name><surname>Chan</surname><given-names>V</given-names></name><name><surname>Krummel</surname><given-names>MF</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>A natural killer-dendritic cell axis defines checkpoint therapy-responsive tumor microenvironments</article-title><source>Nature Medicine</source><volume>24</volume><fpage>1178</fpage><lpage>1191</lpage><pub-id pub-id-type="doi">10.1038/s41591-018-0085-8</pub-id><pub-id pub-id-type="pmid">29942093</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Basha</surname><given-names>G</given-names></name><name><surname>Omilusik</surname><given-names>K</given-names></name><name><surname>Chavez-Steenbock</surname><given-names>A</given-names></name><name><surname>Reinicke</surname><given-names>AT</given-names></name><name><surname>Lack</surname><given-names>N</given-names></name><name><surname>Choi</surname><given-names>KB</given-names></name><name><surname>Jefferies</surname><given-names>WA</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>A CD74-dependent MHC class I endolysosomal cross-presentation pathway</article-title><source>Nature Immunology</source><volume>13</volume><fpage>237</fpage><lpage>245</lpage><pub-id pub-id-type="doi">10.1038/ni.2225</pub-id><pub-id pub-id-type="pmid">22306692</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benkhaled</surname><given-names>S</given-names></name><name><surname>Peters</surname><given-names>C</given-names></name><name><surname>Jullian</surname><given-names>N</given-names></name><name><surname>Arsenijevic</surname><given-names>T</given-names></name><name><surname>Navez</surname><given-names>J</given-names></name><name><surname>Van Gestel</surname><given-names>D</given-names></name><name><surname>Moretti</surname><given-names>L</given-names></name><name><surname>Van Laethem</surname><given-names>J-L</given-names></name><name><surname>Bouchart</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Combination, modulation and interplay of modern radiotherapy with the tumor microenvironment and targeted therapies in pancreatic cancer: which candidates to boost radiotherapy?</article-title><source>Cancers</source><volume>15</volume><elocation-id>768</elocation-id><pub-id pub-id-type="doi">10.3390/cancers15030768</pub-id><pub-id pub-id-type="pmid">36765726</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bialecki</surname><given-names>E</given-names></name><name><surname>Macho Fernandez</surname><given-names>E</given-names></name><name><surname>Ivanov</surname><given-names>S</given-names></name><name><surname>Paget</surname><given-names>C</given-names></name><name><surname>Fontaine</surname><given-names>J</given-names></name><name><surname>Rodriguez</surname><given-names>F</given-names></name><name><surname>Lebeau</surname><given-names>L</given-names></name><name><surname>Ehret</surname><given-names>C</given-names></name><name><surname>Frisch</surname><given-names>B</given-names></name><name><surname>Trottein</surname><given-names>F</given-names></name><name><surname>Faveeuw</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Spleen-resident CD4+ and CD4- CD8α- dendritic cell subsets differ in their ability to prime invariant natural killer T lymphocytes</article-title><source>PLOS ONE</source><volume>6</volume><elocation-id>e26919</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0026919</pub-id><pub-id pub-id-type="pmid">22066016</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bockorny</surname><given-names>B</given-names></name><name><surname>Semenisty</surname><given-names>V</given-names></name><name><surname>Macarulla</surname><given-names>T</given-names></name><name><surname>Borazanci</surname><given-names>E</given-names></name><name><surname>Wolpin</surname><given-names>BM</given-names></name><name><surname>Stemmer</surname><given-names>SM</given-names></name><name><surname>Golan</surname><given-names>T</given-names></name><name><surname>Geva</surname><given-names>R</given-names></name><name><surname>Borad</surname><given-names>MJ</given-names></name><name><surname>Pedersen</surname><given-names>KS</given-names></name><name><surname>Park</surname><given-names>JO</given-names></name><name><surname>Ramirez</surname><given-names>RA</given-names></name><name><surname>Abad</surname><given-names>DG</given-names></name><name><surname>Feliu</surname><given-names>J</given-names></name><name><surname>Muñoz</surname><given-names>A</given-names></name><name><surname>Ponz-Sarvise</surname><given-names>M</given-names></name><name><surname>Peled</surname><given-names>A</given-names></name><name><surname>Lustig</surname><given-names>TM</given-names></name><name><surname>Bohana-Kashtan</surname><given-names>O</given-names></name><name><surname>Shaw</surname><given-names>SM</given-names></name><name><surname>Sorani</surname><given-names>E</given-names></name><name><surname>Chaney</surname><given-names>M</given-names></name><name><surname>Kadosh</surname><given-names>S</given-names></name><name><surname>Vainstein Haras</surname><given-names>A</given-names></name><name><surname>Von Hoff</surname><given-names>DD</given-names></name><name><surname>Hidalgo</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial</article-title><source>Nature Medicine</source><volume>26</volume><fpage>878</fpage><lpage>885</lpage><pub-id pub-id-type="doi">10.1038/s41591-020-0880-x</pub-id><pub-id pub-id-type="pmid">32451495</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Böttcher</surname><given-names>JP</given-names></name><name><surname>Bonavita</surname><given-names>E</given-names></name><name><surname>Chakravarty</surname><given-names>P</given-names></name><name><surname>Blees</surname><given-names>H</given-names></name><name><surname>Cabeza-Cabrerizo</surname><given-names>M</given-names></name><name><surname>Sammicheli</surname><given-names>S</given-names></name><name><surname>Rogers</surname><given-names>NC</given-names></name><name><surname>Sahai</surname><given-names>E</given-names></name><name><surname>Zelenay</surname><given-names>S</given-names></name><name><surname>Reis e Sousa</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>NK cells stimulate recruitment of cdc1 into the tumor microenvironment promoting cancer immune control</article-title><source>Cell</source><volume>172</volume><fpage>1022</fpage><lpage>1037</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2018.01.004</pub-id><pub-id pub-id-type="pmid">29429633</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brownlie</surname><given-names>D</given-names></name><name><surname>Scharenberg</surname><given-names>M</given-names></name><name><surname>Mold</surname><given-names>JE</given-names></name><name><surname>Hård</surname><given-names>J</given-names></name><name><surname>Kekäläinen</surname><given-names>E</given-names></name><name><surname>Buggert</surname><given-names>M</given-names></name><name><surname>Nguyen</surname><given-names>S</given-names></name><name><surname>Wilson</surname><given-names>JN</given-names></name><name><surname>Al-Ameri</surname><given-names>M</given-names></name><name><surname>Ljunggren</surname><given-names>HG</given-names></name><name><surname>Marquardt</surname><given-names>N</given-names></name><name><surname>Michaëlsson</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Expansions of adaptive-like NK cells with a tissue-resident phenotype in human lung and blood</article-title><source>PNAS</source><volume>118</volume><elocation-id>e2016580118</elocation-id><pub-id pub-id-type="doi">10.1073/pnas.2016580118</pub-id><pub-id pub-id-type="pmid">33836578</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brownlie</surname><given-names>D</given-names></name><name><surname>von Kries</surname><given-names>A</given-names></name><name><surname>Valenzano</surname><given-names>G</given-names></name><name><surname>Wild</surname><given-names>N</given-names></name><name><surname>Yilmaz</surname><given-names>E</given-names></name><name><surname>Säfholm</surname><given-names>J</given-names></name><name><surname>Al-Ameri</surname><given-names>M</given-names></name><name><surname>Alici</surname><given-names>E</given-names></name><name><surname>Ljunggren</surname><given-names>HG</given-names></name><name><surname>Schliemann</surname><given-names>I</given-names></name><name><surname>Aricak</surname><given-names>O</given-names></name><name><surname>Haglund de Flon</surname><given-names>F</given-names></name><name><surname>Michaëlsson</surname><given-names>J</given-names></name><name><surname>Marquardt</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Accumulation of tissue-resident natural killer cells, innate lymphoid cells, and CD8<sup>+</sup> T cells towards the center of human lung tumors</article-title><source>Oncoimmunology</source><volume>12</volume><elocation-id>2233402</elocation-id><pub-id pub-id-type="doi">10.1080/2162402X.2023.2233402</pub-id><pub-id pub-id-type="pmid">37448786</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bryceson</surname><given-names>YT</given-names></name><name><surname>Ljunggren</surname><given-names>HG</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Tumor cell recognition by the NK cell activating receptor NKG2D</article-title><source>European Journal of Immunology</source><volume>38</volume><fpage>2957</fpage><lpage>2961</lpage><pub-id pub-id-type="doi">10.1002/eji.200838833</pub-id><pub-id pub-id-type="pmid">18979516</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Butler</surname><given-names>A</given-names></name><name><surname>Choudhary</surname><given-names>S</given-names></name><name><surname>Collins</surname><given-names>D</given-names></name><name><surname>Darby</surname><given-names>C</given-names></name><name><surname>Farrell</surname><given-names>J</given-names></name><name><surname>Grabski</surname><given-names>I</given-names></name><name><surname>Hafemeister</surname><given-names>C</given-names></name><name><surname>Hao</surname><given-names>Y</given-names></name><name><surname>Hartman</surname><given-names>A</given-names></name><name><surname>Hoffman</surname><given-names>P</given-names></name><name><surname>Jain</surname><given-names>J</given-names></name><name><surname>Jiang</surname><given-names>L</given-names></name><name><surname>Kowalski</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Molla</surname><given-names>G</given-names></name><name><surname>Papalexi</surname><given-names>E</given-names></name><name><surname>Roelli</surname><given-names>P</given-names></name><name><surname>Satija</surname><given-names>R</given-names></name><name><surname>Shekhar</surname><given-names>K</given-names></name><name><surname>Srivastava</surname><given-names>A</given-names></name><name><surname>Stuart</surname><given-names>T</given-names></name><name><surname>Torkenczy</surname><given-names>K</given-names></name><name><surname>Zheng</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2022">2022</year><data-title>Seurat: tools for single cell genomics</data-title><version designator="4.3.0">4.3.0</version><source>CRAN</source><ext-link ext-link-type="uri" xlink:href="https://cran.r-project.org/package=Seurat">https://cran.r-project.org/package=Seurat</ext-link></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>L</given-names></name><name><surname>Huang</surname><given-names>C</given-names></name><name><surname>Cui Zhou</surname><given-names>D</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Lih</surname><given-names>TM</given-names></name><name><surname>Savage</surname><given-names>SR</given-names></name><name><surname>Krug</surname><given-names>K</given-names></name><name><surname>Clark</surname><given-names>DJ</given-names></name><name><surname>Schnaubelt</surname><given-names>M</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Veiga Leprevost</surname><given-names>F</given-names></name><name><surname>Eguez</surname><given-names>RV</given-names></name><name><surname>Yang</surname><given-names>W</given-names></name><name><surname>Pan</surname><given-names>J</given-names></name><name><surname>Wen</surname><given-names>B</given-names></name><name><surname>Dou</surname><given-names>Y</given-names></name><name><surname>Jiang</surname><given-names>W</given-names></name><name><surname>Liao</surname><given-names>Y</given-names></name><name><surname>Shi</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Proteogenomic characterization of pancreatic ductal adenocarcinoma</article-title><source>Cell</source><volume>184</volume><fpage>5031</fpage><lpage>5052</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2021.08.023</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Castelo</surname><given-names>R</given-names></name><name><surname>Guinney</surname><given-names>J</given-names></name><name><surname>Sergushichev</surname><given-names>A</given-names></name><name><surname>Rodriguez</surname><given-names>PS</given-names></name><name><surname>Klenk</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2004">2004</year><data-title>Gene set variation analysis for microarray and RNA-seq data</data-title><version designator="1.44.0">1.44.0</version><source>Bioconductor</source><ext-link ext-link-type="uri" xlink:href="https://bioconductor.org/packages/GSVA/">https://bioconductor.org/packages/GSVA/</ext-link></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caushi</surname><given-names>JX</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Ji</surname><given-names>Z</given-names></name><name><surname>Vaghasia</surname><given-names>A</given-names></name><name><surname>Zhang</surname><given-names>B</given-names></name><name><surname>Hsiue</surname><given-names>EHC</given-names></name><name><surname>Mog</surname><given-names>BJ</given-names></name><name><surname>Hou</surname><given-names>W</given-names></name><name><surname>Justesen</surname><given-names>S</given-names></name><name><surname>Blosser</surname><given-names>R</given-names></name><name><surname>Tam</surname><given-names>A</given-names></name><name><surname>Anagnostou</surname><given-names>V</given-names></name><name><surname>Cottrell</surname><given-names>TR</given-names></name><name><surname>Guo</surname><given-names>H</given-names></name><name><surname>Chan</surname><given-names>HY</given-names></name><name><surname>Singh</surname><given-names>D</given-names></name><name><surname>Thapa</surname><given-names>S</given-names></name><name><surname>Dykema</surname><given-names>AG</given-names></name><name><surname>Burman</surname><given-names>P</given-names></name><name><surname>Choudhury</surname><given-names>B</given-names></name><name><surname>Aparicio</surname><given-names>L</given-names></name><name><surname>Cheung</surname><given-names>LS</given-names></name><name><surname>Lanis</surname><given-names>M</given-names></name><name><surname>Belcaid</surname><given-names>Z</given-names></name><name><surname>El Asmar</surname><given-names>M</given-names></name><name><surname>Illei</surname><given-names>PB</given-names></name><name><surname>Wang</surname><given-names>R</given-names></name><name><surname>Meyers</surname><given-names>J</given-names></name><name><surname>Schuebel</surname><given-names>K</given-names></name><name><surname>Gupta</surname><given-names>A</given-names></name><name><surname>Skaist</surname><given-names>A</given-names></name><name><surname>Wheelan</surname><given-names>S</given-names></name><name><surname>Naidoo</surname><given-names>J</given-names></name><name><surname>Marrone</surname><given-names>KA</given-names></name><name><surname>Brock</surname><given-names>M</given-names></name><name><surname>Ha</surname><given-names>J</given-names></name><name><surname>Bush</surname><given-names>EL</given-names></name><name><surname>Park</surname><given-names>BJ</given-names></name><name><surname>Bott</surname><given-names>M</given-names></name><name><surname>Jones</surname><given-names>DR</given-names></name><name><surname>Reuss</surname><given-names>JE</given-names></name><name><surname>Velculescu</surname><given-names>VE</given-names></name><name><surname>Chaft</surname><given-names>JE</given-names></name><name><surname>Kinzler</surname><given-names>KW</given-names></name><name><surname>Zhou</surname><given-names>S</given-names></name><name><surname>Vogelstein</surname><given-names>B</given-names></name><name><surname>Taube</surname><given-names>JM</given-names></name><name><surname>Hellmann</surname><given-names>MD</given-names></name><name><surname>Brahmer</surname><given-names>JR</given-names></name><name><surname>Merghoub</surname><given-names>T</given-names></name><name><surname>Forde</surname><given-names>PM</given-names></name><name><surname>Yegnasubramanian</surname><given-names>S</given-names></name><name><surname>Ji</surname><given-names>H</given-names></name><name><surname>Pardoll</surname><given-names>DM</given-names></name><name><surname>Smith</surname><given-names>KN</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers</article-title><source>Nature</source><volume>596</volume><fpage>126</fpage><lpage>132</lpage><pub-id pub-id-type="doi">10.1038/s41586-021-03752-4</pub-id><pub-id pub-id-type="pmid">34290408</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Lun</surname><given-names>ATL</given-names></name><name><surname>McCarthy</surname><given-names>DJ</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Baldoni</surname><given-names>P</given-names></name><name><surname>Ritchie</surname><given-names>ME</given-names></name><name><surname>Phipson</surname><given-names>B</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Zhou</surname><given-names>X</given-names></name><name><surname>Robinson</surname><given-names>MD</given-names></name><name><surname>Smyth</surname><given-names>GK</given-names></name></person-group><year iso-8601-date="2016">2016</year><data-title>Empirical analysis of digital gene expression data in R</data-title><version designator="3.38.0">3.38.0</version><source>Bioconductor</source><ext-link ext-link-type="uri" xlink:href="https://bioconductor.org/packages/edgeR/">https://bioconductor.org/packages/edgeR/</ext-link></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>IM</given-names></name><name><surname>Johansen</surname><given-names>JS</given-names></name><name><surname>Theile</surname><given-names>S</given-names></name><name><surname>Hjaltelin</surname><given-names>JX</given-names></name><name><surname>Novitski</surname><given-names>SI</given-names></name><name><surname>Brunak</surname><given-names>S</given-names></name><name><surname>Hasselby</surname><given-names>JP</given-names></name><name><surname>Willemoe</surname><given-names>GL</given-names></name><name><surname>Lorentzen</surname><given-names>T</given-names></name><name><surname>Madsen</surname><given-names>K</given-names></name><name><surname>Jensen</surname><given-names>BV</given-names></name><name><surname>Wilken</surname><given-names>EE</given-names></name><name><surname>Geertsen</surname><given-names>P</given-names></name><name><surname>Behrens</surname><given-names>C</given-names></name><name><surname>Nolsoe</surname><given-names>C</given-names></name><name><surname>Hermann</surname><given-names>KL</given-names></name><name><surname>Svane</surname><given-names>IM</given-names></name><name><surname>Nielsen</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Randomized phase ii study of nivolumab with or without ipilimumab combined with stereotactic body radiotherapy for refractory metastatic pancreatic cancer (CheckPAC)</article-title><source>Journal of Clinical Oncology</source><volume>40</volume><fpage>3180</fpage><lpage>3189</lpage><pub-id pub-id-type="doi">10.1200/JCO.21.02511</pub-id><pub-id pub-id-type="pmid">35476508</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chouari</surname><given-names>T</given-names></name><name><surname>La Costa</surname><given-names>FS</given-names></name><name><surname>Merali</surname><given-names>N</given-names></name><name><surname>Jessel</surname><given-names>MD</given-names></name><name><surname>Sivakumar</surname><given-names>S</given-names></name><name><surname>Annels</surname><given-names>N</given-names></name><name><surname>Frampton</surname><given-names>AE</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Advances in immunotherapeutics in pancreatic ductal adenocarcinoma</article-title><source>Cancers</source><volume>15</volume><elocation-id>4265</elocation-id><pub-id pub-id-type="doi">10.3390/cancers15174265</pub-id><pub-id pub-id-type="pmid">37686543</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Colaprico</surname><given-names>A</given-names></name><name><surname>Silva</surname><given-names>TC</given-names></name><name><surname>Olsen</surname><given-names>C</given-names></name><name><surname>Garofano</surname><given-names>L</given-names></name><name><surname>Garolini</surname><given-names>D</given-names></name><name><surname>Cava</surname><given-names>C</given-names></name><name><surname>Sabedot</surname><given-names>T</given-names></name><name><surname>Malta</surname><given-names>T</given-names></name><name><surname>Pagnotta</surname><given-names>SM</given-names></name><name><surname>Castiglioni</surname><given-names>I</given-names></name><name><surname>Ceccarelli</surname><given-names>M</given-names></name><name><surname>Bontempi</surname><given-names>G</given-names></name><name><surname>Noushmehr</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2008">2008</year><data-title>TCGAbiolinks: an R/bioconductor package for integrative analysis with GDC data</data-title><version designator="2.24.3">2.24.3</version><source>Bioconductor</source><ext-link ext-link-type="uri" xlink:href="https://bioconductor.org/packages/TCGAbiolinks/">https://bioconductor.org/packages/TCGAbiolinks/</ext-link></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cruikshank</surname><given-names>WW</given-names></name><name><surname>Berman</surname><given-names>JS</given-names></name><name><surname>Theodore</surname><given-names>AC</given-names></name><name><surname>Bernardo</surname><given-names>J</given-names></name><name><surname>Center</surname><given-names>DM</given-names></name></person-group><year iso-8601-date="1987">1987</year><article-title>Lymphokine activation of T4+ T lymphocytes and monocytes</article-title><source>Journal of Immunology</source><volume>138</volume><fpage>3817</fpage><lpage>3823</lpage><pub-id pub-id-type="pmid">3108375</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Andrade</surname><given-names>LF</given-names></name><name><surname>Lu</surname><given-names>Y</given-names></name><name><surname>Luoma</surname><given-names>A</given-names></name><name><surname>Ito</surname><given-names>Y</given-names></name><name><surname>Pan</surname><given-names>D</given-names></name><name><surname>Pyrdol</surname><given-names>JW</given-names></name><name><surname>Yoon</surname><given-names>CH</given-names></name><name><surname>Yuan</surname><given-names>GC</given-names></name><name><surname>Wucherpfennig</surname><given-names>KW</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Discovery of specialized NK cell populations infiltrating human melanoma metastases</article-title><source>JCI Insight</source><volume>4</volume><elocation-id>23</elocation-id><pub-id pub-id-type="doi">10.1172/jci.insight.133103</pub-id><pub-id pub-id-type="pmid">31801909</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Di Pilato</surname><given-names>M</given-names></name><name><surname>Kfuri-Rubens</surname><given-names>R</given-names></name><name><surname>Pruessmann</surname><given-names>JN</given-names></name><name><surname>Ozga</surname><given-names>AJ</given-names></name><name><surname>Messemaker</surname><given-names>M</given-names></name><name><surname>Cadilha</surname><given-names>BL</given-names></name><name><surname>Sivakumar</surname><given-names>R</given-names></name><name><surname>Cianciaruso</surname><given-names>C</given-names></name><name><surname>Warner</surname><given-names>RD</given-names></name><name><surname>Marangoni</surname><given-names>F</given-names></name><name><surname>Carrizosa</surname><given-names>E</given-names></name><name><surname>Lesch</surname><given-names>S</given-names></name><name><surname>Billingsley</surname><given-names>J</given-names></name><name><surname>Perez-Ramos</surname><given-names>D</given-names></name><name><surname>Zavala</surname><given-names>F</given-names></name><name><surname>Rheinbay</surname><given-names>E</given-names></name><name><surname>Luster</surname><given-names>AD</given-names></name><name><surname>Gerner</surname><given-names>MY</given-names></name><name><surname>Kobold</surname><given-names>S</given-names></name><name><surname>Pittet</surname><given-names>MJ</given-names></name><name><surname>Mempel</surname><given-names>TR</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>CXCR6 positions cytotoxic T cells to receive critical survival signals in the tumor microenvironment</article-title><source>Cell</source><volume>184</volume><fpage>4512</fpage><lpage>4530</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2021.07.015</pub-id><pub-id pub-id-type="pmid">34343496</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Doi</surname><given-names>T</given-names></name><name><surname>Muro</surname><given-names>K</given-names></name><name><surname>Ishii</surname><given-names>H</given-names></name><name><surname>Kato</surname><given-names>T</given-names></name><name><surname>Tsushima</surname><given-names>T</given-names></name><name><surname>Takenoyama</surname><given-names>M</given-names></name><name><surname>Oizumi</surname><given-names>S</given-names></name><name><surname>Gemmoto</surname><given-names>K</given-names></name><name><surname>Suna</surname><given-names>H</given-names></name><name><surname>Enokitani</surname><given-names>K</given-names></name><name><surname>Kawakami</surname><given-names>T</given-names></name><name><surname>Nishikawa</surname><given-names>H</given-names></name><name><surname>Yamamoto</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>A phase i study of the anti-cc chemokine receptor 4 antibody, mogamulizumab, in combination with nivolumab in patients with advanced or metastatic solid tumors</article-title><source>Clinical Cancer Research</source><volume>25</volume><fpage>6614</fpage><lpage>6622</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-19-1090</pub-id><pub-id pub-id-type="pmid">31455681</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Groh</surname><given-names>V</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Yee</surname><given-names>C</given-names></name><name><surname>Spies</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation</article-title><source>Nature</source><volume>419</volume><fpage>734</fpage><lpage>738</lpage><pub-id pub-id-type="doi">10.1038/nature01112</pub-id><pub-id pub-id-type="pmid">12384702</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hashemi</surname><given-names>E</given-names></name><name><surname>Malarkannan</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Tissue-resident NK Cells: development, maturation, and clinical relevance</article-title><source>Cancers</source><volume>12</volume><elocation-id>1553</elocation-id><pub-id pub-id-type="doi">10.3390/cancers12061553</pub-id><pub-id pub-id-type="pmid">32545516</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hemmatazad</surname><given-names>H</given-names></name><name><surname>Berger</surname><given-names>MD</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>CCR5 is a potential therapeutic target for cancer</article-title><source>Expert Opinion on Therapeutic Targets</source><volume>25</volume><fpage>311</fpage><lpage>327</lpage><pub-id pub-id-type="doi">10.1080/14728222.2021.1902505</pub-id><pub-id pub-id-type="pmid">33719836</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>H</given-names></name><name><surname>Zepp</surname><given-names>M</given-names></name><name><surname>Georges</surname><given-names>RB</given-names></name><name><surname>Jarahian</surname><given-names>M</given-names></name><name><surname>Kazemi</surname><given-names>M</given-names></name><name><surname>Eyol</surname><given-names>E</given-names></name><name><surname>Berger</surname><given-names>MR</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>The CCR5 antagonist maraviroc causes remission of pancreatic cancer liver metastasis in nude rats based on cell cycle inhibition and apoptosis induction</article-title><source>Cancer Letters</source><volume>474</volume><fpage>82</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1016/j.canlet.2020.01.009</pub-id><pub-id pub-id-type="pmid">31954769</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>S</given-names></name><name><surname>Guerrero-Juarez</surname><given-names>CF</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Chang</surname><given-names>I</given-names></name><name><surname>Ramos</surname><given-names>R</given-names></name><name><surname>Kuan</surname><given-names>CH</given-names></name><name><surname>Myung</surname><given-names>P</given-names></name><name><surname>Plikus</surname><given-names>MV</given-names></name><name><surname>Nie</surname><given-names>Q</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Inference and analysis of cell-cell communication using CellChat</article-title><source>Nature Communications</source><volume>12</volume><elocation-id>1088</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-021-21246-9</pub-id><pub-id pub-id-type="pmid">33597522</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2023">2023</year><data-title>CellChat</data-title><version designator="1.6.1">1.6.1</version><source>GitHub</source><ext-link ext-link-type="uri" xlink:href="https://github.com/sqjin/CellChat">https://github.com/sqjin/CellChat</ext-link></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaiser</surname><given-names>BK</given-names></name><name><surname>Yim</surname><given-names>D</given-names></name><name><surname>Chow</surname><given-names>IT</given-names></name><name><surname>Gonzalez</surname><given-names>S</given-names></name><name><surname>Dai</surname><given-names>Z</given-names></name><name><surname>Mann</surname><given-names>HH</given-names></name><name><surname>Strong</surname><given-names>RK</given-names></name><name><surname>Groh</surname><given-names>V</given-names></name><name><surname>Spies</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Disulphide-isomerase-enabled shedding of tumour-associated NKG2D ligands</article-title><source>Nature</source><volume>447</volume><fpage>482</fpage><lpage>486</lpage><pub-id pub-id-type="doi">10.1038/nature05768</pub-id><pub-id pub-id-type="pmid">17495932</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaser</surname><given-names>A</given-names></name><name><surname>Dunzendorfer</surname><given-names>S</given-names></name><name><surname>Offner</surname><given-names>FA</given-names></name><name><surname>Ryan</surname><given-names>T</given-names></name><name><surname>Schwabegger</surname><given-names>A</given-names></name><name><surname>Cruikshank</surname><given-names>WW</given-names></name><name><surname>Wiedermann</surname><given-names>CJ</given-names></name><name><surname>Tilg</surname><given-names>H</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>A role for IL-16 in the cross-talk between dendritic cells and T cells</article-title><source>Journal of Immunology</source><volume>163</volume><fpage>3232</fpage><lpage>3238</lpage><pub-id pub-id-type="pmid">10477592</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Kassambara</surname><given-names>A</given-names></name><name><surname>Kosinski</surname><given-names>M</given-names></name><name><surname>Biecek</surname><given-names>P</given-names></name><name><surname>Fabian</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2021">2021</year><data-title>Survminer: drawing survival curves using “ggplot2”</data-title><version designator="0.4.9">0.4.9</version><source>CRAN</source><ext-link ext-link-type="uri" xlink:href="https://cran.r-project.org/package=survminer">https://cran.r-project.org/package=survminer</ext-link></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kinchesh</surname><given-names>P</given-names></name><name><surname>Allen</surname><given-names>PD</given-names></name><name><surname>Gilchrist</surname><given-names>S</given-names></name><name><surname>Kersemans</surname><given-names>V</given-names></name><name><surname>Lanfredini</surname><given-names>S</given-names></name><name><surname>Thapa</surname><given-names>A</given-names></name><name><surname>O’Neill</surname><given-names>E</given-names></name><name><surname>Smart</surname><given-names>SC</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Reduced respiratory motion artefact in constant TR multi-slice MRI of the mouse</article-title><source>Magnetic Resonance Imaging</source><volume>60</volume><fpage>1</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1016/j.mri.2019.03.018</pub-id><pub-id pub-id-type="pmid">30928386</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kirchhammer</surname><given-names>N</given-names></name><name><surname>Trefny</surname><given-names>MP</given-names></name><name><surname>Natoli</surname><given-names>M</given-names></name><name><surname>Brücher</surname><given-names>D</given-names></name><name><surname>Smith</surname><given-names>SN</given-names></name><name><surname>Werner</surname><given-names>F</given-names></name><name><surname>Koch</surname><given-names>V</given-names></name><name><surname>Schreiner</surname><given-names>D</given-names></name><name><surname>Bartoszek</surname><given-names>E</given-names></name><name><surname>Buchi</surname><given-names>M</given-names></name><name><surname>Schmid</surname><given-names>M</given-names></name><name><surname>Breu</surname><given-names>D</given-names></name><name><surname>Hartmann</surname><given-names>KP</given-names></name><name><surname>Zaytseva</surname><given-names>P</given-names></name><name><surname>Thommen</surname><given-names>DS</given-names></name><name><surname>Läubli</surname><given-names>H</given-names></name><name><surname>Böttcher</surname><given-names>JP</given-names></name><name><surname>Stanczak</surname><given-names>MA</given-names></name><name><surname>Kashyap</surname><given-names>AS</given-names></name><name><surname>Plückthun</surname><given-names>A</given-names></name><name><surname>Zippelius</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>NK cells with tissue-resident traits shape response to immunotherapy by inducing adaptive antitumor immunity</article-title><source>Science Translational Medicine</source><volume>14</volume><elocation-id>eabm9043</elocation-id><pub-id pub-id-type="doi">10.1126/scitranslmed.abm9043</pub-id><pub-id pub-id-type="pmid">35857639</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lander</surname><given-names>VE</given-names></name><name><surname>Belle</surname><given-names>JI</given-names></name><name><surname>Kingston</surname><given-names>NL</given-names></name><name><surname>Herndon</surname><given-names>JM</given-names></name><name><surname>Hogg</surname><given-names>GD</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Kang</surname><given-names>LI</given-names></name><name><surname>Knolhoff</surname><given-names>BL</given-names></name><name><surname>Bogner</surname><given-names>SJ</given-names></name><name><surname>Baer</surname><given-names>JM</given-names></name><name><surname>Zuo</surname><given-names>C</given-names></name><name><surname>Borcherding</surname><given-names>NC</given-names></name><name><surname>Lander</surname><given-names>DP</given-names></name><name><surname>Mpoy</surname><given-names>C</given-names></name><name><surname>Scott</surname><given-names>J</given-names></name><name><surname>Zahner</surname><given-names>M</given-names></name><name><surname>Rogers</surname><given-names>BE</given-names></name><name><surname>Schwarz</surname><given-names>JK</given-names></name><name><surname>Kim</surname><given-names>H</given-names></name><name><surname>DeNardo</surname><given-names>DG</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Stromal reprogramming by fak inhibition overcomes radiation resistance to allow for immune priming and response to checkpoint blockade</article-title><source>Cancer Discovery</source><volume>12</volume><fpage>2774</fpage><lpage>2799</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-22-0192</pub-id><pub-id pub-id-type="pmid">36165893</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>López-Botet</surname><given-names>M</given-names></name><name><surname>De Maria</surname><given-names>A</given-names></name><name><surname>Muntasell</surname><given-names>A</given-names></name><name><surname>Della Chiesa</surname><given-names>M</given-names></name><name><surname>Vilches</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Adaptive NK cell response to human cytomegalovirus: facts and open issues</article-title><source>Seminars in Immunology</source><volume>65</volume><elocation-id>101706</elocation-id><pub-id pub-id-type="doi">10.1016/j.smim.2022.101706</pub-id><pub-id pub-id-type="pmid">36542944</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mantovani</surname><given-names>A</given-names></name><name><surname>Marchesi</surname><given-names>F</given-names></name><name><surname>Malesci</surname><given-names>A</given-names></name><name><surname>Laghi</surname><given-names>L</given-names></name><name><surname>Allavena</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Tumour-associated macrophages as treatment targets in oncology</article-title><source>Nature Reviews. Clinical Oncology</source><volume>14</volume><fpage>399</fpage><lpage>416</lpage><pub-id pub-id-type="doi">10.1038/nrclinonc.2016.217</pub-id><pub-id pub-id-type="pmid">28117416</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marcon</surname><given-names>F</given-names></name><name><surname>Zuo</surname><given-names>J</given-names></name><name><surname>Pearce</surname><given-names>H</given-names></name><name><surname>Nicol</surname><given-names>S</given-names></name><name><surname>Margielewska-Davies</surname><given-names>S</given-names></name><name><surname>Farhat</surname><given-names>M</given-names></name><name><surname>Mahon</surname><given-names>B</given-names></name><name><surname>Middleton</surname><given-names>G</given-names></name><name><surname>Brown</surname><given-names>R</given-names></name><name><surname>Roberts</surname><given-names>KJ</given-names></name><name><surname>Moss</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>NK cells in pancreatic cancer demonstrate impaired cytotoxicity and a regulatory IL-10 phenotype</article-title><source>Oncoimmunology</source><volume>9</volume><elocation-id>1845424</elocation-id><pub-id pub-id-type="doi">10.1080/2162402X.2020.1845424</pub-id><pub-id pub-id-type="pmid">33299656</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marquardt</surname><given-names>N</given-names></name><name><surname>Béziat</surname><given-names>V</given-names></name><name><surname>Nyström</surname><given-names>S</given-names></name><name><surname>Hengst</surname><given-names>J</given-names></name><name><surname>Ivarsson</surname><given-names>MA</given-names></name><name><surname>Kekäläinen</surname><given-names>E</given-names></name><name><surname>Johansson</surname><given-names>H</given-names></name><name><surname>Mjösberg</surname><given-names>J</given-names></name><name><surname>Westgren</surname><given-names>M</given-names></name><name><surname>Lankisch</surname><given-names>TO</given-names></name><name><surname>Wedemeyer</surname><given-names>H</given-names></name><name><surname>Ellis</surname><given-names>EC</given-names></name><name><surname>Ljunggren</surname><given-names>HG</given-names></name><name><surname>Michaëlsson</surname><given-names>J</given-names></name><name><surname>Björkström</surname><given-names>NK</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Cutting edge: identification and characterization of human intrahepatic CD49a+ NK cells</article-title><source>Journal of Immunology</source><volume>194</volume><fpage>2467</fpage><lpage>2471</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1402756</pub-id><pub-id pub-id-type="pmid">25672754</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matzke-Ogi</surname><given-names>A</given-names></name><name><surname>Jannasch</surname><given-names>K</given-names></name><name><surname>Shatirishvili</surname><given-names>M</given-names></name><name><surname>Fuchs</surname><given-names>B</given-names></name><name><surname>Chiblak</surname><given-names>S</given-names></name><name><surname>Morton</surname><given-names>J</given-names></name><name><surname>Tawk</surname><given-names>B</given-names></name><name><surname>Lindner</surname><given-names>T</given-names></name><name><surname>Sansom</surname><given-names>O</given-names></name><name><surname>Alves</surname><given-names>F</given-names></name><name><surname>Warth</surname><given-names>A</given-names></name><name><surname>Schwager</surname><given-names>C</given-names></name><name><surname>Mier</surname><given-names>W</given-names></name><name><surname>Kleeff</surname><given-names>J</given-names></name><name><surname>Ponta</surname><given-names>H</given-names></name><name><surname>Abdollahi</surname><given-names>A</given-names></name><name><surname>Orian-Rousseau</surname><given-names>V</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Inhibition of tumor growth and metastasis in pancreatic cancer models by interference with cd44v6 signaling</article-title><source>Gastroenterology</source><volume>150</volume><fpage>513</fpage><lpage>525</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2015.10.020</pub-id><pub-id pub-id-type="pmid">26597578</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McFadden</surname><given-names>C</given-names></name><name><surname>Morgan</surname><given-names>R</given-names></name><name><surname>Rahangdale</surname><given-names>S</given-names></name><name><surname>Green</surname><given-names>D</given-names></name><name><surname>Yamasaki</surname><given-names>H</given-names></name><name><surname>Center</surname><given-names>D</given-names></name><name><surname>Cruikshank</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Preferential migration of T regulatory cells induced by IL-16</article-title><source>Journal of Immunology</source><volume>179</volume><fpage>6439</fpage><lpage>6445</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.179.10.6439</pub-id><pub-id pub-id-type="pmid">17982032</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Melaiu</surname><given-names>O</given-names></name><name><surname>Chierici</surname><given-names>M</given-names></name><name><surname>Lucarini</surname><given-names>V</given-names></name><name><surname>Jurman</surname><given-names>G</given-names></name><name><surname>Conti</surname><given-names>LA</given-names></name><name><surname>De Vito</surname><given-names>R</given-names></name><name><surname>Boldrini</surname><given-names>R</given-names></name><name><surname>Cifaldi</surname><given-names>L</given-names></name><name><surname>Castellano</surname><given-names>A</given-names></name><name><surname>Furlanello</surname><given-names>C</given-names></name><name><surname>Barnaba</surname><given-names>V</given-names></name><name><surname>Locatelli</surname><given-names>F</given-names></name><name><surname>Fruci</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Cellular and gene signatures of tumor-infiltrating dendritic cells and natural-killer cells predict prognosis of neuroblastoma</article-title><source>Nature Communications</source><volume>11</volume><elocation-id>5992</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-020-19781-y</pub-id><pub-id pub-id-type="pmid">33239635</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mijnheer</surname><given-names>G</given-names></name><name><surname>Lutter</surname><given-names>L</given-names></name><name><surname>Mokry</surname><given-names>M</given-names></name><name><surname>van der Wal</surname><given-names>M</given-names></name><name><surname>Scholman</surname><given-names>R</given-names></name><name><surname>Fleskens</surname><given-names>V</given-names></name><name><surname>Pandit</surname><given-names>A</given-names></name><name><surname>Tao</surname><given-names>W</given-names></name><name><surname>Wekking</surname><given-names>M</given-names></name><name><surname>Vervoort</surname><given-names>S</given-names></name><name><surname>Roberts</surname><given-names>C</given-names></name><name><surname>Petrelli</surname><given-names>A</given-names></name><name><surname>Peeters</surname><given-names>JGC</given-names></name><name><surname>Knijff</surname><given-names>M</given-names></name><name><surname>de Roock</surname><given-names>S</given-names></name><name><surname>Vastert</surname><given-names>S</given-names></name><name><surname>Taams</surname><given-names>LS</given-names></name><name><surname>van Loosdregt</surname><given-names>J</given-names></name><name><surname>van Wijk</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Conserved human effector Treg cell transcriptomic and epigenetic signature in arthritic joint inflammation</article-title><source>Nature Communications</source><volume>12</volume><elocation-id>2710</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-021-22975-7</pub-id><pub-id pub-id-type="pmid">33976194</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mills</surname><given-names>BN</given-names></name><name><surname>Qiu</surname><given-names>H</given-names></name><name><surname>Drage</surname><given-names>MG</given-names></name><name><surname>Chen</surname><given-names>C</given-names></name><name><surname>Mathew</surname><given-names>JS</given-names></name><name><surname>Garrett-Larsen</surname><given-names>J</given-names></name><name><surname>Ye</surname><given-names>J</given-names></name><name><surname>Uccello</surname><given-names>TP</given-names></name><name><surname>Murphy</surname><given-names>JD</given-names></name><name><surname>Belt</surname><given-names>BA</given-names></name><name><surname>Lord</surname><given-names>EM</given-names></name><name><surname>Katz</surname><given-names>AW</given-names></name><name><surname>Linehan</surname><given-names>DC</given-names></name><name><surname>Gerber</surname><given-names>SA</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Modulation of the human pancreatic ductal adenocarcinoma immune microenvironment by stereotactic body radiotherapy</article-title><source>Clinical Cancer Research</source><volume>28</volume><fpage>150</fpage><lpage>162</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-21-2495</pub-id><pub-id pub-id-type="pmid">34862242</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mohindra</surname><given-names>NA</given-names></name><name><surname>Kircher</surname><given-names>SM</given-names></name><name><surname>Nimeiri</surname><given-names>HS</given-names></name><name><surname>Benson</surname><given-names>AB</given-names></name><name><surname>Rademaker</surname><given-names>A</given-names></name><name><surname>Alonso</surname><given-names>E</given-names></name><name><surname>Blatner</surname><given-names>N</given-names></name><name><surname>Khazaie</surname><given-names>K</given-names></name><name><surname>Mulcahy</surname><given-names>MF</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Results of the phase Ib study of ipilimumab and gemcitabine for advanced pancreas cancer</article-title><source>Journal of Clinical Oncology</source><volume>33</volume><elocation-id>e15281</elocation-id><pub-id pub-id-type="doi">10.1200/jco.2015.33.15_suppl.e15281</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Monti</surname><given-names>P</given-names></name><name><surname>Marchesi</surname><given-names>F</given-names></name><name><surname>Reni</surname><given-names>M</given-names></name><name><surname>Mercalli</surname><given-names>A</given-names></name><name><surname>Sordi</surname><given-names>V</given-names></name><name><surname>Zerbi</surname><given-names>A</given-names></name><name><surname>Balzano</surname><given-names>G</given-names></name><name><surname>Di Carlo</surname><given-names>V</given-names></name><name><surname>Allavena</surname><given-names>P</given-names></name><name><surname>Piemonti</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>A comprehensive in vitro characterization of pancreatic ductal carcinoma cell line biological behavior and its correlation with the structural and genetic profile</article-title><source>Virchows Archiv</source><volume>445</volume><fpage>236</fpage><lpage>247</lpage><pub-id pub-id-type="doi">10.1007/s00428-004-1053-x</pub-id><pub-id pub-id-type="pmid">15258755</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nersesian</surname><given-names>S</given-names></name><name><surname>Schwartz</surname><given-names>SL</given-names></name><name><surname>Grantham</surname><given-names>SR</given-names></name><name><surname>MacLean</surname><given-names>LK</given-names></name><name><surname>Lee</surname><given-names>SN</given-names></name><name><surname>Pugh-Toole</surname><given-names>M</given-names></name><name><surname>Boudreau</surname><given-names>JE</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>NK cell infiltration is associated with improved overall survival in solid cancers: a systematic review and meta-analysis</article-title><source>Translational Oncology</source><volume>14</volume><elocation-id>100930</elocation-id><pub-id pub-id-type="doi">10.1016/j.tranon.2020.100930</pub-id><pub-id pub-id-type="pmid">33186888</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parikh</surname><given-names>AR</given-names></name><name><surname>Szabolcs</surname><given-names>A</given-names></name><name><surname>Allen</surname><given-names>JN</given-names></name><name><surname>Clark</surname><given-names>JW</given-names></name><name><surname>Wo</surname><given-names>JY</given-names></name><name><surname>Raabe</surname><given-names>M</given-names></name><name><surname>Thel</surname><given-names>H</given-names></name><name><surname>Hoyos</surname><given-names>D</given-names></name><name><surname>Mehta</surname><given-names>A</given-names></name><name><surname>Arshad</surname><given-names>S</given-names></name><name><surname>Lieb</surname><given-names>DJ</given-names></name><name><surname>Drapek</surname><given-names>LC</given-names></name><name><surname>Blaszkowsky</surname><given-names>LS</given-names></name><name><surname>Giantonio</surname><given-names>BJ</given-names></name><name><surname>Weekes</surname><given-names>CD</given-names></name><name><surname>Zhu</surname><given-names>AX</given-names></name><name><surname>Goyal</surname><given-names>L</given-names></name><name><surname>Nipp</surname><given-names>RD</given-names></name><name><surname>Dubois</surname><given-names>JS</given-names></name><name><surname>Van Seventer</surname><given-names>EE</given-names></name><name><surname>Foreman</surname><given-names>BE</given-names></name><name><surname>Matlack</surname><given-names>LE</given-names></name><name><surname>Ly</surname><given-names>L</given-names></name><name><surname>Meurer</surname><given-names>JA</given-names></name><name><surname>Hacohen</surname><given-names>N</given-names></name><name><surname>Ryan</surname><given-names>DP</given-names></name><name><surname>Yeap</surname><given-names>BY</given-names></name><name><surname>Corcoran</surname><given-names>RB</given-names></name><name><surname>Greenbaum</surname><given-names>BD</given-names></name><name><surname>Ting</surname><given-names>DT</given-names></name><name><surname>Hong</surname><given-names>TS</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Radiation therapy enhances immunotherapy response in microsatellite stable colorectal and pancreatic adenocarcinoma in a phase II trial</article-title><source>Nature Cancer</source><volume>2</volume><fpage>1124</fpage><lpage>1135</lpage><pub-id pub-id-type="doi">10.1038/s43018-021-00269-7</pub-id><pub-id pub-id-type="pmid">35122060</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peng</surname><given-names>YP</given-names></name><name><surname>Zhu</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>JJ</given-names></name><name><surname>Xu</surname><given-names>ZK</given-names></name><name><surname>Qian</surname><given-names>ZY</given-names></name><name><surname>Dai</surname><given-names>CC</given-names></name><name><surname>Jiang</surname><given-names>KR</given-names></name><name><surname>Wu</surname><given-names>JL</given-names></name><name><surname>Gao</surname><given-names>WT</given-names></name><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Du</surname><given-names>Q</given-names></name><name><surname>Miao</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Comprehensive analysis of the percentage of surface receptors and cytotoxic granules positive natural killer cells in patients with pancreatic cancer, gastric cancer, and colorectal cancer</article-title><source>Journal of Translational Medicine</source><volume>11</volume><elocation-id>262</elocation-id><pub-id pub-id-type="doi">10.1186/1479-5876-11-262</pub-id><pub-id pub-id-type="pmid">24138752</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Piper</surname><given-names>M</given-names></name><name><surname>Hoen</surname><given-names>M</given-names></name><name><surname>Darragh</surname><given-names>LB</given-names></name><name><surname>Knitz</surname><given-names>MW</given-names></name><name><surname>Nguyen</surname><given-names>D</given-names></name><name><surname>Gadwa</surname><given-names>J</given-names></name><name><surname>Durini</surname><given-names>G</given-names></name><name><surname>Karakoc</surname><given-names>I</given-names></name><name><surname>Grier</surname><given-names>A</given-names></name><name><surname>Neupert</surname><given-names>B</given-names></name><name><surname>Van Court</surname><given-names>B</given-names></name><name><surname>Abdelazeem</surname><given-names>KNM</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Olimpo</surname><given-names>NA</given-names></name><name><surname>Corbo</surname><given-names>S</given-names></name><name><surname>Ross</surname><given-names>RB</given-names></name><name><surname>Pham</surname><given-names>TT</given-names></name><name><surname>Joshi</surname><given-names>M</given-names></name><name><surname>Kedl</surname><given-names>RM</given-names></name><name><surname>Saviola</surname><given-names>AJ</given-names></name><name><surname>Amann</surname><given-names>M</given-names></name><name><surname>Umaña</surname><given-names>P</given-names></name><name><surname>Codarri Deak</surname><given-names>L</given-names></name><name><surname>Klein</surname><given-names>C</given-names></name><name><surname>D’Alessandro</surname><given-names>A</given-names></name><name><surname>Karam</surname><given-names>SD</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Simultaneous targeting of PD-1 and IL-2Rβγ with radiation therapy inhibits pancreatic cancer growth and metastasis</article-title><source>Cancer Cell</source><volume>41</volume><fpage>950</fpage><lpage>969</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2023.04.001</pub-id><pub-id pub-id-type="pmid">37116489</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Poli</surname><given-names>A</given-names></name><name><surname>Michel</surname><given-names>T</given-names></name><name><surname>Thérésine</surname><given-names>M</given-names></name><name><surname>Andrès</surname><given-names>E</given-names></name><name><surname>Hentges</surname><given-names>F</given-names></name><name><surname>Zimmer</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>CD56bright natural killer (NK) cells: an important NK cell subset</article-title><source>Immunology</source><volume>126</volume><fpage>458</fpage><lpage>465</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2567.2008.03027.x</pub-id><pub-id pub-id-type="pmid">19278419</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quatrini</surname><given-names>L</given-names></name><name><surname>Molfetta</surname><given-names>R</given-names></name><name><surname>Zitti</surname><given-names>B</given-names></name><name><surname>Peruzzi</surname><given-names>G</given-names></name><name><surname>Fionda</surname><given-names>C</given-names></name><name><surname>Capuano</surname><given-names>C</given-names></name><name><surname>Galandrini</surname><given-names>R</given-names></name><name><surname>Cippitelli</surname><given-names>M</given-names></name><name><surname>Santoni</surname><given-names>A</given-names></name><name><surname>Paolini</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Ubiquitin-dependent endocytosis of NKG2D-DAP10 receptor complexes activates signaling and functions in human NK cells</article-title><source>Science Signaling</source><volume>8</volume><elocation-id>ra108</elocation-id><pub-id pub-id-type="doi">10.1126/scisignal.aab2724</pub-id><pub-id pub-id-type="pmid">26508790</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rand</surname><given-names>TH</given-names></name><name><surname>Cruikshank</surname><given-names>WW</given-names></name><name><surname>Center</surname><given-names>DM</given-names></name><name><surname>Weller</surname><given-names>PF</given-names></name></person-group><year iso-8601-date="1991">1991</year><article-title>CD4-mediated stimulation of human eosinophils: lymphocyte chemoattractant factor and other CD4-binding ligands elicit eosinophil migration</article-title><source>The Journal of Experimental Medicine</source><volume>173</volume><fpage>1521</fpage><lpage>1528</lpage><pub-id pub-id-type="doi">10.1084/jem.173.6.1521</pub-id><pub-id pub-id-type="pmid">1851800</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raphael</surname><given-names>BJ</given-names></name><name><surname>Hruban</surname><given-names>RH</given-names></name><name><surname>Aguirre</surname><given-names>AJ</given-names></name><name><surname>Moffitt</surname><given-names>RA</given-names></name><name><surname>Yeh</surname><given-names>JJ</given-names></name><name><surname>Stewart</surname><given-names>C</given-names></name><name><surname>Robertson</surname><given-names>AG</given-names></name><name><surname>Cherniack</surname><given-names>AD</given-names></name><name><surname>Gupta</surname><given-names>M</given-names></name><name><surname>Getz</surname><given-names>G</given-names></name><name><surname>Gabriel</surname><given-names>SB</given-names></name><name><surname>Meyerson</surname><given-names>M</given-names></name><name><surname>Cibulskis</surname><given-names>C</given-names></name><name><surname>Fei</surname><given-names>SS</given-names></name><name><surname>Hinoue</surname><given-names>T</given-names></name><name><surname>Shen</surname><given-names>H</given-names></name><name><surname>Laird</surname><given-names>PW</given-names></name><name><surname>Ling</surname><given-names>S</given-names></name><name><surname>Lu</surname><given-names>Y</given-names></name><name><surname>Mills</surname><given-names>GB</given-names></name><name><surname>Akbani</surname><given-names>R</given-names></name><name><surname>Loher</surname><given-names>P</given-names></name><name><surname>Londin</surname><given-names>ER</given-names></name><name><surname>Rigoutsos</surname><given-names>I</given-names></name><name><surname>Telonis</surname><given-names>AG</given-names></name><name><surname>Gibb</surname><given-names>EA</given-names></name><name><surname>Goldenberg</surname><given-names>A</given-names></name><name><surname>Mezlini</surname><given-names>AM</given-names></name><name><surname>Hoadley</surname><given-names>KA</given-names></name><name><surname>Collisson</surname><given-names>E</given-names></name><name><surname>Lander</surname><given-names>E</given-names></name><name><surname>Murray</surname><given-names>BA</given-names></name><name><surname>Hess</surname><given-names>J</given-names></name><name><surname>Rosenberg</surname><given-names>M</given-names></name><name><surname>Bergelson</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Cho</surname><given-names>J</given-names></name><name><surname>Tiao</surname><given-names>G</given-names></name><name><surname>Kim</surname><given-names>J</given-names></name><name><surname>Livitz</surname><given-names>D</given-names></name><name><surname>Leshchiner</surname><given-names>I</given-names></name><name><surname>Reardon</surname><given-names>B</given-names></name><name><surname>Van Allen</surname><given-names>E</given-names></name><name><surname>Kamburov</surname><given-names>A</given-names></name><name><surname>Beroukhim</surname><given-names>R</given-names></name><name><surname>Saksena</surname><given-names>G</given-names></name><name><surname>Schumacher</surname><given-names>SE</given-names></name><name><surname>Noble</surname><given-names>MS</given-names></name><name><surname>Heiman</surname><given-names>DI</given-names></name><name><surname>Gehlenborg</surname><given-names>N</given-names></name><name><surname>Kim</surname><given-names>J</given-names></name><name><surname>Lawrence</surname><given-names>MS</given-names></name><name><surname>Adsay</surname><given-names>V</given-names></name><name><surname>Petersen</surname><given-names>G</given-names></name><name><surname>Klimstra</surname><given-names>D</given-names></name><name><surname>Bardeesy</surname><given-names>N</given-names></name><name><surname>Leiserson</surname><given-names>MDM</given-names></name><name><surname>Bowlby</surname><given-names>R</given-names></name><name><surname>Kasaian</surname><given-names>K</given-names></name><name><surname>Birol</surname><given-names>I</given-names></name><name><surname>Mungall</surname><given-names>KL</given-names></name><name><surname>Sadeghi</surname><given-names>S</given-names></name><name><surname>Weinstein</surname><given-names>JN</given-names></name><name><surname>Spellman</surname><given-names>PT</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Amundadottir</surname><given-names>LT</given-names></name><name><surname>Tepper</surname><given-names>J</given-names></name><name><surname>Singhi</surname><given-names>AD</given-names></name><name><surname>Dhir</surname><given-names>R</given-names></name><name><surname>Paul</surname><given-names>D</given-names></name><name><surname>Smyrk</surname><given-names>T</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Kim</surname><given-names>P</given-names></name><name><surname>Bowen</surname><given-names>J</given-names></name><name><surname>Frick</surname><given-names>J</given-names></name><name><surname>Gastier-Foster</surname><given-names>JM</given-names></name><name><surname>Gerken</surname><given-names>M</given-names></name><name><surname>Lau</surname><given-names>K</given-names></name><name><surname>Leraas</surname><given-names>KM</given-names></name><name><surname>Lichtenberg</surname><given-names>TM</given-names></name><name><surname>Ramirez</surname><given-names>NC</given-names></name><name><surname>Renkel</surname><given-names>J</given-names></name><name><surname>Sherman</surname><given-names>M</given-names></name><name><surname>Wise</surname><given-names>L</given-names></name><name><surname>Yena</surname><given-names>P</given-names></name><name><surname>Zmuda</surname><given-names>E</given-names></name><name><surname>Shih</surname><given-names>J</given-names></name><name><surname>Ally</surname><given-names>A</given-names></name><name><surname>Balasundaram</surname><given-names>M</given-names></name><name><surname>Carlsen</surname><given-names>R</given-names></name><name><surname>Chu</surname><given-names>A</given-names></name><name><surname>Chuah</surname><given-names>E</given-names></name><name><surname>Clarke</surname><given-names>A</given-names></name><name><surname>Dhalla</surname><given-names>N</given-names></name><name><surname>Holt</surname><given-names>RA</given-names></name><name><surname>Jones</surname><given-names>SJM</given-names></name><name><surname>Lee</surname><given-names>D</given-names></name><name><surname>Ma</surname><given-names>Y</given-names></name><name><surname>Marra</surname><given-names>MA</given-names></name><name><surname>Mayo</surname><given-names>M</given-names></name><name><surname>Moore</surname><given-names>RA</given-names></name><name><surname>Mungall</surname><given-names>AJ</given-names></name><name><surname>Schein</surname><given-names>JE</given-names></name><name><surname>Sipahimalani</surname><given-names>P</given-names></name><name><surname>Tam</surname><given-names>A</given-names></name><name><surname>Thiessen</surname><given-names>N</given-names></name><name><surname>Tse</surname><given-names>K</given-names></name><name><surname>Wong</surname><given-names>T</given-names></name><name><surname>Brooks</surname><given-names>D</given-names></name><name><surname>Auman</surname><given-names>JT</given-names></name><name><surname>Balu</surname><given-names>S</given-names></name><name><surname>Bodenheimer</surname><given-names>T</given-names></name><name><surname>Hayes</surname><given-names>DN</given-names></name><name><surname>Hoyle</surname><given-names>AP</given-names></name><name><surname>Jefferys</surname><given-names>SR</given-names></name><name><surname>Jones</surname><given-names>CD</given-names></name><name><surname>Meng</surname><given-names>S</given-names></name><name><surname>Mieczkowski</surname><given-names>PA</given-names></name><name><surname>Mose</surname><given-names>LE</given-names></name><name><surname>Perou</surname><given-names>CM</given-names></name><name><surname>Perou</surname><given-names>AH</given-names></name><name><surname>Roach</surname><given-names>J</given-names></name><name><surname>Shi</surname><given-names>Y</given-names></name><name><surname>Simons</surname><given-names>JV</given-names></name><name><surname>Skelly</surname><given-names>T</given-names></name><name><surname>Soloway</surname><given-names>MG</given-names></name><name><surname>Tan</surname><given-names>D</given-names></name><name><surname>Veluvolu</surname><given-names>U</given-names></name><name><surname>Parker</surname><given-names>JS</given-names></name><name><surname>Wilkerson</surname><given-names>MD</given-names></name><name><surname>Korkut</surname><given-names>A</given-names></name><name><surname>Senbabaoglu</surname><given-names>Y</given-names></name><name><surname>Burch</surname><given-names>P</given-names></name><name><surname>McWilliams</surname><given-names>R</given-names></name><name><surname>Chaffee</surname><given-names>K</given-names></name><name><surname>Oberg</surname><given-names>A</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Gingras</surname><given-names>MC</given-names></name><name><surname>Wheeler</surname><given-names>DA</given-names></name><name><surname>Xi</surname><given-names>L</given-names></name><name><surname>Albert</surname><given-names>M</given-names></name><name><surname>Bartlett</surname><given-names>J</given-names></name><name><surname>Sekhon</surname><given-names>H</given-names></name><name><surname>Stephen</surname><given-names>Y</given-names></name><name><surname>Howard</surname><given-names>Z</given-names></name><name><surname>Judy</surname><given-names>M</given-names></name><name><surname>Breggia</surname><given-names>A</given-names></name><name><surname>Shroff</surname><given-names>RT</given-names></name><name><surname>Chudamani</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Lolla</surname><given-names>L</given-names></name><name><surname>Naresh</surname><given-names>R</given-names></name><name><surname>Pihl</surname><given-names>T</given-names></name><name><surname>Sun</surname><given-names>Q</given-names></name><name><surname>Wan</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Jennifer</surname><given-names>S</given-names></name><name><surname>Roggin</surname><given-names>K</given-names></name><name><surname>Becker</surname><given-names>KF</given-names></name><name><surname>Behera</surname><given-names>M</given-names></name><name><surname>Bennett</surname><given-names>J</given-names></name><name><surname>Boice</surname><given-names>L</given-names></name><name><surname>Burks</surname><given-names>E</given-names></name><name><surname>Carlotti Junior</surname><given-names>CG</given-names></name><name><surname>Chabot</surname><given-names>J</given-names></name><name><surname>Pretti da Cunha Tirapelli</surname><given-names>D</given-names></name><name><surname>Sebastião dos Santos</surname><given-names>J</given-names></name><name><surname>Dubina</surname><given-names>M</given-names></name><name><surname>Eschbacher</surname><given-names>J</given-names></name><name><surname>Huang</surname><given-names>M</given-names></name><name><surname>Huelsenbeck-Dill</surname><given-names>L</given-names></name><name><surname>Jenkins</surname><given-names>R</given-names></name><name><surname>Karpov</surname><given-names>A</given-names></name><name><surname>Kemp</surname><given-names>R</given-names></name><name><surname>Lyadov</surname><given-names>V</given-names></name><name><surname>Maithel</surname><given-names>S</given-names></name><name><surname>Manikhas</surname><given-names>G</given-names></name><name><surname>Montgomery</surname><given-names>E</given-names></name><name><surname>Noushmehr</surname><given-names>H</given-names></name><name><surname>Osunkoya</surname><given-names>A</given-names></name><name><surname>Owonikoko</surname><given-names>T</given-names></name><name><surname>Paklina</surname><given-names>O</given-names></name><name><surname>Potapova</surname><given-names>O</given-names></name><name><surname>Ramalingam</surname><given-names>S</given-names></name><name><surname>Rathmell</surname><given-names>WK</given-names></name><name><surname>Rieger-Christ</surname><given-names>K</given-names></name><name><surname>Saller</surname><given-names>C</given-names></name><name><surname>Setdikova</surname><given-names>G</given-names></name><name><surname>Shabunin</surname><given-names>A</given-names></name><name><surname>Sica</surname><given-names>G</given-names></name><name><surname>Su</surname><given-names>T</given-names></name><name><surname>Sullivan</surname><given-names>T</given-names></name><name><surname>Swanson</surname><given-names>P</given-names></name><name><surname>Tarvin</surname><given-names>K</given-names></name><name><surname>Tavobilov</surname><given-names>M</given-names></name><name><surname>Thorne</surname><given-names>LB</given-names></name><name><surname>Urbanski</surname><given-names>S</given-names></name><name><surname>Voronina</surname><given-names>O</given-names></name><name><surname>Wang</surname><given-names>T</given-names></name><name><surname>Crain</surname><given-names>D</given-names></name><name><surname>Curley</surname><given-names>E</given-names></name><name><surname>Gardner</surname><given-names>J</given-names></name><name><surname>Mallery</surname><given-names>D</given-names></name><name><surname>Morris</surname><given-names>S</given-names></name><name><surname>Paulauskis</surname><given-names>J</given-names></name><name><surname>Penny</surname><given-names>R</given-names></name><name><surname>Shelton</surname><given-names>C</given-names></name><name><surname>Shelton</surname><given-names>T</given-names></name><name><surname>Janssen</surname><given-names>KP</given-names></name><name><surname>Bathe</surname><given-names>O</given-names></name><name><surname>Bahary</surname><given-names>N</given-names></name><name><surname>Slotta-Huspenina</surname><given-names>J</given-names></name><name><surname>Johns</surname><given-names>A</given-names></name><name><surname>Hibshoosh</surname><given-names>H</given-names></name><name><surname>Hwang</surname><given-names>RF</given-names></name><name><surname>Sepulveda</surname><given-names>A</given-names></name><name><surname>Radenbaugh</surname><given-names>A</given-names></name><name><surname>Baylin</surname><given-names>SB</given-names></name><name><surname>Berrios</surname><given-names>M</given-names></name><name><surname>Bootwalla</surname><given-names>MS</given-names></name><name><surname>Holbrook</surname><given-names>A</given-names></name><name><surname>Lai</surname><given-names>PH</given-names></name><name><surname>Maglinte</surname><given-names>DT</given-names></name><name><surname>Mahurkar</surname><given-names>S</given-names></name><name><surname>Triche</surname><given-names>TJ</given-names></name><name><surname>Van Den Berg</surname><given-names>DJ</given-names></name><name><surname>Weisenberger</surname><given-names>DJ</given-names></name><name><surname>Chin</surname><given-names>L</given-names></name><name><surname>Kucherlapati</surname><given-names>R</given-names></name><name><surname>Kucherlapati</surname><given-names>M</given-names></name><name><surname>Pantazi</surname><given-names>A</given-names></name><name><surname>Park</surname><given-names>P</given-names></name><name><surname>Saksena</surname><given-names>G</given-names></name><name><surname>Voet</surname><given-names>D</given-names></name><name><surname>Lin</surname><given-names>P</given-names></name><name><surname>Frazer</surname><given-names>S</given-names></name><name><surname>Defreitas</surname><given-names>T</given-names></name><name><surname>Meier</surname><given-names>S</given-names></name><name><surname>Chin</surname><given-names>L</given-names></name><name><surname>Kwon</surname><given-names>SY</given-names></name><name><surname>Kim</surname><given-names>YH</given-names></name><name><surname>Park</surname><given-names>SJ</given-names></name><name><surname>Han</surname><given-names>SS</given-names></name><name><surname>Kim</surname><given-names>SH</given-names></name><name><surname>Kim</surname><given-names>H</given-names></name><name><surname>Furth</surname><given-names>E</given-names></name><name><surname>Tempero</surname><given-names>M</given-names></name><name><surname>Sander</surname><given-names>C</given-names></name><name><surname>Biankin</surname><given-names>A</given-names></name><name><surname>Chang</surname><given-names>D</given-names></name><name><surname>Bailey</surname><given-names>P</given-names></name><name><surname>Gill</surname><given-names>A</given-names></name><name><surname>Kench</surname><given-names>J</given-names></name><name><surname>Grimmond</surname><given-names>S</given-names></name><name><surname>Johns</surname><given-names>A</given-names></name><name><surname>Cancer Genome Initiative (APGI</surname><given-names>AP</given-names></name><name><surname>Postier</surname><given-names>R</given-names></name><name><surname>Zuna</surname><given-names>R</given-names></name><name><surname>Sicotte</surname><given-names>H</given-names></name><name><surname>Demchok</surname><given-names>JA</given-names></name><name><surname>Ferguson</surname><given-names>ML</given-names></name><name><surname>Hutter</surname><given-names>CM</given-names></name><name><surname>Mills Shaw</surname><given-names>KR</given-names></name><name><surname>Sheth</surname><given-names>M</given-names></name><name><surname>Sofia</surname><given-names>HJ</given-names></name><name><surname>Tarnuzzer</surname><given-names>R</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Felau</surname><given-names>I</given-names></name><name><surname>Zenklusen</surname><given-names>JC</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Integrated genomic characterization of pancreatic ductal adenocarcinoma</article-title><source>Cancer Cell</source><volume>32</volume><fpage>185</fpage><lpage>203</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2017.07.007</pub-id><pub-id pub-id-type="pmid">28810144</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Royal</surname><given-names>RE</given-names></name><name><surname>Levy</surname><given-names>C</given-names></name><name><surname>Turner</surname><given-names>K</given-names></name><name><surname>Mathur</surname><given-names>A</given-names></name><name><surname>Hughes</surname><given-names>M</given-names></name><name><surname>Kammula</surname><given-names>US</given-names></name><name><surname>Sherry</surname><given-names>RM</given-names></name><name><surname>Topalian</surname><given-names>SL</given-names></name><name><surname>Yang</surname><given-names>JC</given-names></name><name><surname>Lowy</surname><given-names>I</given-names></name><name><surname>Rosenberg</surname><given-names>SA</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma</article-title><source>Journal of Immunotherapy</source><volume>33</volume><fpage>828</fpage><lpage>833</lpage><pub-id pub-id-type="doi">10.1097/CJI.0b013e3181eec14c</pub-id><pub-id pub-id-type="pmid">20842054</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rückert</surname><given-names>T</given-names></name><name><surname>Lareau</surname><given-names>CA</given-names></name><name><surname>Mashreghi</surname><given-names>MF</given-names></name><name><surname>Ludwig</surname><given-names>LS</given-names></name><name><surname>Romagnani</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Clonal expansion and epigenetic inheritance of long-lasting NK cell memory</article-title><source>Nature Immunology</source><volume>23</volume><fpage>1551</fpage><lpage>1563</lpage><pub-id pub-id-type="doi">10.1038/s41590-022-01327-7</pub-id><pub-id pub-id-type="pmid">36289449</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simhadri</surname><given-names>VR</given-names></name><name><surname>Reiners</surname><given-names>KS</given-names></name><name><surname>Hansen</surname><given-names>HP</given-names></name><name><surname>Topolar</surname><given-names>D</given-names></name><name><surname>Simhadri</surname><given-names>VL</given-names></name><name><surname>Nohroudi</surname><given-names>K</given-names></name><name><surname>Kufer</surname><given-names>TA</given-names></name><name><surname>Engert</surname><given-names>A</given-names></name><name><surname>Pogge von Strandmann</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Dendritic cells release HLA-B-associated transcript-3 positive exosomes to regulate natural killer function</article-title><source>PLOS ONE</source><volume>3</volume><elocation-id>e3377</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0003377</pub-id><pub-id pub-id-type="pmid">18852879</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>SK</given-names></name><name><surname>Mishra</surname><given-names>MK</given-names></name><name><surname>Eltoum</surname><given-names>IEA</given-names></name><name><surname>Bae</surname><given-names>S</given-names></name><name><surname>Lillard</surname><given-names>JW</given-names><suffix>Jr</suffix></name><name><surname>Singh</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>CCR5/CCL5 axis interaction promotes migratory and invasiveness of pancreatic cancer cells</article-title><source>Scientific Reports</source><volume>8</volume><elocation-id>1323</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-018-19643-0</pub-id><pub-id pub-id-type="pmid">29358632</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siolas</surname><given-names>D</given-names></name><name><surname>Morrissey</surname><given-names>C</given-names></name><name><surname>Oberstein</surname><given-names>PE</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>The achilles’ heel of pancreatic cancer: targeting pancreatic cancer’s unique immunologic characteristics and metabolic dependencies in clinical trials</article-title><source>Journal of Pancreatology</source><volume>3</volume><fpage>121</fpage><lpage>131</lpage><pub-id pub-id-type="doi">10.1097/JP9.0000000000000052</pub-id><pub-id pub-id-type="pmid">33133736</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>SL</given-names></name><name><surname>Kennedy</surname><given-names>PR</given-names></name><name><surname>Stacey</surname><given-names>KB</given-names></name><name><surname>Worboys</surname><given-names>JD</given-names></name><name><surname>Yarwood</surname><given-names>A</given-names></name><name><surname>Seo</surname><given-names>S</given-names></name><name><surname>Solloa</surname><given-names>EH</given-names></name><name><surname>Mistretta</surname><given-names>B</given-names></name><name><surname>Chatterjee</surname><given-names>SS</given-names></name><name><surname>Gunaratne</surname><given-names>P</given-names></name><name><surname>Allette</surname><given-names>K</given-names></name><name><surname>Wang</surname><given-names>YC</given-names></name><name><surname>Smith</surname><given-names>ML</given-names></name><name><surname>Sebra</surname><given-names>R</given-names></name><name><surname>Mace</surname><given-names>EM</given-names></name><name><surname>Horowitz</surname><given-names>A</given-names></name><name><surname>Thomson</surname><given-names>W</given-names></name><name><surname>Martin</surname><given-names>P</given-names></name><name><surname>Eyre</surname><given-names>S</given-names></name><name><surname>Davis</surname><given-names>DM</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Diversity of peripheral blood human NK cells identified by single-cell RNA sequencing</article-title><source>Blood Advances</source><volume>4</volume><fpage>1388</fpage><lpage>1406</lpage><pub-id pub-id-type="doi">10.1182/bloodadvances.2019000699</pub-id><pub-id pub-id-type="pmid">32271902</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sodergren</surname><given-names>MH</given-names></name><name><surname>Mangal</surname><given-names>N</given-names></name><name><surname>Wasan</surname><given-names>H</given-names></name><name><surname>Sadanandam</surname><given-names>A</given-names></name><name><surname>Balachandran</surname><given-names>VP</given-names></name><name><surname>Jiao</surname><given-names>LR</given-names></name><name><surname>Habib</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Immunological combination treatment holds the key to improving survival in pancreatic cancer</article-title><source>Journal of Cancer Research and Clinical Oncology</source><volume>146</volume><fpage>2897</fpage><lpage>2911</lpage><pub-id pub-id-type="doi">10.1007/s00432-020-03332-5</pub-id><pub-id pub-id-type="pmid">32748119</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steele</surname><given-names>CW</given-names></name><name><surname>Karim</surname><given-names>SA</given-names></name><name><surname>Foth</surname><given-names>M</given-names></name><name><surname>Rishi</surname><given-names>L</given-names></name><name><surname>Leach</surname><given-names>JDG</given-names></name><name><surname>Porter</surname><given-names>RJ</given-names></name><name><surname>Nixon</surname><given-names>C</given-names></name><name><surname>Jeffry Evans</surname><given-names>TR</given-names></name><name><surname>Carter</surname><given-names>CR</given-names></name><name><surname>Nibbs</surname><given-names>RJB</given-names></name><name><surname>Sansom</surname><given-names>OJ</given-names></name><name><surname>Morton</surname><given-names>JP</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>CXCR2 inhibition suppresses acute and chronic pancreatic inflammation</article-title><source>The Journal of Pathology</source><volume>237</volume><fpage>85</fpage><lpage>97</lpage><pub-id pub-id-type="doi">10.1002/path.4555</pub-id><pub-id pub-id-type="pmid">25950520</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steele</surname><given-names>NG</given-names></name><name><surname>Carpenter</surname><given-names>ES</given-names></name><name><surname>Kemp</surname><given-names>SB</given-names></name><name><surname>Sirihorachai</surname><given-names>VR</given-names></name><name><surname>The</surname><given-names>S</given-names></name><name><surname>Delrosario</surname><given-names>L</given-names></name><name><surname>Lazarus</surname><given-names>J</given-names></name><name><surname>Amir</surname><given-names>ED</given-names></name><name><surname>Gunchick</surname><given-names>V</given-names></name><name><surname>Espinoza</surname><given-names>C</given-names></name><name><surname>Bell</surname><given-names>S</given-names></name><name><surname>Harris</surname><given-names>L</given-names></name><name><surname>Lima</surname><given-names>F</given-names></name><name><surname>Irizarry-Negron</surname><given-names>V</given-names></name><name><surname>Paglia</surname><given-names>D</given-names></name><name><surname>Macchia</surname><given-names>J</given-names></name><name><surname>Chu</surname><given-names>AKY</given-names></name><name><surname>Schofield</surname><given-names>H</given-names></name><name><surname>Wamsteker</surname><given-names>EJ</given-names></name><name><surname>Magliano</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Multimodal mapping of the tumor and peripheral blood immune landscape in human pancreatic cancer</article-title><source>Nat Cancer</source><volume>1</volume><fpage>1097</fpage><lpage>1112</lpage><pub-id pub-id-type="doi">10.1038/s43018-020-00121-4</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>MCB</given-names></name><name><surname>Goedegebuure</surname><given-names>PS</given-names></name><name><surname>Belt</surname><given-names>BA</given-names></name><name><surname>Flaherty</surname><given-names>B</given-names></name><name><surname>Sankpal</surname><given-names>N</given-names></name><name><surname>Gillanders</surname><given-names>WE</given-names></name><name><surname>Eberlein</surname><given-names>TJ</given-names></name><name><surname>Hsieh</surname><given-names>CS</given-names></name><name><surname>Linehan</surname><given-names>DC</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Disruption of CCR5-dependent homing of regulatory T cells inhibits tumor growth in a murine model of pancreatic cancer</article-title><source>Journal of Immunology</source><volume>182</volume><fpage>1746</fpage><lpage>1755</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.182.3.1746</pub-id><pub-id pub-id-type="pmid">19155524</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Therneau</surname><given-names>TM</given-names></name><name><surname>Lumley</surname><given-names>T</given-names></name><name><surname>Elizabeth</surname><given-names>A</given-names></name><name><surname>Cynthia</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2022">2022</year><data-title>Survival: survival analysis</data-title><version designator="3.3-1">3.3-1</version><source>CRAN</source><ext-link ext-link-type="uri" xlink:href="https://cran.r-project.org/package=survival">https://cran.r-project.org/package=survival</ext-link></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uhlen</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Lee</surname><given-names>S</given-names></name><name><surname>Sjöstedt</surname><given-names>E</given-names></name><name><surname>Fagerberg</surname><given-names>L</given-names></name><name><surname>Bidkhori</surname><given-names>G</given-names></name><name><surname>Benfeitas</surname><given-names>R</given-names></name><name><surname>Arif</surname><given-names>M</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Edfors</surname><given-names>F</given-names></name><name><surname>Sanli</surname><given-names>K</given-names></name><name><surname>von Feilitzen</surname><given-names>K</given-names></name><name><surname>Oksvold</surname><given-names>P</given-names></name><name><surname>Lundberg</surname><given-names>E</given-names></name><name><surname>Hober</surname><given-names>S</given-names></name><name><surname>Nilsson</surname><given-names>P</given-names></name><name><surname>Mattsson</surname><given-names>J</given-names></name><name><surname>Schwenk</surname><given-names>JM</given-names></name><name><surname>Brunnström</surname><given-names>H</given-names></name><name><surname>Glimelius</surname><given-names>B</given-names></name><name><surname>Sjöblom</surname><given-names>T</given-names></name><name><surname>Edqvist</surname><given-names>PH</given-names></name><name><surname>Djureinovic</surname><given-names>D</given-names></name><name><surname>Micke</surname><given-names>P</given-names></name><name><surname>Lindskog</surname><given-names>C</given-names></name><name><surname>Mardinoglu</surname><given-names>A</given-names></name><name><surname>Ponten</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>A pathology atlas of the human cancer transcriptome</article-title><source>Science</source><volume>357</volume><elocation-id>eaan2507</elocation-id><pub-id pub-id-type="doi">10.1126/science.aan2507</pub-id><pub-id pub-id-type="pmid">28818916</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vella</surname><given-names>JL</given-names></name><name><surname>Molodtsov</surname><given-names>A</given-names></name><name><surname>Angeles</surname><given-names>CV</given-names></name><name><surname>Branchini</surname><given-names>BR</given-names></name><name><surname>Turk</surname><given-names>MJ</given-names></name><name><surname>Huang</surname><given-names>YH</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Dendritic cells maintain anti-tumor immunity by positioning CD8 skin-resident memory T cells</article-title><source>Life Science Alliance</source><volume>4</volume><elocation-id>e202101056</elocation-id><pub-id pub-id-type="doi">10.26508/lsa.202101056</pub-id><pub-id pub-id-type="pmid">34362825</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vremec</surname><given-names>D</given-names></name><name><surname>Pooley</surname><given-names>J</given-names></name><name><surname>Hochrein</surname><given-names>H</given-names></name><name><surname>Wu</surname><given-names>L</given-names></name><name><surname>Shortman</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>CD4 and CD8 expression by dendritic cell subtypes in mouse thymus and spleen</article-title><source>Journal of Immunology</source><volume>164</volume><fpage>2978</fpage><lpage>2986</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.164.6.2978</pub-id><pub-id pub-id-type="pmid">10706685</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2021">2021</year><data-title>Ezcox: easily process a batch of cox models</data-title><version designator="1.0.2">1.0.2</version><source>CRAN</source><ext-link ext-link-type="uri" xlink:href="https://cran.r-project.org/package=ezcox">https://cran.r-project.org/package=ezcox</ext-link></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>He</surname><given-names>T</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Tai</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Quan</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Pan-cancer analysis reveals tumor-associated macrophage communication in the tumor microenvironment</article-title><source>Experimental Hematology &amp; Oncology</source><volume>10</volume><elocation-id>31</elocation-id><pub-id pub-id-type="doi">10.1186/s40164-021-00226-1</pub-id><pub-id pub-id-type="pmid">33971970</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Saung</surname><given-names>MT</given-names></name><name><surname>Li</surname><given-names>K</given-names></name><name><surname>Fu</surname><given-names>J</given-names></name><name><surname>Fujiwara</surname><given-names>K</given-names></name><name><surname>Niu</surname><given-names>N</given-names></name><name><surname>Muth</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Rozich</surname><given-names>N</given-names></name><name><surname>Zlomke</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Espinoza</surname><given-names>B</given-names></name><name><surname>Henderson</surname><given-names>M</given-names></name><name><surname>Funes</surname><given-names>V</given-names></name><name><surname>Herbst</surname><given-names>B</given-names></name><name><surname>Ding</surname><given-names>D</given-names></name><name><surname>Twyman-Saint Victor</surname><given-names>C</given-names></name><name><surname>Zhao</surname><given-names>Q</given-names></name><name><surname>Narang</surname><given-names>A</given-names></name><name><surname>He</surname><given-names>J</given-names></name><name><surname>Zheng</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>CCR2/CCR5 inhibitor permits the radiation-induced effector T cell infiltration in pancreatic adenocarcinoma</article-title><source>The Journal of Experimental Medicine</source><volume>219</volume><elocation-id>e20211631</elocation-id><pub-id pub-id-type="doi">10.1084/jem.20211631</pub-id><pub-id pub-id-type="pmid">35404390</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weiss</surname><given-names>GJ</given-names></name><name><surname>Waypa</surname><given-names>J</given-names></name><name><surname>Blaydorn</surname><given-names>L</given-names></name><name><surname>Coats</surname><given-names>J</given-names></name><name><surname>McGahey</surname><given-names>K</given-names></name><name><surname>Sangal</surname><given-names>A</given-names></name><name><surname>Niu</surname><given-names>J</given-names></name><name><surname>Lynch</surname><given-names>CA</given-names></name><name><surname>Farley</surname><given-names>JH</given-names></name><name><surname>Khemka</surname><given-names>V</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>A phase Ib study of pembrolizumab plus chemotherapy in patients with advanced cancer (PembroPlus)</article-title><source>British Journal of Cancer</source><volume>117</volume><fpage>33</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1038/bjc.2017.145</pub-id><pub-id pub-id-type="pmid">28588322</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weiss</surname><given-names>GJ</given-names></name><name><surname>Blaydorn</surname><given-names>L</given-names></name><name><surname>Beck</surname><given-names>J</given-names></name><name><surname>Bornemann-Kolatzki</surname><given-names>K</given-names></name><name><surname>Urnovitz</surname><given-names>H</given-names></name><name><surname>Schütz</surname><given-names>E</given-names></name><name><surname>Khemka</surname><given-names>V</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Phase Ib/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma</article-title><source>Investigational New Drugs</source><volume>36</volume><fpage>96</fpage><lpage>102</lpage><pub-id pub-id-type="doi">10.1007/s10637-017-0525-1</pub-id><pub-id pub-id-type="pmid">29119276</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Wickham</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2023">2023</year><data-title>Tidyverse: easily install and load the “tidyverse”</data-title><version designator="2.0.0">2.0.0</version><source>CRAN</source><ext-link ext-link-type="uri" xlink:href="https://cran.r-project.org/package=tidyverse">https://cran.r-project.org/package=tidyverse</ext-link></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Willenbrock</surname><given-names>F</given-names></name><name><surname>Cox</surname><given-names>CM</given-names></name><name><surname>Parkes</surname><given-names>EE</given-names></name><name><surname>Wilhelm-Benartzi</surname><given-names>CS</given-names></name><name><surname>Abraham</surname><given-names>AG</given-names></name><name><surname>Owens</surname><given-names>R</given-names></name><name><surname>Sabbagh</surname><given-names>A</given-names></name><name><surname>Jones</surname><given-names>CM</given-names></name><name><surname>Hughes</surname><given-names>DLI</given-names></name><name><surname>Maughan</surname><given-names>T</given-names></name><name><surname>Hurt</surname><given-names>CN</given-names></name><name><surname>O’Neill</surname><given-names>EE</given-names></name><name><surname>Mukherjee</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Circulating biomarkers and outcomes from a randomised phase 2 trial of gemcitabine versus capecitabine-based chemoradiotherapy for pancreatic cancer</article-title><source>British Journal of Cancer</source><volume>124</volume><fpage>581</fpage><lpage>586</lpage><pub-id pub-id-type="doi">10.1038/s41416-020-01120-z</pub-id><pub-id pub-id-type="pmid">33100327</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>SY</given-names></name><name><surname>Fu</surname><given-names>T</given-names></name><name><surname>Jiang</surname><given-names>YZ</given-names></name><name><surname>Shao</surname><given-names>ZM</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Natural killer cells in cancer biology and therapy</article-title><source>Molecular Cancer</source><volume>19</volume><elocation-id>120</elocation-id><pub-id pub-id-type="doi">10.1186/s12943-020-01238-x</pub-id><pub-id pub-id-type="pmid">32762681</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="confproc"><person-group person-group-type="author"><name><surname>Yushkevich</surname><given-names>PA</given-names></name><name><surname>Gerig</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>ITK-SNAP: An interactive tool for semi-automatic segmentation of multi-modality biomedical images</article-title><conf-name>Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference</conf-name><fpage>3342</fpage><lpage>3345</lpage><pub-id pub-id-type="doi">10.1109/EMBC.2016.7591443</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zou</surname><given-names>GM</given-names></name><name><surname>Hu</surname><given-names>WY</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>LIGHT regulates CD86 expression on dendritic cells through NF-kappaB, but not JNK/AP-1 signal transduction pathway</article-title><source>Journal of Cellular Physiology</source><volume>205</volume><fpage>437</fpage><lpage>443</lpage><pub-id pub-id-type="doi">10.1002/jcp.20420</pub-id><pub-id pub-id-type="pmid">15895390</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.92672.3.sa0</article-id><title-group><article-title>eLife assessment</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Baiocchi</surname><given-names>Robert</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution>The Ohio State University</institution><country>United States</country></aff></contrib></contrib-group><kwd-group kwd-group-type="evidence-strength"><kwd>Convincing</kwd></kwd-group><kwd-group kwd-group-type="claim-importance"><kwd>Valuable</kwd></kwd-group></front-stub><body><p>This <bold>valuable</bold> manuscript provides an interesting account documenting the role of resident CD56(br) NK cells in driving interaction with dendritic cells that attract CD8+ T cells to the pancreas cancer tumor microenvironment (TME). The work <bold>convincingly</bold> illustrates how irradiation combined with CCR5i and PD1 blockade leads to a reduction in pancreatic cancer growth that correlates with a reduction in Treg cells and enhancement of NK and CD8 T cells in the TME. The correlation of NKC1 signature with survival in pancreatic cancer patients is indeed of broader interest regarding potential relevance to other types of cancer.</p></body></sub-article><sub-article article-type="referee-report" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.92672.3.sa1</article-id><title-group><article-title>Reviewer #1 (Public Review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>Summary:</p><p>The authors demonstrate that the immunosuppressive environment in pancreatic ductal adenocarcinoma (PDAC) can be mitigated by a combination of ionizing radiation (IR), CCR5 inhibition, and PD1 blockade. This combination therapy increases tissue-resident natural killer (trNK) cells that facilitate CD8 T cell activity, resulting in a reduction of E-cadherin positive tumor cells. They identify a specific &quot;hypofunctional&quot; NK cell population in both mouse and human PDAC that supports CD8 T cell involvement. A trNK signature is found to be associated with better survival outcomes in PDAC and other solid tumors.</p><p>Overall, I think this is an interesting study that combines testing of therapeutic concepts in mice with bioinformatics analysis of single cell transcriptome data in primary tumors and exploration of clinical outcomes using signature genes in TCGA data. The key finding is that immunoregulatory properties of tumor infiltrating/resident CD56-bright NK cells (assumed to be non-cytotoxic) are beneficial for outcome through cross-talk with DC and recruitment of CD8 T cells. The latter is specifically induced by irradiation combined with CCR5i and PD1 blockade.</p><p>These results support the notion that IR/CCR5i/αPD1 combination treatment alters immune infiltration by reducing Tregs and increasing NK and CD8 T cells, thereby resulting in greater local tumor control.</p><p>Although the language was slightly modified in the revised version I think it is important to point out that transcripts (not protein expression) of KLRC2 is common in CD56bright NK cells and does not really reflect &quot;adaptive-like&quot; NK cells.</p></body></sub-article><sub-article article-type="referee-report" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.92672.3.sa2</article-id><title-group><article-title>Reviewer #2 (Public Review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>Summary:</p><p>This work elaborates on a combined therapeutic approach comprising ionizing radiation and CCR5i/αPD1 immunotherapy as a promising strategy in pancreatic cancer. Previous research has established that NK cell-derived CCL5 and XCL1 play a crucial role in recruiting cDC1 cells to the tumor microenvironment, contributing to tumor control. In this study, by using a murine pancreatic cancer model, the authors propose that the addition of radiation therapy to CCR5i and αPD1 immunotherapy could upregulate CD8+ T cells and a subgroup of NK cells within the tumor and result in better tumor control. They further analyzed human single-cell sequencing data from pancreatic cancer patients and identified one subgroup of NK cells (NK C1) with tissue-resident features. Subsequent cell-cell contact analysis reveals the NK-cDC1-CD8 cell axis in pancreatic cancer. By analyzing TCGA data, they found that high NK C1 signature levels were associated with better survival in pancreatic cancer patients. Thus, radiotherapy could benefit the outcome of patients bearing low NK C1 signatures. Importantly, the positive correlation between NK C1 score with survival extends beyond pancreatic cancer, showing potential applicability across various solid cancers.</p><p>Strengths:</p><p>This study could add new insight into the clinical practice by introducing such novel combined therapy and shed light on the underlying immune cell dynamics. These findings hold potential for more effective and targeted treatment in the future. Mouse experiments nicely confirmed that such combined therapy could significantly reduce tumor volume. The elegant use of single-cell sequencing analysis and human database examination enriches the narrative and strengthens the study's foundation. Additionally, the notion that NK C1 signature correlates with patient survival in various solid cancers is of high interest and relevance.</p><p>Weaknesses:</p><p>The authors have addressed some of my concerns. However, others remain and should be discussed.</p><p>(1) The role of CCR5i requires further clarification/ discussion. While the authors demonstrated its capacity to reduce Treg in murine tumors, its impact on other cell populations, including NK cells and CD8+ T cells, was not observed. Nevertheless, the effect of CCR5i on tumor growth in Figure 2B seems pathogenic. If the combination of radiotherapy and αPD1 already can achieve good outcomes as shown in Figure 3A, the necessity to include CCR5i is questioned. Overall, a more comprehensive elucidation of the roles of CCL5 and CCR5i in this context would be good. Alternatively, this limitation should be discussed.</p><p>(2) In line with this, spatial plots in Figure 4 did not include the group with only radiotherapy and αPD1. This inclusion would facilitate a clearer comparison and better highlight the essential role of CCR5i.</p><p>(3) Human database analysis showed a positive correlation between NK C1 score and CCL5 in pancreatic cancer. Furthermore, radiotherapy could benefit the outcome of patients bearing low NK C1 scores. It would be interesting to test, if radiotherapy could also benefit patients with low CCL5 levels in this cohort. This is a key question since the role of CCL5/CCR5i is not well verified. Alternatively, this point could be mentioned and discussed.</p></body></sub-article><sub-article article-type="referee-report" id="sa3"><front-stub><article-id pub-id-type="doi">10.7554/eLife.92672.3.sa3</article-id><title-group><article-title>Reviewer #3 (Public Review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>Summary:</p><p>In the submitted manuscript by Go et al, the authors evaluated the tumor microenvironment in pancreatic ductal adenocarcinoma (PDAC) and made a number of interesting observations, including the following: (1) CCL5 expression within the tumor microenvironment negatively correlated with clinical outcomes in human patients with PDAC; (2) there were both positive and negative correlations between CCL5 expression and the expression of specific genes (e.g. those encoding CD56 and CD16, respectively) included among gene signature lists for Treg, MDSC, TAM, and NK cells; (3) CCR5 inhibition with the inhibitor, maraviroc, reduced Treg infiltration but not that of other immune cell types in an orthotopic murine model of PDAC; (4) CCR5 inhibition augmented anti-PD1 immunotherapy when combined with ionizing radiation (IR) therapy in the murine model; (5) the above therapy resulted in increased infiltration of CD8+ cytotoxic T cells as well as of a subset of NKG2D-negative, tissue-residency (tr) marker expressing NK cells (deemed Cluster 1 NK in their data sets) that inversely correlated with the number of E-cadherin+ cells (i.e. tumor cells) and showed predicted interactions with cDC1 dendritic cells (including XCL1/XCL2 expressed by the NK and XCR1 expressed by the cDC1); (6) the authors identified a number of putative signals stemming from the trNK (e.g. IL-16, TNFSF14, FASLG, CSF, MIF) as well as incoming from cDC1s to NK (e.g. BAG6-NKp30); (7) these trNK cells positively correlated with good outcomes and with CD8+ T cell infiltrations in human PDAC as well as in many other solid tumor types; and (8) importantly, the benefit of IR therapy was specific to the subset of PDAC patients (represented in the TCGA dataset) that were predicted to have low amounts of trNK cells. The authors used murine experimental models, multi-plexed imaging analyses, and a number of publicly available sequencing data sets from human tumor samples to perform their investigations. Based on their findings, the authors proposed that combining IR with CCR5 inhibition and anti-PD1 immunotherapy is a promising strategy to treat solid cancers.</p><p>Strengths:</p><p>Overall, the collective analyses and conclusions appear to be novel and could be of high and rapid impact on the field, particularly in terms of directing clinical trials to incorporate IR with CCR5 inhibition and immunotherapy. The manuscript is well written; the figures are for the most part clear; and the Discussion is very thoughtful.</p><p>Weaknesses:</p><p>In the revised manuscript, the authors addressed my original concerns. I have no new major concerns with the study. One of the limitations is that the authors did not perform functional in vivo or ex vivo assays to address some of the major hypotheses that arose from the descriptive, correlative data; but overall, this does not detract from the enthusiasm for the work or the potential significance and impact of the study.</p></body></sub-article><sub-article article-type="author-comment" id="sa4"><front-stub><article-id pub-id-type="doi">10.7554/eLife.92672.3.sa4</article-id><title-group><article-title>Author response</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Go</surname><given-names>Simei</given-names></name><role specific-use="author">Author</role><aff><institution>University of Oxford</institution><addr-line><named-content content-type="city">Oxford</named-content></addr-line><country>United Kingdom</country></aff></contrib><contrib contrib-type="author"><name><surname>Demetriou</surname><given-names>Constantinos</given-names></name><role specific-use="author">Author</role><aff><institution>University of Oxford</institution><addr-line><named-content content-type="city">Oxford</named-content></addr-line><country>United Kingdom</country></aff></contrib><contrib contrib-type="author"><name><surname>Valenzano</surname><given-names>Giampiero</given-names></name><role specific-use="author">Author</role><aff><institution>University of Oxford</institution><addr-line><named-content content-type="city">Oxford</named-content></addr-line><country>United Kingdom</country></aff></contrib><contrib contrib-type="author"><name><surname>Hughes</surname><given-names>Sophie</given-names></name><role specific-use="author">Author</role><aff><institution>University of Oxford</institution><addr-line><named-content content-type="city">Oxford</named-content></addr-line><country>United Kingdom</country></aff></contrib><contrib contrib-type="author"><name><surname>Lanfredini</surname><given-names>Simone</given-names></name><role specific-use="author">Author</role><aff><institution>University of Oxford</institution><addr-line><named-content content-type="city">Oxford</named-content></addr-line><country>United Kingdom</country></aff></contrib><contrib contrib-type="author"><name><surname>Ferry</surname><given-names>Helen</given-names></name><role specific-use="author">Author</role><aff><institution>University of Oxford</institution><addr-line><named-content content-type="city">Oxford</named-content></addr-line><country>United Kingdom</country></aff></contrib><contrib contrib-type="author"><name><surname>Arbe-Barnes</surname><given-names>Edward</given-names></name><role specific-use="author">Author</role><aff><institution>University of Oxford</institution><addr-line><named-content content-type="city">Oxford</named-content></addr-line><country>United Kingdom</country></aff></contrib><contrib contrib-type="author"><name><surname>Sivakumar</surname><given-names>Shivan</given-names></name><role specific-use="author">Author</role><aff><institution>University of Oxford</institution><addr-line><named-content content-type="city">Oxford</named-content></addr-line><country>United Kingdom</country></aff></contrib><contrib contrib-type="author"><name><surname>Bashford-Rogers</surname><given-names>Rachel</given-names></name><role specific-use="author">Author</role><aff><institution>University of Oxford</institution><addr-line><named-content content-type="city">Oxford</named-content></addr-line><country>United Kingdom</country></aff></contrib><contrib contrib-type="author"><name><surname>Middleton</surname><given-names>Mark R</given-names></name><role specific-use="author">Author</role><aff><institution>University of Oxford</institution><addr-line><named-content content-type="city">Oxford</named-content></addr-line><country>United Kingdom</country></aff></contrib><contrib contrib-type="author"><name><surname>Mukherjee</surname><given-names>Somnath</given-names></name><role specific-use="author">Author</role><aff><institution>Oxford University Hospitals NHS Trust</institution><addr-line><named-content content-type="city">Oxford</named-content></addr-line><country>United Kingdom</country></aff></contrib><contrib contrib-type="author"><name><surname>Morton</surname><given-names>Jennifer</given-names></name><role specific-use="author">Author</role><aff><institution>Cancer Research UK Beatson Institute</institution><addr-line><named-content content-type="city">Glasgow</named-content></addr-line><country>United Kingdom</country></aff></contrib><contrib contrib-type="author"><name><surname>Jones</surname><given-names>Keaton</given-names></name><role specific-use="author">Author</role><aff><institution>University of Oxford</institution><addr-line><named-content content-type="city">Oxford</named-content></addr-line><country>United Kingdom</country></aff></contrib><contrib contrib-type="author"><name><surname>Neill</surname><given-names>Eric O</given-names></name><role specific-use="author">Author</role><aff><institution>University of Oxford</institution><addr-line><named-content content-type="city">Oxford</named-content></addr-line><country>United Kingdom</country></aff></contrib></contrib-group></front-stub><body><p>The following is the authors’ response to the previous reviews.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #1 (Public Review):</bold></p><p>Summary:</p><p>The authors demonstrate that the immunosuppressive environment in pancreatic ductal adenocarcinoma (PDAC) can be mitigated by a combination of ionizing radiation (IR), CCR5 inhibition, and PD1 blockade. This combination therapy increases tissue-resident natural killer (trNK) cells that facilitate CD8 T cell activity, resulting in a reduction of E-cadherin positive tumor cells. They identify a specific &quot;hypofunctional&quot; NK cell population in both mouse and human PDAC that supports CD8 T cell involvement. A trNK signature is found to be associated with better survival outcomes in PDAC and other solid tumors.</p><p>Strengths:</p><p>Overall, I think this is an interesting study that combines testing of therapeutic concepts in mice with bioinformatics analysis of single-cell transcriptome data in primary tumors and exploration of clinical outcomes using signature genes in TCGA data. The key finding is that immunoregulatory properties of tumor-infiltrating/resident CD56-bright NK cells (assumed to be non-cytotoxic) are beneficial for outcome through cross-talk with DC and recruitment of CD8 T cells. The latter is specifically induced by irradiation combined with CCR5i and PD1 blockade.</p><p>&quot;These results collectively support the notion that IR/CCR5i/αPD1 combination treatment alters immune infiltration by reducing Tregs and increasing NK and CD8 T cells, thereby resulting in greater local tumor control.&quot; I agree with this conclusion.</p><p>Weaknesses:</p><p>There are a few points to discuss and that the authors may want to address.</p><p>(1) &quot;Notably, CCR5i significantly reduced Treg infiltration but had no effect on the infiltration of other immune cells, indicating the active recruitment of CCR5+ Tregs in PDAC (Figure 2B).&quot;</p><p>CCR5i treatment seems to inhibit infiltration of CD8 T cells and NK cells to a greater extent, in relative terms, compared to Treg, albeit it is not statistically significant. If this visual inspection of the graph does not reflect reality, additional experiments may be needed to verify the selective targeting of Tregs or confirm the fact that also CD8 T cells and NK cells are affected by single agent CCR5i. The reduced recruitment of Treg, NK cells, and CD8T cells was completely reversed when combined with irradiation. In the data shown in Figure 3E it seems as if CCR5i induced infiltration of Tregs along with other immune cells. However, this said, I agree with the conclusion of the authors that this combined treatment leads to an altered immune composition and ratio between Tregs and effector cells (CD8T cells and NK cells). Could this altered composition be displayed more clearly?</p></disp-quote><p>We would like to thank the reviewer for their comments and agree that there is a trend for reduced NK and T-cell infiltration during CCR5i standalone treatment (as seen in Figure 2B), although it does not reach significance. To reflect this more clearly, we have added n.s (non-significant) for the NK cells and CD8+ T-cells and adjusted the text to reflect a trend for decreased NK and CD8+ T-cell infiltration (See Lines 162-165). Moreover, to reflect the data accurately, we have taken the Treg data out of the original Figure 2B and present it separately as a percentage of CD45+CD3+ T-cells.</p><disp-quote content-type="editor-comment"><p>(2) The definition of active and hypofunctional NK cells based on solely NKG2D expression alone seems like an oversimplification. I realize it is not trivial to test tumor-infiltrating NK cells from these tumors functionally but perhaps scRNAseq of the tumors would allow for characterization of cytotoxicity scores using KEGG or GO analysis or reversed gene set enrichment in responders/non-responders.</p></disp-quote><p>We agree that scRNA-seq of tumors would add to the overall characterization of the tumor-infiltrating NK cells and their characterization, however we are currently unfortunately not in the position to carry out this experiment. We did however immunophenotype the tumor infiltrating NK cell population in more depth by also looking at NKp46 and NKG2D surface expression. This newly added data demonstrates not only increased infiltration of “bona-fide” trNK cells (based on surface expression of CD103+CD49a+) under the triple treatment combination, but more importantly these trNK have reduced levels of CD69, NKp46, NKG2D and increased TIM-3 surface expression compared to conventional NK cells – suggesting that these trNKs could be more hypoactive compared to the conventional NK cells. These data have been added to the manuscript as Figure 4E, F; Figure supplement 4E-G and Lines 244-260 in the revised manuscript. To clarify this difference, we have replaced the word “hypofunctional” with “hypoactive” throughout the manuscript.</p><disp-quote content-type="editor-comment"><p>(3) It seems as if the abstract refers to this phenotype incorrectly since the &quot;hyporesponsive&quot; subset is described as NKG2C-negative.</p></disp-quote><p>We apologize for the typographic confusion and have corrected our abstract and changed the subset to NKG2D-negative (as was intended).</p><disp-quote content-type="editor-comment"><p>(4) &quot;The NK_C1 cluster correlates best with the hypofunction NK phenotype observed in mice as similarly displayed reduced activation (reduced NKG7, NKp80, GZMA, and PRF1) with additional expression of tissue residency markers CD103, CD49a and, surprisingly, the adaptive activating receptor NKG2C (KLRC2) (Figure 5B, C).&quot;</p></disp-quote><p>There is no doubt that NK_C1 represents tumor-infiltrating NK cells with a CD56bright gene signature with a strong tissue resident score. However, the transcriptional expression of KLRC2 on these is not surprising! It is well established that KLRC2 transcripts (but not protein) are highly expressed on conventional CD56bright NK cells. There are several published sources where the authors can find such data for confirmation. Thus, this is not to be confused with adaptive NK cells having an entirely different transcriptional signature and expressing high levels of NKG2C at the cell surface. I strongly recommend reinterpreting the results based on the fact that KLRC2 is expressed at high levels in conventional CD56bright NK cells. If not, it would be important to verify that these tissueresident NK cells express NKG2C and not NKG2A at the cell surface.</p><p>We agree with the reviewer and have modified the text accordingly in the revised manuscript (Lines 279-283), including references to tissue-resident adaptive-like cells as described previously in literature.</p><disp-quote content-type="editor-comment"><p>(5) NCAM1 transcript alone is not sufficient to deconvolute CD56bright NK cells in TCGA data (Figure 7A). As a single marker, it likely reflects NK cell infiltration without providing further evidence on the contribution of the bright/dim components. Therefore, the use of the bright Tr NK signature described in Table 1 is very important (Figure 7B). Table 1 is not provided. Nor Supplementary Table 1. There is only one supplementary figure in the ppt attached.</p></disp-quote><p>We agree that a high NCAM1/CD56 single gene signature could also represent NK cell infiltration. We have rephrased this in the text accordingly (Lines 354-357). We apologize for the missing tables and Supplementary figures. We have added these now to the manuscript as Supplementary table 1.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #2 (Public Review)</bold></p><p>Summary:</p><p>This work elaborates on a combined therapeutic approach comprising ionizing radiation and CCR5i/αPD1 immunotherapy as a promising strategy in pancreatic cancer. Previous research has established that NK cell-derived CCL5 and XCL1 play a crucial role in recruiting cDC1 cells to the tumor microenvironment, contributing to tumor control. In this study, by using a murine pancreatic cancer model, the authors propose that the addition of radiation therapy to CCR5i and αPD1 immunotherapy could upregulate CD8+ T cells and a subgroup of NK cells within the tumor and result in better tumor control. They further analyzed human single-cell sequencing data from pancreatic cancer patients and identified one subgroup of NK cells (NK C1) with tissue-resident features. Subsequent cell-cell contact analysis reveals the NK-cDC1-CD8 cell axis in pancreatic cancer. By analyzing TCGA data, they found that high NK C1 signature levels were associated with better survival in pancreatic cancer patients. Thus, radiotherapy could benefit the outcome of patients bearing low NK C1 signatures. Importantly, the positive correlation between NK C1 score with survival extends beyond pancreatic cancer, showing potential applicability across various solid cancers.</p><p>Strengths:</p><p>This study could add new insight into the clinical practice by introducing such novel combined therapy and shed light on the underlying immune cell dynamics. These findings hold potential for more effective and targeted treatment in the future. Mouse experiments nicely confirmed that such combined therapy could significantly reduce tumor volume. The elegant use of single-cell sequencing analysis and human database examination enriches the narrative and strengthens the study's foundation. Additionally, the notion that NK C1 signature correlates with patient survival in various solid cancers is of high interest and relevance.</p><p>Weaknesses:</p><p>The role of CCR5i requires further clarification. While the authors demonstrated its capacity to reduce Treg in murine tumors, its impact on other cell populations, including NK cells and CD8+ T cells, was not observed. Nevertheless, the effect of CCR5i on tumor growth in Figure 2B should be shown. If the combination of radiotherapy and αPD1 already can achieve good outcomes as shown in Figure 3A, the necessity to include CCR5i is questioned. Overall, a more comprehensive elucidation of the roles of CCL5 and CCR5i in this context would be good.</p></disp-quote><p>We would like to thank the reviewer for their comments and agree that standalone CCR5i also shows a trend of reduced infiltrating NK cells and CD8+ T-cells, although this does not reach significance. We have mentioned this trend in the manuscript (see Lines 162-165) and added n.s to Figure 2B as well. In regards to adding CCR5i; although we observe volumetric control by radiotherapy and anti-PD1, we observe an increase in necrosis induction only in the triple combination compared to radiotherapy combined with anti-PD1 – suggesting that there is an additive effect of CCR5i in our model only as a combination modality. We therefore believe that addition of CCR5i to radiotherapy and anti-PD1 has a beneficial effect. The growth curves for CCR5i alone were already presented in Figure 3A, and we have modified our manuscript to refer to this (see Lines 165-167).</p><disp-quote content-type="editor-comment"><p>(1) In line with this, spatial plots in Figure 4 did not include the group with only radiotherapy and αPD1. This inclusion would facilitate a clearer comparison and better highlight the essential role of CCR5i.</p></disp-quote><p>We agree with the reviewer that inclusion of radiotherapy and αPD1 would facilitate a clear comparison of our data and our experiments did include single controls for radiotherapy and αPD1; however, unfortunately, the tissue slides were of bad quality and therefore not suitable for quantification. In line with this, we have added references to other studies that investigated the effect of immune checkpoint inhibitors in combination with radiotherapy (see Lines 169-172).</p><disp-quote content-type="editor-comment"><p>(2) NK C1 cells should be also analyzed in the mouse model. The authors suggest that NKNKG2Dve could be the cell population. Staining of inhibitory markers should be considered, for example, TIGIT and TIM3 as presented in Figure 5B.</p></disp-quote><p>As per the reviewer suggestion, we have now included some additional data on the surface expression of inhibitory markers/activating receptor on tumor-infiltrating NK cells in our model under the triple combination. These additional data demonstrate increased infiltration of trNK under the triple combination that seem to be more ‘hypoactive’ than conventional NK cells. This data has been added as Figure 4E in the revised Figure.</p><disp-quote content-type="editor-comment"><p>(3) While the cell-cell contact analysis generated from single-cell sequencing data is insightful, extending this analysis to the mouse model under therapy would be highly informative. NK and CD8 cells in the tumor increased upon the combined therapy. However, cDC1 was not characterized. Analysis regarding cDC1 would provide more information on the NK/cDC1/CD8 axis.</p></disp-quote><p>We agree that looking into cDC1 would be highly interesting in our treatment model and its characterization is currently under investigation. The importance about the interaction between cDC1-NK cells has been described before by various groups, and we have provided additional references for that in our manuscript (see Lines 449-455)</p><disp-quote content-type="editor-comment"><p>(4) Human database analysis showed a positive correlation between NK C1 score and CCL5 in pancreatic cancer. Furthermore, radiotherapy could benefit the outcome of patients bearing low NK C1 scores. It would be interesting to test if radiotherapy could also benefit patients with low CCL5 levels in this cohort.</p></disp-quote><p>We would like to thank the reviewer for their suggestion and please see the figure below for the comparison. Patients with CCL5high are enriched for NK_C1 (Figure 7D) and CCL5high patients with NK_C1high have significantly increased overall and disease-free survival compared to NK_C1low (Figure 7E); where those with NK_C1low significantly benefit from radiotherapy (Figure 7B). Accordingly, patients with CCL5high have significantly decreased overall survival compared to CCL5low patients, again confirming CCL5 as a prognostic marker (Figure 1A, Figure R1). When we look at CCL5low patients however, there is no additional significant benefit for radiotherapy (see insert below) in the CCL5low group (not significant; only significant p-values are shown). These data collectively support the strong correlation between CCL5 levels and NK_C1 enrichment, and imply that radiotherapy alone is insufficient to drive NK_C1 cells in the absence of high CCL5 gradients to improve overall survival. However, given the increased overall survival of CCL5low compared to CCL5high it is likely that other factors are at play. Future studies will be required to further elucidate the role of CCL5 gradients on NK_C1 cells and the beneficial effect of radiotherapy.</p><fig id="sa4fig1" position="float"><label>Author response image 1.</label><caption><title>Overall survival of CCL5high versus CCL5low patients stratified into groups with and without radiotherapy using TCGA-PAAD.</title><p>Log-rank p-value indicates the significance level across all groups while individual significant comparisons are shown as indicated.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-92672-sa4-fig1-v1.tif"/></fig><disp-quote content-type="editor-comment"><p><bold>Reviewer #3 (Public Review):</bold></p><p>Summary</p><p>In the submitted manuscript by Go et al, the authors evaluated the tumor microenvironment in pancreatic ductal adenocarcinoma (PDAC) and made a number of interesting observations, including the following: (1) CCL5 expression within the tumor microenvironment negatively correlated with clinical outcomes in human patients with PDAC; (2) there were both positive and negative correlations between CCL5 expression and the expression of specific genes (e.g. those encoding CD56 and CD16, respectively) included among gene signature lists for Treg, MDSC, TAM, and NK cells; (3) CCR5 inhibition with the inhibitor, maraviroc, reduced Treg infiltration but not that of other immune cell types in an orthotopic murine model of PDAC; (4) CCR5 inhibition augmented anti-PD1 immunotherapy when combined with ionizing radiation (IR) therapy in the murine model; (5) the above therapy resulted in increased infiltration of CD8+ cytotoxic T cells as well as of a subset of NKG2D-negative, tissueresidency (tr) marker expressing NK cells (deemed Cluster 1 NK in their data sets) that inversely correlated with the number of E-cadherin+ cells (i.e. tumor cells) and showed predicted interactions with cDC1 dendritic cells (including XCL1/XCL2 expressed by the NK and XCR1 expressed by the cDC1); (6) the authors identified a number of putative signals stemming from the trNK (e.g. IL-16, TNFSF14, FASLG, CSF, MIF) as well as incoming from cDC1s to NK (e.g. BAG6-NKp30); (7) these trNK cells positively correlated with good outcomes and with CD8+ T cell infiltrations in human PDAC as well as in many other solid tumor types; and (8) importantly, the benefit of IR therapy was specific to the subset of PDAC patients (represented in the TCGA dataset <xref ref-type="bibr" rid="bib55">Raphael et al., 2017</xref>) that were predicted to have low amounts of trNK cells. The authors used murine experimental models, multiplexed imaging analyses, and a number of publicly available sequencing data sets from human tumor samples to perform their investigations. Based on their findings, the authors proposed that combining IR with CCR5 inhibition and anti-PD1 immunotherapy is a promising strategy to treat solid cancers.</p><p>Strengths</p><p>Overall, the collective analyses and conclusions appear to be novel and could be of high and rapid impact on the field, particularly in terms of directing clinical trials to incorporate IR with CCR5 inhibition and immunotherapy. The manuscript is well written; the figures are for the most part clear; and the Discussion is very thoughtful.</p><p>Weaknesses</p><p>There were a number of minor typographical errors, missing references, or minor issues with the figures. In general, while many of the observations provided strong suggestive evidence of relationships, phenotypes, and functions, the authors often used language to indicate that such things were confirmed, validated, or proven. In fact, there was a paucity of such functional/confirmatory experiments. This does not necessarily detract from the overall significance, excitement for, and potential impact of the study; but the language could likely be adjusted to be more in keeping with the true nature of the findings. The main title and running title are a bit different; consider making them more similar.</p></disp-quote><p>We apologize for the typographical errors, missing references and issues with the figures. We have revised our manuscript, with a major focus on adjusting our language to more carefully reflect our data, and hope to have addressed all the concerns of the reviewer. The slight discrepancy between the main title and running title are to be able to convey the contents of this manuscript in a comprehensive way.</p><disp-quote content-type="editor-comment"><p><bold>Recommendations for the authors:</bold></p><p><bold>Reviewer #1 (Recommendations For The Authors):</bold></p><p>Please make sure all files are made available. Also please check available datasets describing KLRC2 transcripts in CD56brights. This is not to be confused with an adaptive-like signature.</p></disp-quote><p>We have added the missing table to the supplementary figures and revised the manuscript text in regards to KLRC2 transcript in our NK_C1 cluster and its implications for an adaptive-like signature in the context of tissue-residency (see Lines 279-283; 465-474).</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #2 (Recommendations For The Authors):</bold></p><p>Additional experiments as mentioned in the 'weakness' section could help to further strengthen this study. Besides these points, I would recommend the following:</p><p>(1) The description in the figure should be more precise and clear. Especially in Figure 3A, it seems the addition of IR into CCR5i or CCR5i/aPD1 leads to a bigger tumor volume.</p></disp-quote><p>We have adjusted the figure descriptions to more clearly describe the figures. We apologise for the confusion in Figure 3A, this was a figure legend error and has been correctly rectified in the revised Figures (i.e. closed symbols represent +IR conditions).</p><disp-quote content-type="editor-comment"><p>(2) The definition of Tregs in figures should be described, e.g. it is not specified which population is shown in Figure S2c.</p></disp-quote><p>We have added a definition of Tregs (i.e. Live/CD45+CD3+CD4+FOXP3+) in our revised manuscript (see Lines 162-165). To avoid confusion, we have removed the subsequent gating of CCR5 and PD-1 of Tregs in our revised Supplementary Figures.</p><disp-quote content-type="editor-comment"><p>(3) Please add a bar in all histology figures, for example, Figure 2A, S2A, S3E. It seems in Figure S3D, E, the green group is missing.</p></disp-quote><p>We have added the scale bar to all the indicated figures. Unfortunately, indeed as correctly pointed out by the reviewer, we are missing the green group (i.e. IR+CCR5i) as we felt that the excessive growth seen with CCR5i alone may have given a false impression of the extent of infiltration, therefore we did not include this in the original analysis and do not have the data in the Figure.</p><disp-quote content-type="editor-comment"><p>(4) Please check through the manuscript, there are some grammar mistakes.</p></disp-quote><p>We apologise for the grammar mistakes in our original manuscript and have carefully revised the current manuscript to avoid grammar mistakes</p><disp-quote content-type="editor-comment"><p>(5) Figure S7B, the left cell lacks a name.</p></disp-quote><p>We have annotated the left cell accordingly in our revised supplementary figure.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #3 (Recommendations For The Authors):</bold></p><p>(1) Abbreviations (e.g. PDAC) should be spelled out the first time introduced in the manuscript.</p></disp-quote><p>We have adjusted this in our revised manuscript.</p><disp-quote content-type="editor-comment"><p>(2) Referring to the tissue-resident NK cells as &quot;hypofunctional&quot; may not be useful...they seem to be functional, just not in the conventional sense. The authors may want to consider another term, such as non-cytotoxic (given the low expression of cytolytic granules, etc) or immunoregulatory (as they actually refer to them on line 310).</p></disp-quote><p>We agree with the reviewer and have revised the manuscript to refer to them as “immunoregulatory” or “hypoactive” when appropriate. The latter is supported by the additional experiments as shown in Figure 4E.</p><disp-quote content-type="editor-comment"><p>(3) Barry et al 2018 Nat Med demonstrated that NK cells in melanoma could support cDC1s and promote positive clinical outcomes in the setting of immunotherapy. It would likely be beneficial to also cite this paper (e.g. on line 425).</p></disp-quote><p>Thank you for the suggestion, which would work in line with our hypothesis of crosstalk between NK_C1 and cDC1. We have looked for FLT3L in our NK_C1 cluster and did not find any enrichment for FLT3L transcript (see Figure 5E). Nevertheless, we have added the reference in the discussion of our manuscript to further support the importance of crosstalk between cDC1 and NK cells (see Lines 449455)</p><disp-quote content-type="editor-comment"><p>(4) Figure 2B: by eye, it looks like the difference between CD8+ T cells in the two conditions would be significantly different; is this not the case? Same thing for the NK cells...what are the pvalues?</p></disp-quote><p>We have added n.s. to our revised Figure 2B. The p-values for CD8+ T-cells and NK cells were 0.14 and 0.19 {2-tailed students t-test}, respectively.</p><disp-quote content-type="editor-comment"><p>(5) The murine data strongly suggest that the combination therapy promotes trNK cell infiltration into the tumors, in turn resulting in cDC1-mediated CD8+ T cell infiltration and/or activation. It could be highly valuable/useful to functionally determine (e.g. by depleting NK cells in this model) if NK cells are required for the effects seen.</p></disp-quote><p>We agree that depletion of NK cells could really solidify the findings even more, and it is part of ongoing investigations for future projects. However, it would be imperative to first characterise these NK cells in more depth as conventional global ablation of NK cells is excepted to highly impact immunosurveillance as well. This is part of current ongoing work.</p><disp-quote content-type="editor-comment"><p>(6) Figure 7B: how were &quot;high&quot; and &quot;low&quot; defined (for the NK signature)?</p></disp-quote><p>An enrichment score of the NK_C1 gene signature (see Table supplement 1) was first calculated per patient sample in the TCGA RNA-seq dataset using the Gene Set Variation Analysis (GSVA) method. A cut-off value was then determined using the maximally selected rank statistics (max-stat R package) method to divide patients into “high” and “low”.</p><disp-quote content-type="editor-comment"><p>(7) Lines 164-165 of the Results: it would be good to include a reference supporting the statement.</p></disp-quote><p>We have added rephrased the manuscript and added corresponding references (see Lines 170-173 in revised manuscript).</p><disp-quote content-type="editor-comment"><p>(8) There are many conclusions and very speculative language based only on sequencing results, and these have not been validated (e.g. in the Discussion, lines 447-453). As another example, it was concluded that a decrease in NKG2D+ NK cells implied a reduction in overall NK cell cytolytic activity and that NKG2D- NK cells were hypofunctional and did not kill well. This was not tested. Generally, it would be useful for the authors to use language that conveys that the data are primarily suggestive (rather than &quot;confirmatory&quot;, line 447) of relationships, phenotypes, and functions at this point.</p></disp-quote><p>We thank the reviewer for their concerns and have carefully adapted the manuscript text to more clearly clarify the findings in a careful manner.</p><disp-quote content-type="editor-comment"><p>(9) On lines 246-247 the authors refer to cluster 3 NK cells, which express CD16, as &quot;immature&quot;. The rationale for this designation is not provided, and most human NK cell development models hold that CD16+ NK cells represent the most mature subset(s).</p></disp-quote><p>We apologize for the typographic error – later on we refer to the NK_C3 cluster as cytotoxic NK cells and we have corrected this in our revised manuscript (see Lines 273-275).</p><disp-quote content-type="editor-comment"><p>(10) On line 351, the authors reference supplemental Figure 7C...but I don't see this figure in the accompanying powerpoint file.</p></disp-quote><p>This should have been Supplementary Figure 7B, and we have corrected it in the revised manuscript (see Lines 374-377)</p><disp-quote content-type="editor-comment"><p>(11) On line 417, the authors reference NKp40; this is likely a typographical error.</p></disp-quote><p>This has been corrected in the revised manuscript to NKp46 (see Lines 439-442).</p></body></sub-article></article>